Nucleotide sequence variation and expression levels of TP53 in cancers of the upper gastro-intestinal tract by Barnard, Desire
Nucleotide sequence variation and
expression levels of TP53 in cancers of
the upper gastro-intestinal tract
Oesiré Barnard
Thesis presented for the approval for the Masters degree of
Science in Medical Science at the Faculty of Medicine,
University of Stellenbosch
Promoter: Prof. T.G. Victor
April2004
DECLARATION
I, the undersigned, hereby declare that the work contained in this thesis is my
own original work and has not previously in its entirety or in part been submitted
at any university for a degree.
Signature Date
Stellenbosch University http://scholar.sun.ac.za
SUMMARY
The work presented in this thesis deals with the association between cancers of
the upper gastro-intestinal tract and the tumor suppressor gene, TP53, and can
be divided into three parts: (i) the analysis of the mutational spectrum of TP53
with respect to laryngeal cancer, (ii) the analysis of the mutational spectrum of
TP53 with respect to esophageal cancer and (iii) the analysis of TP53
transcriptional levels in esophageal cancer.
Laryngeal cancer (LC) is the 6th most common cancer in the world and the 2nd
most common respiratory cancer, with approximately 500 000 new cases per
annum detected worldwide. Over the last few years, LC has become
increasingly prevalent within the Coloured Community of the Western Cape. The
mechanisms of tumorigenesis in LC remain unknown, although smoking and
alcohol consumption are considered to be major risk factors. Mutations within
the gene TP53 have been strongly implicated as playing a role in cancer
development, as they are frequently found in several cancer types. We therefore
screened exons 5 - 8 of TP53 for mutations in DNA from tumor biopsies (n=44)
and blood samples (n=42) from Coloured LC patients, using polymerase chain
reaction - single strand conformation polymorphism (PCR-SSCP) analysis and
direct sequencing. Blood samples from a healthy, matched control group (n=40)
were included in the study as controls. Significant correlations were found
between the occurrence of LC and age and smoking, whereas daily meat
consumption was a possible protective factor. In tumor-derived samples,
mutations were found in 3 of the exons under investigation, representing 25% of
the samples. The mutations were unique to the tumor biopsies, indicating a
somatic origin for mutations. The data confirms that the region between codons
175 and 273 of TP53 is a mutational hotspot for cancers in general. This study
reports 6 novel mutations within this same region.
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Esophageal cancer (EC) has a very high incidence in South Africa, relative to the
rest of the world, and is particularly common amongst the Black Transkei
population. The goal of this study was to determine whether there are
differences in the TP53 mutational pattern observed in the Coloured Western
Cape community as compared to that observed in the Black Transkei community.
This required the analysis of the molecular structure of TP53, specifically exons 5
- 8, in a group of Coloured EC patients (n=44) treated at Tygerberg Hospital,
Cape Town, South Africa. DNA obtained from tumor biopsies and blood (from
patients) as well as from apparently healthy surrounding tissue was screened via
PCR-SSCP and direct sequencing analysis. Only 4 nucleotide changes were
observed from a total of 124 sequences obtained, of which two were novel to
esophageal squamous cell carcinoma. These 4 nucleotide alterations were
found only within the tumor biopsy sample set, representing 9% of the tumors
investigated. This study revealed that the mutational spectrum of TP53 within
the Coloured population of the Western Cape greatly differs from that of the
Black community of the Transkei. This suggests that a different set of etiological
factors are involved in the tumorigenic process for each of these distinct
geographical communities, which is the subject of an epidemiological study
undertaken by the MRC.
The final part of this thesis deals with the quantification and comparison of TP53
transcription levels in esophageal cancer tumor tissue to the TP53 levels in
healthy esophageal tissue obtained from patients from a unique geographical
and ethnic background. The cohort used in this study consisted of Coloured
patients (n=2) treated at Tygerberg Hospital. The LightCycler system was
implemented in order to try to accurately quantify TP53 mRNA levels.
Unfortunately, the desired results were unattainable due to unforeseen difficulties
encountered during the study. These difficulties included the insufficient
preservation of samples for RNA based studies. Several recommendations were
made concerning future similar studies, including an improved planning strategy
as well as the employment of an RNA stabilizing agent. Additionally, a few
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important contributions were made through this study, including the design and
optimization of TP53 primers specifically intended for future RNA studies. These
primers would enable the identification of the presence of TP53 RNA species as
well as the absence of DNA contamination in a single PCR amplification step.
Other contributions include the development of a well-optimized RNA extraction
method for the extraction of RNA from tough tissues (such as the human
esophageal tissue used in this study). This method makes the extraction of large
quantities of RNA from small amounts of tough tissue types possible.
In conclusion, this study has made a significant contribution to the field of cancer
research, by shedding light on the TP53 mutational spectrum with regards to
laryngeal as well as esophageal cancer in a population unique to the Western
Cape.
The first part of this thesis has been published in Cancer Genetics and
Cytogenetics (Barnard, D., K. Lehmann, E.G. Haal, P.O. van Heiden, and l.C.
Victor. 2003. The spectrum of mutations in TP53 in laryngeal cancer patients
from a high-incidence population shows similarities to many of the known
mutational hotspots. Cancer Genetics and Cytogenetics 145:126-132), of which
a copy can be found in Appendix I. This work has also been presented (by D.
Barnard) at an international conference entitled "Cancer of the Esophagus and
Gastric Cardia: From Gene to Cure", held in Amsterdam, the Netherlands during
the period 13 - 15 December 2002.
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OPSOMMING
Die werk wat in hierdie tesis voorgelê word handeloor die assosiasie tussen
kankers van die boonste gastrointestinale weg en die tumor suppressor geen,
TP53, en kan in 3 dele gedeel word, (i) die analise van die mutasiespektrum van
TP53 in laringiale kanker (LK), (ii) die analise van die mutasiespektrum van TP53
in slukderm kanker (SK) en (iii) die analise van die transkripsievlakke van TP53
in SK.
Laringeal kanker (LK) is die e= algemeenste kanker in die wêreld en die z=
algemeenste respiratoriese kanker, met "n benaderde 500 000 nuwe gevalle
jaarliks wêreldwyd. Oor die afgelope paar jare het LK "n toenemende probleem
geraak, veral in die Kleurling gemeenskap van die Wes Kaap. Die meganismes
van die tumorvorming in LK is onbekend, alhoewel rook-en alkoholgebruik
vername risiko faktore is. Die voorkoms van mutasies in TP53 is verskeie kere
aangetoon in verskillende kanker tipes en daar word vermoed dat dit "n rol speel
in tumorvorming. In hierdie studie is dus na mutasies in eksons 5 - 8 van TP53
gesoek in tumor biopsie weefsel (n=44) en bloed isolate (n=42) van Kleurling LK
pasiënte d.m.v. polimerase ketting reaksie - enkelstring konformasie
polimorfisme (PKR-ESKP) analisering en direkte volgorde bepaling. Bloed
monsters van "n vergelykbare groep (n=40) is ook in die studie ingesluit as "n
kontrole. Betekenisvolle positiewe korrelasies is gevind tussen die voorkoms van
LK en ouderdom sowel as rook. Daarmee saam is daaglikse vleisinname as
potensiële beskermende faktor gevind. In tumor biopsies is mutasies in 3 van
die ondersoekte eksons gevind, wat 25% van die biopsie monsters
verteenwoordig. Hierdie mutasies is uniek aan die tumor biopsie weefsels en dui
op "n somatiese oorsprong van mutasies. Hierdie bevindinge bevestig dat die
gedeelte tussen kodons 173 - 273 van TP53 "n hipermuteerbare gebied
geassosieer met kankers is. Hierdie studie bevestig 6 nuwe mutasies.
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Daar is 'n hoë insidensie van slukderm kanker (SK) in Suid Afrika relatief tot die
res van die wêreld. Hierdie soort kanker word veral gevind by die Swart
populasie van die Transkei. Die doel van hierdie studie was om verskille tussen
die TP53 mutasie patroon van die Kleurling gemeenskap van die Wes Kaap en
die Swart gemeenskap van die Transkei te vergelyk. Hiervoor is die molekulêre
struktuur van TP53, veral eksons 5 - 8, in 'n groep Kleurling SK pasiënte (n=42)
wat behandel is by Tygerberg Hospitaal, Kaapstad, Suid Afrika, geanaliseer.
Analisering is gedoen deur ONS van tumor, bloed en ook oënskynlike gesonde
aangrensende weefsel van dieselfde pasiënte te onderwerp aan PKR-ESKP
analise en direkte volgorde bepaling. Slegs 4 nukleotied veranderings is gevind
in 124 volgorde bepalings, waarvan 2 nuwe veranderings is in SK. Hierdie 4
nukleotied veranderinge verteenwoordig 9% van al die tumors wat ondersoek is
in die studie. Hierdie studie bewys dat die mutasiespektrum van TP53 in die
Kleurling gemeenskap van die Wes Kaap grootliks verskil van die Swart
gemeenskap van die Transkei. Dit impliseer dat verskillende etiologiese faktore
moontlik 'n rol mag speel op die tumorvormingsproses in die 2 afsonderlike
geografiese gemeenskappe. Hierdie is die onderwerp van 'n epidemiologiese
studie wat deur die MNR onderneem word.
Die laaste deel van hierdie tesis handeloor die kwantifisering en vergelyking van
TP53 transkripsievlakke in SK tumor weefsel teenoor TP53 vlakke in gesonde
slukderm weefsel van pasiënte in 'n unieke geografiese en etniese agtergrond.
Die studie populasie in hierdie projek het bestaan uit Kleurling pasiënte (n=2) wat
by Tygerberg hospitaal behandel is. Die "LightCycler" sisteem is gebruik vir die
akkurate kwantifisering van TP53 boodskapper RNS vlakke. Ongelukkig is die
verlangde resultate nie gekry nie as gevolg van onvoorsiene probleme wat
ondervind is tydens die studie. Hierdie probleme sluit in die onvoldoende
preserv
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RNS studies. Hierdie inleiers maak dit nou moontlik om die teenwoordigheid van
TP53 RNS spesies sowel as die afwesigheid van ONS kontaminasie in een PKR
amplifikasie stap te kan identifiseer. 'n Ander belangrike bydrae is die
ontwikkeling van 'n goed geoptimaliseerde RNS ekstraksie metode vir moeilike
starre weelfsel tipes (soos menslike slukderm weefsel in hierdie studie) en maak
die ekstraksie van groot hoeveelhede RNS uit klein hoeveelhede van moeilik
hanteerbare weefsel tipes moontlik.
Om saam te vat, hierdie studie het betekenisvolle bydraes gemaak tot die veld
van kankernavorsing deur die ontrafeling van die TP53 mutasiespektrum in beide
laringeale sowel as slukderm kanker, in 'n populasie uniek aan die Wes Kaap.
Die eerste deel van hierdie tesis is gepubliseer in Cancer Geneties and
Cytogenetics (Barnard, D., K. Lehmann, E. G. Hoal, P. D. van Heiden, and T. C.
Victor. 2003. The spectrum of mutations in TP53 in laryngeal cancer patients
from a high-incidence population shows similarites to many of the known
mutational hotspots. Cancer Genetics and Cytogenetics 145: 126-132) en 'n
afskrif van die artikel is ingesluit in Appendix I. Hierdie werk is ook voorgedra
(deur D. Barnard) by 'n internasionale kongres getiteld "Cancer of the
Esophagus and Gastric Cardia: From Gene to Cure", wat in Amsterdam,
Nederland gehou is gedurende 13 - 15 Desember 2002
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3"Nobody knows what the cause is, though some pretend they do; it is like a
hidden assassin waiting to strike at you. Childless women get it, and men when
they retire; it is as if there had to be some outlet for their foiled creative fire"
W.H. Auden
1.1 The History of Cancer
1.1.1 Centuries of Cancer
The word 'cancer', accredited to the "Father of Medicine", Hippocrates (460 -
370 BC), is derived from the Greek words carcinos and carcinoma, referring to a
crab, apparently due to the resemblance between the veins surrounding tumors
and the appearance of a crab crawling out from its shell (American Cancer
Society ::The History of Cancer 2002; Cancer Association of Southern Africa
2002). Some of the earliest evidence of the presence of cancer comes from
human mummies in ancient Egypt and fossilized bone tumors displaying growths
suggestive of osteosarcoma and head and neck cancer (American Cancer
Society ::The History of Cancer 2002). Cancer has also been recorded in
ancient Chinese and Arabic medical manuscripts (Higginson et al. 1992), dating
as far back as 1600 BC. The earliest recorded cure for cancer can also be found
in the Ramayana, the Hindu epic, where arsenic pastes are recommended for
prevention (Through the Years ...Brief History of Cancer 1998).
Through the years many theories have existed on the causes of cancer. The
ancient Egyptians believed the Gods to be responsible (American Cancer
Society ::The History of Cancer 2002). Hippocrates proposed the Humoral
Theory, whereby it was believed that the body contains 4 humors (body fluids):
blood, phlegm, yellow bile and black bile. As long as these 4 fluids were in
balance, the body was in a natural, healthy state, however, when an imbalance
occurred, the consequences included diseases such as cancer (American
Cancer Society ::The History of Cancer 2002).
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4Due to prohibition of autopsies during the Middle Ages very little was known
about the function of the human body and consequently, the Humoral theory was
believed for more than 1300 years (American Cancer Society ::The History of
Cancer 2002). As the years passed, scientists gained more and more
knowledge and one theory replaced another, with the list including theories such
as the Lymph Theory, the Blastema Theory, and the Parasite theory, which was
wrongly awarded a Nobel Prize in 1926 (American Cancer Society ::The History
of Cancer 2002).
It was scientists such as Galileo and Newton who were responsible for laying the
foundation for scientific research as early as the beginning of the 15th century,
during the Renaissance period (American Cancer Society ::The History of
Cancer 2002). In 1628, Harvey was the first to perform a novel procedure,
known as an autopsy, in order to unravel mysteries such as the circulation of
blood throughout the human body (American Cancer Society ::The History of
Cancer 2002). Giovanni Morgagni in turn, was the first to perform an autopsy in
an attempt to relate cause of death to post-mortem findings (American Cancer
Society ::The History of Cancer 2002). Soon after, Rudolf Virchow was the first to
implement microscopy in the pathological study of cancer (American Cancer
Society ::The History of Cancer 2002). This laid the basis for what is today known
as the science of oncology and both these procedures are routinely performed in
current medical practices (American Cancer Society ::The History of Cancer
2002).
The first cancer hospital was then founded during the 18th century in Reims,
France, based on the belief that cancer was a contagious disease (Through the
Years ...Brief History of Cancer 1998). However, it was only during the next
century that great surgeons such as Bilroth (Germany), Handley (London) and
Halsted (Johns Hopkins) (Through the Years ...Brief History of Cancer 1998), now
renown for their contribution to the science of cancer surgery, laid the basis for
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5tumor removal as well as surrounding lymph node excision (American Cancer
Society ::The History of Cancer 2002). Accredited to the French gynecologist,
Josheph Recaimer, metastasis was the term given to the process whereby
cancer cells spread throughout the body via the bloodstream, a further
complication originally concluded by Paget (Through the Years ...Brief History of
Cancer 1998).
During the 19th century, Wilhelm Roentgen discovered the x-ray (1895) and only
three years later, Pierre and Marie Curie, two French scientists, discovered an
element called radium. It was found that this element is capable of discharging
intense radiation, which sadly, led to their eventual death (Through the
Years ...Brief History of Cancer 1998).
But is was Jean Bergonie, a fellow French researcher, who made it possible for
21st century doctors to destroy cancer cells, without damaging the surrounding
healthy tissues, by describing the law of radio sensitivity. He too, sacrificed his
life for the progression of cancer research and died in 1925, due to cancer
caused by his research (Through the Years ...Brief History of Cancer 1998).
Today cancer treatments included procedures such as hormone therapy,
radiation, chemotherapy and immunotherapy (American Cancer Society ::The
History of Cancer 2002).
1.1.2 Historical Cancer Epidemiology
The science of epidemiology can be defined as the study of the distribution and
variables involved in human diseases and the application of such results to
developing control or prevention programs (Higginson et al. 1992).
Three major observations allowed the launch of the field of cancer epidemiology
during the 18th century; in 1761, John Hill, was the first to identify tobacco as a
carcinogen (any agent that can induce cancer), and in 1775, Percival Pott
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6demonstrated the relationship between cancer of the scrotum in chimney sweeps
and saat collection under their scrotum (Higginson et al. 1992; Bishop et al.
1996; King 1996). Similarly, in 1775, Bernardino Ramazzini observed the total
absence of cervical cancer as well as a relatively high incidence of breast cancer
in nuns and postulated that it be attributed to their celibate lifestyle (American
Cancer Society ::The History of Cancer 2002). In 1915, Yamagiwa and fellow
scientists at the Tokyo University managed to induce cancer in laboratory rabbits
by applying coal tar to their skin (American Cancer Society ::The History of
Cancer 2002; Bishop et al. 1996). In 1968, Peyton Rous from the Rockefeller
Institute in New York was awarded a Nobel Prize for describing how the Rous
sarcoma virus was responsible for inducing sarcoma in chickens (Higginson et al.
1992; Bishop et al. 1996).
Today, countless numbers of these carcinogens have been identified, with the list
including substances such as benzene, certain hydrocarbons, aniline, asbestos,
arsenic and many more. A number of viruses have also been identified as
participants in the tumorigenic process of certain cancer types (Higginson et al.
1992).
1.2 Defining Cancer Genetically
1.2.1 The Cell Cycle, Oncogenes, Tumor Suppressor Genes and DNA
Repair Genes
During the growing years of a child, cells divide at a more rapid pace, to the point
where the child becomes an adult (American Cancer Society ::The History of
Cancer 2002). Once an adult, cells are no longer required for growth, but rather
for maintenance, where new cells replace old or dead cells (American Cancer
Society ::The History of Cancer 2002). However, if one cell escapes this control,
an entire mass of tumor cells can originate through the cloning of the original
progenitor (Bishop et al. 1996; Fialkow 1979; Fearon et al. 1987). Otherwise
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7stated, cancer cells act in an abnormal fashion by continuously dividing,
irrespective of whether there is a requirement for new cells. Cancer can
therefore simply be defined as cells that have escaped cell cycle (Figure 1.1)
control, or as once stated "a disease of the cell cycle (American Cancer Society
::The History of Cancer 2002). (It should also be kept in mind that tumors
originating from multiple cells do also exist, such as those induced by
transforming RNA tumor viruses (Bishop et al. 1996)).
growth- before
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cluplicated
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avomosomes
are aupticetea)
s
G2
period stter DNA
is ououcetea.
Figure 1.1 The cell cycle starts
in the G 1 phase and is
responsible for the division of a
single parent cells into two
identical daughter cells. Failure
to monitor for DNA damage at
checkpoints within the cell cycle
will result in the accumulation of
mutations, which eventually lead
to the development of tumors
(Thomas 2003).
Generally, mitosis can be regulated in one of two ways. Firstly, by genes that
normally acts to suppress cell division. And secondly, by genes that function to
promote cell division. The first class is referred to as tumor suppressor genes
and represses cell division/proliferation (Table 1.1) (Steele et al. 1998; Bishop et
al. 1996; Pergament and Fiddler 2001 c). The protein products of these tumor
suppressor genes must be absent or inactive for normal cell division to occur.
Once these tumor suppressor genes or their protein products become
permanently inactive, cell cycle control is lost and the cells proliferate in an
uncontrolled fashion, resulting in a malignancy (Klug and Cummings 1997;
Macdonald and Ford 1991; Steele et al. 1998; Pergament and Fiddler 2001 c). In
the case of mutations occurring in such tumor suppressor genes, one mutant
allele is not sufficient for manifestation and the normal allele generally acts in a
Stellenbosch University http://scholar.sun.ac.za
8dominant fashion (Steele et al. 1998; Pergament and Fiddler 2001c). It can
therefore be said that only when loss-of-function mutations occur in such tumor
suppressor genes, are they involved in tumorigenesis (Table 1.2) (Bishop et al.
1996; Pergament and Fiddler 2001c). An example of such a tumor suppressor
gene is TP53 (Table 1.1) (Steele et al. 1998; Imazeki et al. 1992; Hinds et al.
1989; Eliayahu et al. 1984; Pergament and Fiddler 2001 c). The second class of
cell division promoting genes associated with the regulation of cell growth and
differentiation is called proto-oncogenes (Steele et al. 1998; Pergament and
Fiddler 2001 b). Proto-oncogene products can usually be categorized into four
types: growth factors, growth factor receptors, intracellular signal transducers
and transcription factors (Bishop et al. 1996; Macdonald and Ford 1991; Klug
and Cummings 1997). These genes occur in an "on/off' state and need to be in
an "on" state in order to promote cell division. If proto-oncogenes become
permanently switched "on", permanent cell division/differentiation occurs and
these genes are then referred to as oncogenes (Klug and Cummings 1997;
Bishop et al. 1996; Ross 1998; Steele et al. 1998; Pergament and Fiddler
2001 b). There are several mechanisms of proto-oncogene conversion to
oncogene, for example, the gene sequence could be altered by mutation, which
may code for a protein with abnormal activity. Another example of proto-
oncogene conversion to oncogene is with the incorporation of viral genomes,
often placing these genes under the control of foreign promoters or enhancers,
which my lead to excess or inappropriate production of the product (Alberts et al.
1994; Lewin 1994; Pergament and Fiddler 2001b). An oncogene typically acts
in a dominant fashion so that a mutation in only one allele is sufficient for
manifestation (Table 1.2) (Steele et al. 1998; Bishop et al. 1996; Klug and
Cummings 1997; Pergament and Fiddler 2001b). To date, over 50 oncogenes
have been identified to be associated with several cancer types (Table 1.3)
(Klug and Cummings 1997; Macdonald and Ford 1991).
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9Table 1.1 Tumor Suppressor Genes and their functions
Cancer Syndrome Gene Primary Tumors Cellular Mode of Action
Location
Li-Fraumeni TP53 Sarcomas, Nucleus Transcription
breast and factor/regulator
brain tumors
Rentinoblastoma Rb Retinoblastoma, Nucleus Transcriptional
osteosarcoma Regulator
Familial adenomatous APC Colon cancer Cytoplasm Unknown
polyposis
Neurofibromatosis type 1 NF-1 Neurofibromas Cytoplasm p2fas.GTPase
activator
Neurofibromatosis type 2 NF-2 Schwannomas, Inner Cytoskeleton-
meingniomas membrane membrane link
Wilms'Tumor WT-1 Nephroblastoma Nuclues Transcription
factor?
von Hippel-Lindau VHL Renal cell Cytoplasm? Inhibits
Carcinoma transcription
elongation
Familial breast cancer BRCA1 Breast, ovary Nucleus? Transcription
factor?
BRCA2 Breast cancer Unknown Unknown
Colorectal cancer DCC Colon cancer Membrane Cell adhesion
Molecule
Familial melanoma p16 Melanoma, many Nucleus Cyclin-
Others dependent
kinase inhibitor
Hereditary nonpolyposis hMSH2, Colon cancer Nucleus Nucleotide
colon cancer hMLH1, mismatch repair
hPMS1,
hPMS2
UNJVë.~.;li:·=.;,sn~LL:i~GOSCH
E;:r:1 DI:: !_:t\
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Table 1.2 Properties of Tumor Suppressor Genes and Proto-oncogenes
Property Tumor Suppressor Proto-oncogenes
Genes
Alleles mutated in cancer Both alleles One allele
Germ line transmission of Frequently seen Rare
mutant allele
Somatic mutation involved Yes Yes
in tumor formation
Function of mutant allele(s) Loss of function Gain of function
(recessive) (dominant)
Effects on cell growth Inhibits cell growth Promotes cell growth
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Table 1.3(a) Human oncogenes and their chromosomal location
Oncogene Chromosomal location Oncogene Chromosomal location
ABL 9q34 KRAS2 12P12.1
ABLL 1q24-q25 LCO 2014
AKT1 14q32.3 LYN 8013-qter
ARAF1 Xp11.4-p11.2 MAS1 6q24-q27
ARAF2 7p14-q21 MEL 19p13.2-cen
BCL2 18 MET 7q31-q32
CSF1R 5q33-q34 MOS 8q11 or 8q21-q23
EGFR 7p13-p12 MYB 6q22-q23
ELK1 Xp22.1-p11 MYC1 8q24
ELK2 14q32.3 MYCL1 1p32
ERBA2L 17q21-q22 MYCN 2p24
ERBAL2 19 NRAS1 1p22 and/or 1p13
ERBAL3 5 NRASL1 9p
ERBB2 17q11-q12 NRASL2 22
ERG 21q22.3 PDGFB 22q12.3-q13.1
ETS1 11q23.3 PIM1 6p21
ETS2 21q22.3 PVT1 8q24
FES 15q25-qter RAF1 3p25
FGR 1p36.2-p36.1 RAF1P1 4p16.1
FOS 14q24.3 RALA 7p22-p15
GLI 12q13 REL 2p13-cen
HRAS 11p15.5 ROS1 6q21-q22
HRASP Xpter-q26 RRAS 19
HRAS2P Xp11.4-p11.2 SEA 11q13
HSTF1 11q13.3 SKI 1q21.1-q24
INT1 12q13 SPI1 11p12-p11.2
INT2 11q13 SRC 20q12-q13
INT4 17q21-q22 THRA1 17q11-q12
JUN ]1p32-p31 THRB 3p24.1-p22
KIT 4p11-q22 YES1 18q21.3
KRAS1P 6p12-p11 YESP 22q11-q12
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Table 1.3(b) Human tumors associated with certain oncogenes
Tumor
HRAS, KRAS
ERBB
ERBB, HRAS, MYC
MYC
HRAS,KRAS, MYB,MYC
ERBB,MYB,MYC,NRAS, YES
ERBB,HRAS,KRAS,MYC,MYCL,MYCN
HRAS
MYCN
ERBB,KRAS
KRAS, MYC
MYC
MYC
Associated oncogenes(s)
Bladder
Brain
Breast
Cervical
Colorectal
Gastric
Lung
Melanoma
Neuroblastoma
Ovarian
Pancreas
Prostate
Testicular
In addition to proto-oncogenes and tumor suppressor genes, genes involved in
the DNA repair mechanism are vital in the process of inhibiting tumorigenesis.
When DNA damage is detected at critical checkpoints, the cell cycle comes to a
halt. In order to prevent the proliferation of the detected damage, DNA repair
mechanisms come into play. The normal functioning of the genes involved in
these repair mechanisms are essential and it is clear that when these genes
themselves are damaged, the cells are incapable of any DNA repair. Defects in
genes coding for proteins that regulate DNA repair have recently been identified
as the causative factor in syndromes such as xeroderma pigmentosum, Bloom's
syndrome, ataxia telangiectasia and Fanconi's anemia, which have all been
linked with an increased risk for the development of leukemia and lymphoma
(Macdonald and Ford 1991; King 1996; Cleaver and Karentz 1987; Pergament
and Fiddler 2001 a).
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1.2.2 Types of Cancer
Generally speaking, all cancers can be divided into 5 major groups: carcinomas,
sarcomas, leukaemias, lymphomas and myelomas. Carcinomas are the most
common form of cancer, and originate in tissues covering a surface or lining the
internal organs. Sarcomas are known to develop in connective tissue and
therefore affect bones and soft tissues. Leukaemias occur in the blood and
blood-forming tissues. Lymphomas affect the lymphatic system and myelomas
originate in the plasma cells of bone marrow (Cancer Association of Southern
Africa 2002). These can then be further subdivided into 3 categories, defined by
the highly variable nature of an individual's genetic makeup, lifestyle and external
environment. The first category is heritable cancers, where the individual's
genetic background is the major contributor and the environment is largely
uninvolved. Such cancers are usually found to have an earlier onset than non-
inheritable cancers. The second category can be described as cancers occurring
in individuals genetically predisposed i.e. those with an increased risk for
developing a certain type cancer under the appropriate conditions. The third
category is that where the cancer is mainly induced by environmental agents,
e.g. lung cancer as a result of smoking, or bladder cancer as a result of aromatic
amine exposure (Higginson et al. 1992). However, recent studies suggest that a
genetic component is also involved in this last category, resulting in a
modification of the cancer.
It is therefore widely accepted that cancer is mostly likely the consequence of a
multi-factorial, multi-step process, with the outcome being the reflection of a
individuals lifetime-lifestyle (Sur and Cooper 1998; Chang et al. 1992; Bishop et
al. 1996; Ross 1998; Imazeki et al. 1992;).
Nonetheless, one thing remains common to all 3 of these categories: DNA
damage remains the basis for tumorigenesis (American Cancer Society ::The
History of Cancer 2002). This damage includes phenomena such as point
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mutations, gene insertions, gene activation and repression. When these
damaged cancer cells make their way into the bloodstream or lymph vessels,
they are capable of spreading to other parts of the body, away from the site of
primary tumor development (American Cancer Society ::The History of Cancer
2002). This process is known as metastasis and allows for these cancer cells to
replace normal tissue elsewhere, leading to the formation of secondary tumors
(American Cancer Society ::The History of Cancer 2002).
1.3 Causes of Cancer
1.3.1 DNA Damage
Epidemiological data collected over the past two centuries has proven that
external factors are responsible for the development of
most cancers today (Bishop et al. 1996; Wynder and Gori 1977; Doll and Peto
1981; Henderson et al. 1991; Ames et al. 1995). The common end result of any
form of DNA damage is a disturbance in the genetic material carried within the
genome. DNA damage to anyone of a host of genes could potentially result in
the initiation of tumorigenesis; genes involved in cell cycle control, DNA repair,
tumor suppressing, chaperoning of other proteins, cell wall structure and
integrity, detoxification of carcinogens, the list is endless.
There are six main types of damage experienced by DNA; oxidation, radiation,
UV light, misinterpreted codes, cytosine methylation and carcinogens (King
1996). Firstly, oxidation of guanine by reactive oxygen species (ROS) produces
8-hydroxyguanine, which is eventually replaced by thymine during the next round
of DNA synthesis, resulting in a base pair substitution. ROS are formed as by-
products of mitochondrial electron transport or by radiation exposure. ROS can
also be produced from other sources such as phagocytic cells and lipid
metabolism. Other oxidizing agents such as nitric oxide found in tobacco smoke
are also capable of forming ROS (King 1996). Secondly, radiation is responsible
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for the formation of strand breaks which eventually result in deletions (King
1996). Thirdly, UV light has the ability to form cross-links between pyrimidines
leading to thymidine replacements (King 1996). Fourthly, during normal DNA
synthesis, the genetic code is very often misinterpreted. This can happen if the
wrong concentration of a specific nucleotide is present and incorporates the
incorrect base or when the DNA polymerase macromolecule slips on the
template and incorporates additional bases (King 1996). Fifthly, during normal
cellular differentiation, genes are switched off by the methylation of cytosines, a
process that is catalyzed by C-DNA methyltransferases (Mtases). Such
methylated cytosines are capable of being deaminated to uracil, which is an
abnormal constituent of DNA. DNA polymerase therefore treats this as a
thymidine and the end result is a thymidine substitution for a guanine (King
1996). Although it is not yet fully understood exactly how cytosine methylation
results in DNA damage, oxygen radicals have thusfar been suggested as being
involved. However, the largest contributor to DNA damage is the sixth group,
namely carcinogens.
1.3.2 Carcinogens
We live in world where the universe of chemicals is believed to consist of 9 to 10
million compounds, with more than 60,000 being in general commercial use
(Higginson et al. 1992). Many of these chemicals fall in the category of
carcinogens, and can occur in association with the work place, drug therapy, air
and water pollution as well as contaminants in food and beverages, such as
herbicides and pesticides (Higginson et al. 1992). All carcinogens can broadly
be classified into one of two groups; genotoxic and non-genotoxic. Agents that
directly damage DNA are classified as genotoxic carcinogens, whereas those
that exert their carcinogenic effect in any other way are non-genotoxic agents
(King 1996). Often, the genotoxic chemical must first be converted to the harmful
state by the incorporation of epoxide or hydroxyl groups, which is catalyzed by
cytochrome P450-dependant enzymes. The general reaction involves the
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conversion of the initial carcinogen to a proximate carcinogen and finally to the
ultimate carcinogen, which then reacts with the DNA (Figure 1.2) (King 1996).
Carcinogen
Enzymatic activation
(Phase I enzymes)
~Xi~ Ultimate---+ ---+.
carcinogen carcinogen
DNA
---+ adduct
/
Detoxification
(Phase II enzymes)
Repair
~
Mutation
1\
Normal Death Cancer
Figure 1.2 The conversion of a carcinogen into a DNA adduct (King 1996).
Under the category of genotoxic carcinogens, four major classes of compounds
exert their effects by forming covalent adducts with bases of DNA; the polycyclic
aromatic hydrocarbons (PAHs), the aromatic amines, nitrosamines and alkylating
agents. These carcinogens can be found in a number of places, in everyday life;
PAHs are generated in tobacco, whisky, grilled meat and by incomplete
combustion of fossil fuels; aromatic amines were used in dyes and in the rubber
industry as well as in margarine production (however, such uses are banned
today); nitrosamines can be found in smoked meats and fish, and alkylating
agents, such as mustard gas, were used during the first world war. The common
feature to all these compounds is that they all contain electrophilic groups or
groups capable of being metabolically converted to electrophilic. Such groups
then form covalent bonds with nucleophilic groups, such as amino, sulphydryl
and hydroxyl groups, which in turn, can be found as part of macromolecules such
as DNA and RNA. In normal cells, DNA occurs in the double stranded form,
however, in proliferating cells, the two DNA strands separate in preparation for
DNA synthesis, and it is during this particularly vulnerable phase that these
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compounds attack. The resulting complex between DNA and carcinogen, known
as a DNA adduct, distorts the DNA to such an extent that if DNA repair is not
possible, an incorrect base (mutation) is incorporated.
The non-genotoxic carcinogens include agents such as hormonal steroids, which
do not directly damage DNA, but act as tumor promoters. These hormones are
mitogens, which increase cell proliferation by binding to transcription factors.
DNA occurs naturally in the double stranded form, but when cell proliferation is
stimulation (by mitogens), the DNA enters the single-stranded form more often,
thus exposing the bases to the actions of genotoxic carcinogens more often
(King 1996). A list of some of the known carcinogens can be found in Tables
1.4(a) to 1.4(c) (Higginson et al. 1992).
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Table 1.4(a) Chemicals or occupations recognized as representing a carcinogenic
hazard to humans
Ambient exposures
Arsenic an arsenic compounds
Erionite
Cultural habits
Betel quid with tobacco
Tobacco products, smokeless
Tobacco smoke
Ethanol
Maté
Dietary contaminants
Aflotoxins
Arsenic and arsenic compounds
Occupational
Aluminium production
4-Aminobiphenyl
Auramine, manufacture of
Benzene
N,N-Bis(2-Chloroethyl )-2-naphthylamine
Bis ether and chloromethyl methyl ether
Boot and shoe manufacture and repair
Chromium compounds, hexavalent
Coal gasification
Coal-tar pitches
Coal-tars
Coke production
Furniture and cabinet-making
Hematite mining, underground with
exposure to radon
Iron and steel founding
Isopropyl alcohol manufacture, strong
acid process
Magenta, manufacturing of
Mineral oils, untreated and mildly treated
Mustard gas (Sulfur gas)
2-Naphthylamine
Nickel and nickel compounds
Rubber industry
Shale oils
Soots
Vinyl chloride
Therapeutic use
Analgesic mixtures containing phenacetin
Azathioprine
1,4-Butanediol dimethane sulphonate
(Myleran 1-(2-Chloroethyl)-3-( 4-
methylcyclohexyl)-1-nitrosourea
Cyclophosphamide
Diethylstilbestrol
Melphalan
8-Methoxypsoralen plus ultra violet radiation
MOPP (combined therapy with nitrogen
mustard, vincristine procarbazine and
prednisone) and other combined
chemotherapy including alkylating
agents
Estrogen replacement therapy
Estrogen, steroidal
Oral contraceptives, combined oral
contraceptives, sequential
Treosulphan
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Table 1.4(b) Chemicals recognized as representing a probable carcinogenic hazard to
humans
Acrylonitrile
Adrianmycin
Androgenic steriods
Benz[ a]anthracene
Benzidine-based dyes
Beryllium and beryllium compounds
Bischloroethyl nitrosourea
Cadmium and cadmium compounds
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea
Cisplatin
Creosotes
Dibenz[ a,h]anthracene
Diethyl sulphate
Dimethyl sulphate
Epichlorohydrin
Ethylene bromide
Ethylene oxide
N-Ethyl-N-nitrosourea
Formaldehyde
5-Methosypsoralen
4,4'-Methylene bis (2-chloroaniline)
N-Methyl-N'-nitrosoguanidine
Nitrogen mustard
N-Nitrosodiethylamine
N-Nitrosodiemethylamine
Phenacetin
Polychlorinated biphenyls
Probacarbazine hydrochloride
Propylene oxide
Silica, crystalline
Styrene oxide
Tris(1-aziridinyl)phosphine sulphine
Tris(2,3-dibromopropyl) phosphate
Vinyl bromide
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Table 1.4(c) Chemicals or occupations recognized as representing a possible
carcinogenic hazard to humans
A-a-C (2-Amino-9H-pyrideo[2,3-b]indole) 1,2-Dichloroethane
Acetaldehyde Dichloromethane
Acetamide 1,3-Dichloropropene
AF-2[2-(2-Furyl)-3-(5-nitro-2-furyl)] Diepoxybutane
acrylamide Di(2-ethylhexy)phthalate
para-Aminoazobenzene 1,2-Diethylhydrazine
or1ho-Aminoazotoluene Diglycidyl resorcinol ether
2-Amino-5-(5-nitro-2-furyl) 1,3,4thiadiazole Dihydrosafrole
Amitrole 3,3'-Dimethoxybenzidine
or1ho-Anisidine para-Dimethylaminoazobenzene
aramite trans-2-[(Dimethylamino)-
Auramine methylimino]-5-[2-(5-nitro-2-
Azaserine furyl)vinyl]1,3,4-oxadiozole
Benzo[b]fluoranthene 3,3'Dimethylbenzidine
Benzo[J]fluoranthene 1,1-Dimethylhydrazine
Benzo[k]fluoranthene 1,2-Dimethylhydrazine
Benzyl violet 48 1,4-Dioxane
Butamens, extracts of steam and air-refined Ethyl acrylate
Bleanmycins Ethylene thiorurea
Bracken fern Ethyl methanesulphonate
1,3-Butadiene 2-(2-Formylhydrazino)-4-(5-nitro-2-
Butylated hydroxyanisole furyl)thiazole
B-Butyrolactone Glu-P-1 (2-Amino-6-
Carbon-black extracts methyldipyrdio[ 1J 2a:3',2 '-
Carbon tetrachloride d]imidazole
Carpentry and joinery Glu-P-2 (2-Aminodipyrdio[ 1,2-
Carrageenan, degraded a:3',2'-d]imidazole
Chloramphenicol Glycidaldehyde
Chlorodecone Hexachlorobenzene
Chlorophenols Hexachlorocyclohexanes
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Continued ...
Chlorophenoxy herbicides
4-Chloro-ortho-phenylenediamine
para-Chloro-ortho-toluidine
Citrus Red NO.2
para-Cresidine
Dicarbazine
Daunomycin
DDT
N, N'-Diacetylbenzidine
2,4-Diaminoanisole
4,4'-Diaminodiphenyl ether
2,4-Diaminotoluene
Dibenz[a,h]acridine
7H-Dibenzo[ C, g]carbazole
Merphalan
2-Methylaziridine
Methylazoxymethanol and its acetate
5-Methylchrysene
4,4'-Methylene bis(2-methylaniline)
4,4'-Methylenedianiline
Methyl methanesulphonate
2-Methyl-1-nitroanthraquinone
N-Methyl-N-nitrosourethane
Methylthiouracil
Metronidazole
Mirex
Mitomycin C
Monocrotaline
5-(Morpholinomethyl)-3-[(5-nitro-
furfurylidene) ]amino-2-imidazolidinone
N-[4-(5- Nitro-2-furyl)-2-thiaxolyl]acetamide
Nitrogen mustard N-oxide
Hexamethylphosphoramide
Hydrazine
Indeno[ 1,2,3-cd]pyrene
IQ (2-Amino-3-metylimidazo [4,5-
~quinoline
Iron-dextran complex
Lasiocarpine
Lead and lead compounds, inorganic
MeA-a-C (2-Amino-3-methyl-9H-
pyrido[ 2,3,b]indole)
Medroxyprogesterone acetate
N-Nitrosopiperdine
N-Nitrosopyrrolidine
N-Nitrososarcosine
Oil Orange SS
Panfuran S (containing
dihydroxymethylfuratrizine)
Phenazopyridine hydrochloride
Phenobarbitol
Phenoxybenzamine hydrochloride
Phenytoin
Polybrominated biphenyls
Ponceau MX
Ponceau 3R
Potassium bromate
Progestins
1,2-Propane sultone
~-Propiolactone
Propylthiouracil
Saccharin
Safrole
Sodium ortho-phenylphenate
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Continued ...
2-Nitropropane
N-Nitrosodi-n-butylamine
N-Nitrosodiethanolamine
N-Nitrosodi-n-propylamine
3-(N-Nitrosomethylamino )propionitrile
4-(N-Nitrosomethylamino )-1-(3-pyridyl)-1-
butanone
N-Nitrosomethylethylamine
N-Nitrosomethylvinylamine
N-Nitrosomorpholine
N' -N itrosonornicotine
Dibenzo[ a,e]pyrene
Dibenzo[a, h]pyrene
Dibenzo[ a,I]pryene
Dibenzo[ a,npryene
1,2-Dibromo-3-chloropropane
para-Dichlorobenzene
3,3'-Dichlorobenzene
3,3-Dichloro-4,4'-diaminodipheyl
ether
Sterigmatocystin
Streptozotocin
Styrene
Sulfallate
2,3,7,8- Tetrachlorodibenzo-para
(TeDO)
Tetrachloroethylene
Thioacetamide
4,4'- Thiodianiline
Thiourea
Toluene diisocyanates
ortho- Toluidine
Toxa (Polychlorinated camphenes)
Trp-P-1 (30Amino-1,4-dimethyl-5H-
pyrido[4,3-b]indole)
Trypan blue
Uracil mustard
Urethane
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Rofo first demonstrated the carcinogenic qualities of tobacco tar in the 1920's,
and the first epidemiological data confirming smoke as a lung cancer carcinogen
came from MOiler shortly after, in 1939 (Higginson et al. 1992). Today it is known
that cancers caused by smoking include lung, oral cavity, pharynx, larynx,
esophagus, urinary bladder, renal pelvis and pancreas, with lung cancer being
the most prevalent (Higginson et al. 1992; IARC 1995). It is known that cigarette
smoking accounts for more cancer deaths that any other known factor (Higginson
et al. 1992), and even side-stream tobacco smoke, known as passive smoking or
second-hand smoking, may pose a cancer risk (O'Neill et al. 1987; Higginson et
al. 1992).
Cigarette smoke has been defined as a highly complex mixture of a large number
of chemicals, with more than 3 000 already having been identified (Table 1.5)
(Higginson et al. 1992).
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Table 1.5 Several of the biologically active agents found in mainstream smoke"
Smoke constituent II Biological Effect
Total particulate matter
Carbon monoxide
Nicotine
Acetaldehyde
Acetone
NOx
Formic Acid
Hydrogen cyanide
Catechol
Ammonia
Benzene
Acrolein
Acrylonitrile
Phenol
Formaldehyde
Carboxole
2-Nitroporpane
N'-Nirosonornicotine
4-(Methylnitrosamino) 1-(3-pyridyl)-1-butanone
N'-Nirosonabasine
N-Nirosodiethanolamine
N-Nirosophyrrolidine
N-Nirosodimethylanime
N-Niroso diethylamine
N-Nirosodi-n-propylamine
N-Nirosodi-n-butylamine
N-Nirosopiperidine
N-Nirosopyrrolidine
Hydrazine
Urethane
Vinyl chloride
T, HC
T
T
CT
CT
T
CT
CT,T
CoC
T
HC
CT
C
TP
C
C?
C
C
C
C?
C
C
C
C
C
C
C
C
C
C
C
Stellenbosch University http://scholar.sun.ac.za
25
Continued ...
Benz[ a]anthracene
Benzo[a]pyrene
5-Methylachrysene
Dibenz[ a,j]acridine
2-Naphthylamine
4-Aminobiphenyl
2-Toluidine
HC
C
C
C
C
HC
HC
a Quantitative data refer to non-filter cigarettes
T = toxic-agents
HC = human carcinogen
CT = ciliatoxic agent
CoC = co-carcinogen
TP = tumor promoter
C = animal carcinogen
It is due to this chemical complexity that it has thus far been impossible to identify
a single agent as being responsible for inducing tumorigenesis (Higginson et al.
1992). However, considerable progress has been made in identifying the
compounds most likely to have such carcinogenic properties and the effects of
tobacco smoke and tobacco tar have been intensely studied in animal models
(O'Neill et al. 1987; Hecht and Hoffman 1989; Higginson et al. 1992). It has also
been shown that approximately 80% of the tar inhaled from mainstream smoking
is deposited within the respiratory tract (Higginson et al. 1992).
The damaging effect of smoking is further complicated by the fact that alcohol,
which has also been found to have carcinogenic properties, acts as an
accomplice to smoke. This is further aggravated by the observation that many
smokers tend to consume excess amounts of alcohol (Higginson et al. 1992). It
has been noted that many cancers of the oral cavity, pharynx, esophagus and
larynx, occur among individuals working in the alcoholic beverage industry
(Higginson et al. 1992; Clemmesen 1941). This was confirmed by the
observation that residents of Normandy in France, who are heavy drinkers of
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distilled apple cider show and unusually high incidence of esophageal cancer. In
contrast, religious and other groups against the consumption of alcohol have
shown lower frequencies of these cancers (Phillips et al. 1980; Enstrom 1980). It
comes as no surprise then that the two predominant carcinogens considered to
be the major contributors to the development of both esophageal cancer as well
as laryngeal cancer are tobacco smoking and alcohol consumption (Osborne et
al. 1997; Schottenfeld et al. 1974; Saunders et al. 1999; Jussawalla and
Deshpande 1971; Gorgoulis et al. 1994; Hirvikoski et al. 1997; Rowley et al.
1998; The Voice Centre at Eastern Virginia Medical School - The Larynx 2001;
Altieri et al. 2002; Bagnardi 2001; Tuyns and Audigier 1976; Chilvers et al. 1979;
Segal et al. 1988; Hollstein et al. 1991b; Negri et al. 1992; Tavani et al. 1993;
Munoz and Castellsagué 1994; Franceschi et al. 1994; Klimstra 1994;
Montesano et al. 1996; Castellsagué et al. 1999; Pacella-Norman et al. 2002;
Levi et al. 2000; Zambon et al. 2000; Gallus et al. 2001; Higginson et al. 1992;
Peto 2001).
1.3.3 Diet
In addition to those cancers inherited or those induced through previously
mentioned mutagens, it is known that one third of cancers in the United States
can be accounted for by an unbalanced diet. This section will discuss only 2
examples. It has been found that the intake of fruit is indirectly correlated to the
occurrence of cancer. This protective effect could possibly be due to the high
levels of antioxidants present in such foods, which, in correct doses are believed
to have beneficial qualities. A decreased calorie intake has also been shown to
significantly decrease tumor incidence in animal studies. This could possibly be
due to the fact that calorie intake rate is linked to the mitotic rate of some tissue
types. In other words, diet can affect cancer susceptibility and protection by
either stimulating cell proliferation, or by providing advantageous antioxidants
respectively (Bishop et al. 1996).
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1.3.4 Viruses
For more than 30 years, it has been known that DNA viruses such as SV40 and
RNA viruses such as Rous sarcoma, are capable of transforming those cells
infected to a cancerous state (American Cancer Society ::The History of Cancer
20020; Plachy et al. 2001; Macdonald and Ford 1991; Vilchez et al. 2003;
Garcea and Imperiale 2003; Diamandopoulos 1972; Eddy 1962; Eddy et al.
1961; Girardi et al. 1963; Girardi et al. 1962; Rubin 2003). Other examples
include the hepatitis virus, which is associated with liver cancer (Hiraoka et al.
2003; Boldogh et al. 1983; Hashiro et al. 1979; Sanford et al. 1977; Huang and
Roche 1978). A number of the viruses belonging to the human herpes family
have been incriminated as etiological factors for several human cancer types,
including cervical carcinoma, prostate and colon adenocarcinoma as well as
Kaposi's sarcoma (McDougall et al. 1980; McDougall et al. 1984; Rawls et al.
1977; Zafiropoulos et al. 2003; Pacsa et al. 1975; Stoian et al. 1982; Boldogh et
al. 1983; Sanford et al. 1977; Hashiro et al. 1979; Huang and Roche 1978;
Boldogh et al. 1981; Giraldo et al. 1980; Giraldo et al. 1978). The Epstein-Barr
virus has also been implicated in nasopharyngeal cancer and African Burkitt's
lymphoma (Zafiropoulos et al. 2003; Higginson et al. 1992; zur Hausen et al.
1970). The latest epidemic, human immunodeficiency virus (HIV) is also known
to be associated with an increased risk for the development of cancers such as
Kaposi's sarcoma (Newton et al. 2003). Cancers of the penis, vulva and cervix
have also been associated with the human papilloma viruses (HPVs) (Buffet et
al. 2002; Waggoner 2003; Higginson et al. 1992; Rodriguez-Pinilla et al. 2003;
Canavan and Cohen 2002).
Furthermore, retroviruses are also known to activate proto-oncogenes by a
process known as insertional mutagenesis, whereby the insertion of a DNA copy
of the retrovirus into the host genome close enough to a proto-oncogene, is
sufficient to induce abnormal activation of that gene, resulting in malignancy.
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The larynx, also known as the voicebox, is situated in the neck and plays a
central role in speech as well as breathing. It is at this point of the throat that the
common aerodigestive tract splits into the trachea (for breathing) and the
esophagus (for swallowing) (The Voice Centre at Eastern Virginia Medical
School - The Larynx 2001). Furthermore, the vocal chords (vocal folds) are
positioned in the center of the larynx (The Voice Centre at Eastern Virginia
Medical School - The Larynx 2001). Cancer of the larynx (Figure 1.3), which is
sometimes simply referred to as throat cancer, falls in the category of head and
neck cancers.
(a) (b)
Figure 1.3 The larynx (a) The larynx is situated where the common aero-digestive tract
divides into the trachea (for breathing) and the esophagus (for swallowing)
(INTERNATIONAL ASSOCIATION OF LARYNGECTOMEES 2003). (b) A photo of a
typical laryngeal cancer tumor seen on the right vocal chord (Lutte contre Ie Tabac
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This is the sixth most common cancer type in the world (Vokes et al. 1993), and
after lung cancer, it is the second most common type of respiratory cancer
(Cattaruzza et al. 1996), affecting approximately 500 000 new individuals
annually (Dahse et al. 1999). Nearly all are squamous cell carcinoma (SCC)
(Higginson et al. 1992; Gorgoulis et al. 1994; Batsakis 1979), a type of cell that
lines a portion of the larynx and when a malignant tumor arises within this lining,
it is referred to as laryngeal squamous cell carcinoma (The Voice Centre at
Eastern Virginia Medical School - The Larynx 2001). Typical symptoms of
laryngeal cancer (LC) include throat pain, hoarseness, ear pain, breathing
difficulty, coughing blood and lumps in the neck (The Voice Centre at Eastern
Virginia Medical School - The Larynx 2001). Commonly recognized prognostic
factors include the site of the primary tumor, the stage and histological grade of
the tumor, and the sex of the patient. A combination of these factors determines
the appropriate therapy for each individual. To date, the leading cause of
treatment failure, specifically after surgical removal, remains recurrences due to
the presence of tumorigenic cells within the surgical margins and the cervical
lymph nodes (Gasparotto et al. 1995). Treatments of LC include radiation
therapy, chemotherapy and surgical procedures such as a laryngectomy, where
the larynx is partially or totally removed (The Voice Centre at Eastern Virginia
Medical School - The Larynx 2001). Total removal of the larynx renders the
patient incapable of what is known as laryngeal speech. In such cases, the
patient has a choice of three modes of alaryngeal speech; electrolaryngeal
speech, esophageal speech and trachea-esophageal speech (The Voice Centre
at Eastern Virginia Medical School - The Larynx 2001).
Even in high incidence populations, LC is very unusual before the age of 40 and
has been found to be rarer in females than in males (The Voice Centre at
Eastern Virginia Medical School - The Larynx 2001; Cattaruzza et al. 1996).
Generally, the overall 5-year survival rate for LC patients is approximately 60%
(Higginson et al. 1992; Rowley et al. 1998; Snow 1990). It has been shown that
within the South African population, LC occurs predominantly in the Coloured
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community (Hille et al. 1996) (The Coloured population is of mixed ancestry,
consisting mainly of Khoi origins, but also including Caucasian, African Malay
and San origins (Marais 1957)). Although there is little genetic information
concerning the linkage between xenobiotic agents and LC, there is strong
evidence that smoking and alcohol consumption (Osborne et al. 1997; McCoy
and Wynder 1979; Schmidt and Popham 1981; Tuyns 1991; Wynder and
Stellman 1977; Schottenfeld et al. 1974; Saunders et al. 1999; Jussawalla and
Deshpande 1971; The Voice Centre at Eastern Virginia Medical School - The
Larynx 2001; Altieri et al. 2002; Bagnardi 2001; Gorgoulis et al. 1994; Rowleyet
al. 1998; Hirvikoski et al. 1997) are involved in the development of LC, and
together account for 80-90% of all LC (Higginson et al. 1992). This has been
further confirmed by studies done in the UK where it was shown that LC is
common among occupations such as barmen where constant exposure to both
alcohol and tobacco smoking is inevitable (Higginson et al. 1992).
Furthermore, there is evidence that exposure to asbestos and nickel as well as
certain aspects of ethanol production and mustard gas manufacturing are risk
factors in the development of LC (Higginson et al. 1992). Although it has never
been confirmed, the possible role of a virus (e.g. HPV I and II) in the
development of LC cannot be excluded (Higginson et al. 1992; Barnard et al.
2003; Dyson et al. 1989; Scheffner et al. 1990; Nadal and Cardesa 2002;
Brandsma and Abramson 1989; Brandwein et al. 1993; Pérez-Ayala et al. 1990;
Gorgoulis et al. 1999; Lindeberg and Krogdahl 1999).
As mentioned earlier, tobacco smoke is one of the main culprits in the
development of LC and most tobacco-related carcinogens are activated by phase
I enzymes to the ultimate reactive intermediate. This ultimate reactive
intermediate is then capable of binding and damaging DNA directly, as explained
in section 1.3.2. It is clear then that defects in phase I activation enzymes could
confer increased susceptibility to the development of LC. The same argument
could be applied to phase II detoxification enzymes. Examples of such metabolic
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enzymes that either have been or are currently under investigation with respect
to LC susceptibility are glutathione-S-transferases (GST's), microsomal epoxide
hydrolase (EH) and cytochrome P450 (CYP) (To-Figueras et al. 2002; Strange et
al. 1998; Jahnke et al. 1995; Hong et al. 2000; Jourenkova et al. 1998; Gronau et
al. 2003; Jahnke et al. 1997).
Countless other studies have been conducted to determine the involvement of
genes that possibly confer increased susceptibility to the development of LC. A
summary of some of the most frequently investigated genes to date, in relation to
laryngeal cancer development or susceptibility, can be found in Table 1.6,
accompanied by their references.
Table 1.6 A summary of the most frequently investigated genes in relation to LC
development or susceptibility (Nadal and Cardesa 2002)
Gene Reference(s)
e-mye
EGFR
HRAS,KRAS,NRAS
Cye/in 01
Cye/in E
Rb
TP53
(Marcu et al. 1992; Dolcetti et al. 1991; de la Guardia et al.
2001; Fracchiolla et al. 1995; Haughey et al. 1992)
(Irish and Bernstein 1993; Scambia et al. 1991; Almadori et al.
1999)
(Anwar et al. 1993; Shidara et al. 1994; Fracchiolla et al. 1995;
Cazorla et al. 1998; Saranath et al. 1991; Yarbrough et al.
1994; Scambia et al. 1994)
(Somers et al. 1990; Berenson et al. 1989; Jares et al. 1994;
Dong et al. 2001)
(Dong et al. 2000)
(Scholnick et al. 1994; Scholnick et al. 1994; Jares et al. 1997)
(Maestro et al. 1992; Doleetti et al. 1992; Nadal et al. 1995; Xu
et al. 1994; Casey et al. 1996; Nadal et al. 1997; Ogawa et al.
2003; Liu et al. 2003; Vielba et al. 2003)
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continued ...
p21WAF1
p16INK4a
UDP-
glucuronosyltransferase
1A7 (UGT1A7)
TNF
TGFR
Telomerase
Adhesion molecules and
extracellular matrix
components
(Harper et al. 1993; EI-Deiry et al. 1993; Nadal et al. 1997)
(Serrano et al. 1993; Kamb et al. 1994; Merlo et al. 1995; Wing
Yuen et al. 2002; Jares et al. 1997; Jares et al. 1999; Kamijo et
al. 1997)
(Zheng et al. 2001)
(Matthias et al. 2001; Matthias et al. 1998)
(Massagué 1998; Franchi et al. 2001; Sardi et al. 2001)
(Luzar et al. 2001; Hohaus et al. 1996)
(Goussia et al. 2000)
Matrix metalloproteinases (Abramson et al. 1975; Osmak et al. 1999; Osmak et al. 2001)
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The esophagus (gullet) is a long, muscular tube connecting the throat to the
stomach, stretching at least 10 cm in an adult (cancerBACUP 2000) (Figure 1.4).
Typical symptoms of esophageal cancer (EC) include swallowing difficulty,
unexplained weight loss, pain during swallowing, hoarseness, chronic coughing,
vomiting and hiccups with treatments including surgery, radiotherapy and
chemotherapy (cancerBACUP2000). There are two histological types of EC, the
first one known as squamous cell carcinoma or SCC (Ribeiro et al. 1998;
Higginson et al. 1992), accounting for approximately 80-90% of EC (Higginson et
al. 1992). The other form of EC is known as adenocarcinoma, and accounts for
the remaining 10-20% (Higginson et al. 1992). Approximately half of the SCC's
occur in the middle of the esophagus, while the majority of adenocarcinoma
occur in the lower third and are usually associated with Barrett's esophagus
caused by acid reflux (Higginson et al. 1992; cancerBACUP 2000; Montesano et
al. 1996; Spechier et al. 1994). Individuals with chronic gastro-esophageal reflux
are most at risk for the development of this type of cancer (Montesano et al.
1996; cancerBACUP 2000; Thomas and Sobin 1995).
(a) (b)
Figure 1.4 The esophagus (a) The esophagus is situated behind the trachea and
leads to the stomach (Healthcommunities.com 2003). (b) A photo of a typical
esophageal tumor (gihealth.com 1997).
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By 1980 EC was the 6th most common cancer in the world, taking 4th place in
developing countries and 15th place in developed countries (Higginson et al.
1992). Today it is ranked amongst the 10 most frequent cancer types in the
world with more than 300 000 new cases annually (Montesano et al. 1996;
Parkin et al. 1993). Known as one of the most lethal cancer types, it boasts with
a 5-year survival rate of less than 10%, a statistic that has remained unchanged
over the last three decades (Ribeiro et al. 1998; Hendricks and Parker 2002;
Berrino et al. 1995; Montesano et al. 1996). It has also been shown that males
are at a higher risk for the development of EC, with the average age of
presentation being at 56 years (ManneIl and Murray 1989). Notorious for
occurring mostly in developing countries (Montesano et al. 1996; Parkin et al.
1993), the highest incidence and mortality rates can still be found in the 'Asian
esophageal cancer belt', stretching from Eastern China to Russia and Turkey
(Higginson et al. 1992; Yang 1980) as well as northern Iran, and parts of Iraq
(Canon 1997; Day 1994; Joint Iran International Agency for Research on Cancer
group Study 1977). Certain black communities of Southern Africa (Transkei,
Uganda and Zimbabwe) also show very high rates, with South Africa showing the
highest incidence (Canon 1997) (Figure 1.5).
Figure 1.5 The distribution
of the highest incidence
rates of esophagealcancer
(Poon 2(03).
Stellenbosch University http://scholar.sun.ac.za
35
It was first noticed in 1957 that there was a high incidence of EC amongst the
Xhosa speaking people of the Transkei and by 1992, EC was reported to be a
serious health problem in South Africa, affecting both males and females (Sitas
and Mqoqi 1992). Today, this disease is the most common cause of cancer-
related deaths in South African black males (Gamieldien et al. 1998; Vizcaino et
al. 1995; Sitas and Mqoqi 1992; Sitas et al. 1998). In general it can be said that
this disease preferentially attacks groups with a lower socio-economic status or
those afflicted by poverty (ManneIl and Murray 1989), possible due to the
contribution of malnutrition.
As for most other tumors, EC tumorigenesis is a complex, multi-factorial process,
involving numerous suspected risk factors. (Ribeiro et al. 1998; Sur and Cooper
1998; Montesano et al. 1996; Gamieldien et al. 1998). The following section will
briefly discuss merely a few of these suggested risk factors.
Tobacco smoking, alcohol consumption, betel chewing and some dietary habits
have been identified as the major risk factors in ESSC, where tobacco and
alcohol are relevant in Europe and North America. However, in the high-risk
areas of China and northeast Iran, dietary habits are more closely involved than
tobacco and alcohol consumption (Bagnardi 2001; Bagnardi et al. 2001; Gallus et
al. 2001; Pacella-Norman et al. 2002).
These risk factors can be used as criteria for further sub classifications of ESCC;
those arising as a result of alcohol and tobacco consumption, which is the
predominant group, and those due to other factors (Higginson et al. 1992).
Some studies have tried to further categorize this by showing a possible higher
risk for smokers of pipes and hand-rolled cigarettes (Tuyns and Esteve 1983;
Segal et al. 1989) or an increased risk for smokers of high-tar cigarettes (La
Vecchia et al. 1986; Higginson et al. 1992). Other observations suggest that the
swallowing of smoke condensates is worsened by alcohol, which acts as a
solvent for such condensates (Higginson et al. 1992).
Stellenbosch University http://scholar.sun.ac.za
36
The involvement of fumonisin (a family of mycotoxins produced by Fusarium
moniliforme and F. proliferatum) contaminated maize has also been suggested to
play a major role in the development of ESCC (Marasas 1996; Chu and Li 1994;
Yoshizawa et al. 1994).
Even viral agents, such as the human papilloma virus (HPV) have been
implicated in the development of ESCC (Peto 2001; Lavergne and de Villiers
1999; Matsha et al. 2002).
Other factors have also been researched with regards to their potential
involvement in cancer development, and include iron status (Isaacson et al.
1985; MacPhail et al. 1979) allelic imbalance and microsatellite instability
(Naidoo et al. 1999), vitamins and lipotrope deficiencies (Jaskiewicz et al. 1988)
and several geochemical factors (Kibblewhite et al. 1984) .
Furthermore, numerous studies have been conducted on genes, or the
expression of their respective protein products, suspected of conferring genetic
susceptibility to the development of EC, such as the ras protooncogenes (Victor
et al. 1990), cyclin A (Chetty and Simelane 1999), cyclin D1 and retinoblastoma
(Chetty and Chetty 1997) as well as the androgen receptor gene (Dietzsch et al.
2003). Several more such examples can be found listed in Table 1.7 (Mandard
et al. 2000).
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Table 1.7 A summary of the most frequently investigated genes in relation to EC
development or susceptibility
Gene Reference(s)
TP53 I (Hollstein et al. 1991a; Gao et al. 1994; Montesano et al. 1996)
(Vos et al. 2003)
p16/CDKN2,p15 (Xing et al. 1999; Montesano et al. 1996; Busatto et al. 1998)
(MTS1 )
Cyclin D1 I (Jiang et al. 1993; Montesano et al. 1996)
EGFR (Hollstein et al. 1988; Lu et al. 1988; Montesano et al. 1996)
c-myc (Montesano et al. 1996)
Rb (Montesano et al. 1996; Jiang et al. 1993; Busatto et al. 1998)
TOC (von Brevern et al. 1998; Iwaya et al. 1998)
FEZI (Ishii et al. 1999)
DLC1
(Xu et al. 1999)
(Daigo et al. 1999)
RARI3
GST's (van Lieshout et al. 1999; Hori et al. 1997; Lin et al. 1998a; Lin et
al. 1998b; Tan et al. 2000; Lee et al. 2000; Tan et al. 2001; Wang
et al. 2002; Adams et al. 2003; Lin et al. 1998a)
CYP
I
(Lin et al. 1998b; Tan et al. 2000; Wang et al. 2002; Itoga et al.
. 2002)
Cytoplasm ic-l3-
catenin
I (Kimura et al. 1999)
iNOS (Tanaka et al. 1999)
SULT1A1 (Wu et al. 2002)
TP73
(Matsuo et al. 2001; Watanabe et al. 2002; Boonyaphiphat et al.
2002)
ADH's (Hori et al. 1997; Boonyaphiphat et al. 2002; Ballo et al. 2003)
ALDH's
XRCC1 ,ERCC1,
XPC,XPD,XPF,
SRCC3
(Lee et al. 2001; Xing et al. 2002; Goode et al. 2002)
(Nimura et al. 1998)
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These are all merely a few examples of the most frequently investigated genes
that have been investigated based on the grounds of suspicion of their
involvement in conferring susceptibility to the development of EC. This goes to
prove that the genetic component of EC research is a large one, encompassing
numerous facets and remains to be solved.
One of the genes found in both Tables 1.6 and 1.7 is TP53. In 1989, the first
TP53 mutations associated with cancer were identified and within the following
ten years, 10 000 mutations were described. Today, over 14 000 TP53
mutations are known (Hainaut 2001) in more than 10 000 different tumors
(Greenblatt et al. 1994), with EC and LC (head and neck cancer) ranking
amongst the top four cancer types with the highest TP53 mutation prevalence
(Figure 1.6).
~ mUbtlon preyat __
C-'_rded In th_lARe DIbbaM. RT)
Figure 1.6 The prevalence of TP53 mutations in several of the major cancer types
(IARC Database 2003).
To date, more than 13000 publications have come from this topic (Midgley and
Lane 1997; Soussi 2000).
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1.6 TP53 and Friends
Tumor progression is associated with cumulative genetic changes as a result of a
loss of cell cycle control. The progression of the cell cycle is constantly
monitored for DNA damage at the G1-S and G2-M boundaries and genetic
analysis has revealed in the involvement of tumor suppressor proteins in this
process. An example of such a tumor suppressor protein is p53, which has
earned it the renown title of 'guardian of the genome' (Sherbet and Lakshmi
1997; Sun.Y. et al. 1999; Adams and Kaelin 1998b). This protein has been found
to respond to a number stressful stimuli, including DNA damage (for example,
due to X-rays, gamma-rays, and UV oxidative stress) hypoxia, heat shock,
metabolic changes, certain cytokines and certain oncogenes, such as c-myc,
E1F1 and E1A (Steele et al. 1998; Hainaut 2001; Klug and Cummings 1997).
The consequence of p53 activation is the activation of a series of events resulting
in the cell being destined for one of two routes; either the DNA damage is
repaired, where possible, or the cell undergoes programmed cell death, a
process known as apoptosis (Adams and Kaelin 1998b; Pai et al. 1998; Hainaut
2001; Steele et al. 1998) (Figure 1.7).
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Figure 1.7 The course of DNA damage. When DNA damage is detected, the cells
are destined for one of two routes; either the DNA damage is repaired, where
possible, or the cell undergoes programmed cell death, a process known as
apoptosis. p53 has been shown to be involved in this process (Rotter et al. 2003).
First identified more than 20 years ago, it is widely accepted today that TP53
mutations are frequent events in the tumorigenesis of several cancers with the
mutational spectrum varying greatly amongst different types of cancers (Yamada
et al. 2003; Gottschlich et al. 2000; Soussi et al. 2000; Gamieldien et al. 1998).
Li-Fraumeni cancer family syndrome, interestingly, is caused by a germline
mutation in the core domain of TP53 (exons 5 to 8) (Steele et al. 1998; Bishop et
al. 1996; Midgley and Lane 1997; Adams and Kaelin 1998b) and leaves affected
individuals predisposed to the development of a range of cancer types, including
breast carcinoma, soft tissue sarcoma, brain tumors, osteosarcoma, leukemia,
and adrenocortical carcinoma (Srivastava et al. 1990; Malkin et al. 1990; Bishop
et al. 1996). TP53 is located on chromosome 17 at locus p13.1 (Imazeki et al.
1992; Toguchida et al. 1992; Soussi et al. 2000; Gorgoulis et al. 1994) and codes
for a 2,8kb mRNA transcript (Sherbet and Lakshmi 1997). Named the "molecule
of the year" in 1996 by Newsweek magazine, the product of TP53, known as
p53, is a 53-kDa phosphoprotein consisting of 393 amino acids ( Bishop et al.
1996; Imazeki et al. 1992; Soussi et al. 2000; Steele et al. 1998) which functions
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as a transcription factor (Toguchida et al. 1992; Bishop et al. 1996; Gorgoulis et
al. 1994), capable of inducing cell cycle arrest in the G1 phase should any DNA
damage be detected (Ribeiro et al. 1998; Soussi et al. 2000; Kastan et al. 1991;
Smith et al. 1994). Furthermore, p53 has also been found to playa role in DNA
synthesis and repair (Harris 1996; Ribeiro et al. 1998; Hainaut 2001; Kastan et
al. 1991), maintenance of DNA stability (Harris 1996; Ribeiro et al. 1998; Lane
1992), as well as cell proliferation and apoptosis (Harris 1996; Ribeiro et al.
1998; Hainaut 2001; Soussi et al. 2000). Highly conserved in all species studied
to date, this gene consists of 11 exons, of which the first one is non-coding. This
is followed by a large 10kb intron (Sherbet and Lakshmi 1997; Imazeki et al.
1992; Lamb and Crawford 1986b). Two regulatory promoter sites control the
transcription of this gene; the first (P1) occurs 400bp upstream of exon 1 and the
second (P2) occurs within intron 1, approximately 1kb downstream of P1 (Harlow
et al. 1985; Hainaut 2001; Reisman et al. 1988; Tuck and Crawford 1989;
Sherbet and Lakshmi 1997). Furthermore, 5 highly conserved regions have
been identified; region I (codons 13-19), region II (codons 120-143), region III
(codons 172-182), region IV (codons 238-259) and region V (codons 271-290),
i.e. in exons 4, 5, 7 and 8 (Sherbet and Lakshmi 1997; Macdonald and Ford
1991; Levine et al. 1994; Vogeistein and Kinzler 1992). It has been shown that
mutations are prone to occur in clusters, or hotspot regions, specifically in
conserved regions II-V (Sherbet and Lakshmi 1997; Hainaut 2001; Ribeiro et al.
1998; Steele et al. 1998).
As suspected, it was later shown that these regions do in fact code for an
important functional domain of the final protein product (Figure 1.8), representing
the sequence-specific DNA-binding site which stretches from amino acid residue
90 to 290 (Sherbet and Lakshmi 1997; Bishop et al. 1996; Cho et al. 1994;
Hainaut 2000).
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Figure 1.8 The structural organization of TP53; where E and I respectively
indicate the exon and intron number followed by their length in number of
nucleotide bases (Soussi 2001).
This central DNA binding domain contains 10 cysteine residues, which suggest
the involvement of metal ions (Sherbet and Lakshmi 1997). This has in fact been
shown to be true by proving that chelating agents abolishes DNA binding. It has
therefore been suggested that p53 is a metalloprotein (Sherbet and Lakshmi
1997; Pavletich et al. 1993) which occurs and functions predominantly as a
tetramer. It therefore follows that oligomerization is an essential step prior to DNA
binding (Sherbet and Lakshmi 1997; Stenger et al. 1992; Friedman et al. 1993).
A 53-amino acid C-terminal domain, referred to as the oligomerization domain,
mediates the formation of these stable tetramers (Sherbet and Lakshmi 1997;
Macdonald and Ford 1991; Hainaut 2001; Pavletich et al. 1993). DNA-protein
binding is subsequently allosterically regulated by changes in the conformation of
these tetramers between states of high and low affinity for DNA (Hupp et al.
1992; Sherbet and Lakshmi 1997; Halazonetis et al. 1993; Halazonetis and
Kandil 1993). Hetero-oligomers have also been found to form between wild type
and mutant p53, which are unable to bind to DNA (Sherbet and Lakshmi 1997;
Bishop et al. 1996; Milner and Medcalf 1991; Bargonetti et al. 1992) and thus one
mutant allele is enough to completely eliminate p53 activity, acting in a "dominant
negative" fashion.
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The biochemical basis for p53 function lies in its ability to regulate transcription
by direct binding to DNA via the DNA binding domain (Zubay 1993; Sherbet and
Lakshmi 1997), which lies between residues 90 and 290 (Sherbet and Lakshmi
1997). The consensus sequence required for p53 binding to DNA is 5'-Pu-Pu-
Pu-C-AfT-AlT-G-Py-Py-Py-3' (Sherbet and Lakshmi 1997; EI-Deiry et al. 1992;
Funk et al. 1992; Kern et al. 1992) and p53 will enhance the transcription of any
gene that contains a p53 responsive element (Sherbet and Lakshmi 1997;
Farmer et al. 1992; Zarnbetti et al. 1992). It has been shown that the TATA-
binding protein (TBP) interacts with p53 and that this TBP-p53 complex binds to
the TATA-box, which is known to be one of the genetic elements controlling the
transcription of most genes. It has been further suggested that the nature of this
complex could possibly determine the success of p53 induced transcription
(Sherbet and Lakshmi 1997; Martin et al. 1993). This has been confirmed by
showing that in vitro p53 binds only when nuclear extracts are present, indicating
that either p53 undergoes post-translational modification, or, that it may need to
form complexes with other nuclear proteins (Sherbet and Lakshmi 1997; Funk et
al. 1992), such as TBP (Sherbet and Lakshmi 1997).
A number of genes have been shown to contain the appropriate regulatory
sequences capable of binding p53 and whose activity is altered by that
interaction, and depending on the gene involved, the effect could be either
stimulatory or inhibitory (King 1996). In general, four cellular responses are
influenced by p53 interaction with such genes, namely; cell proliferation,
apoptosis, DNA repair and angiogenesis (the growth of new blood vessels)
(Figure 1.9) (King 1996).
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Figure 1.9 p53 Regulates transcription of several genes; solid arrows
indicate activation and broken arrows indicate inhibition (King 1996).
Further examples of genes that are regulated by p53 interaction include: jJ-actin,
HSP70, JUN, FOS, and PCNA (Sherbet and Lakshmi 1997; Chin et al. 1992;
Subier et al. 1992; Zastawny et al. 1993). Some genes are completely repressed
by p53, and include SV40 early promoter enhancer, herpes simplex virus type 1
(HSV-1), thymidine kinase, T-Iymphoblastic virus type 1 and certain LTR
promoters of Rous sarcoma virus and human immunodeficiency virus (HIV)
(Sherbet and Lakshmi 1997; Subier et al. 1992).
Several viral as well as cellular proteins have been found to interact with and
inactivate p53, such as E1B encoded by the adenovirus, E6 encoded by the
human papilloma virus, the X protein encoded by the hepatitis B virus and MOM2
(murine double minute 2), found in human tissues (King 1996; Bishop et al. 1996;
Sherbet and Lakshmi 1997).
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The MDM2 gene has been mapped to chromosome 12q13 and the expression of
its phosphoprotein product has been found to be associated with highly
tumorigenic potential (Bishop et al. 1996; Sherbet and Lakshmi 1997; Cahilly-
Snyder et al. 1987). Multiple transcripts of MDM2 have been identified in breast
epithelial cells, with the protein products ranging from 54 - 68 kDa to 90 - 10
kDa (Sherbet and Lakshmi 1997; Gudas et al. 1995). Furthermore, MDM2 has
been found to be transcriptionally activated by p53, resulting in MDM2 targeting
p53 for destruction, forming an auto regulatory mechanism. (Sherbet and
Lakshmi 1997; Steele et al. 1998; Momand et al. 1992). If p53 is mutated,
MOM2 transcription cannot be induced and thus p53 accumulates (Steele et al.
1998; Midgley and Lane 1997). This indicates that p53 stability depends more
on binding to MDM2 than by any mutation contained (Steele et al. 1998; Lane
and Hall 1997).
The C-terminal domain also contains a signal for nuclear localization (Sherbet
and Lakshmi 1997; Dang and Lee 1989; Addison et al. 1990; Shaulsky et al.
1990), and thus p53 is seen to be a nuclear protein. This has been confirmed by
showing that in cases where mutations occur within this C-terminal region, the
protein was found to be localized within the cytoplasm (Sherbet and Lakshmi
1997; Sturzbecher et al. 1988). Some groups have even found it to be present in
both locations (Sherbet and Lakshmi 1997; Moll et al. 1992; Stenmark-Askmalm
et al. 1994). Similarly, it has been found that mutations occurring even within the
proximity of the nuclear localization signal domain could affect the eventual
localization of p53 (Sherbet and Lakshmi 1997; Diller et al. 1990).
In general, it can be said that p53 is expressed at very low levels in normal cells
(Steele et al. 1998; Soussi et al. 2000; Gottschlich et al. 2000; Sherbet and
Lakshmi 1997) and it has a short half-life, approximately 2-15 min (Montesano et
al. 1996; Sherbet and Lakshmi 1997). However, high levels of this protein have
been found in many tumors, resulting from an increase in p53 stability leading to
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a longer half-life, which is usually associated with TP53 mutations (Steele et al.
1998; Midgley and Lane 1997; Pai et al. 1998; Hainaut 2001 .).
Several other functional domains have also been identified within TP53, showing
similarity to heat shock proteins, MDM2 and SV40 large T-antigen-binding
domains (Figure 1.10).
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Figure 1.10 The structural and functional domains of p53 (Sherbet and Lakshmi
1997).
It has been known for several years that one the mechanisms of gene regulation
is the generation of splice variants. Although no alternative splice variants of p53
have been identified in rat tissues, p53 psuedogenes have been found, which is
suggested to have been the result of the incorporation of spliced mRNA's into the
germline (Sherbet and Lakshmi 1997; Lin and Chan 1995). Furthermore, the
expression of splice variants have been reported in mouse epidermal cells,
where the predominant form is said to be expressed during the G1 phase and an
alternative splice variant, with an additional 96 nucleotides, is expressed mainly
in the G2 phase (Sherbet and Lakshmi 1997; Kulesz-Martin et al. 1994; Bayle et
al. 1995). Also, spliced p53 transcripts have been found to occur in normal
human lymphocytes. It has therefor been suggested that p53 splice variants may
be expressed in a tissue- or even a species-specific fashion and may possibly
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have a role in the regulation of the function of this gene (Sherbet and Lakshmi
1997; Will et al. 1995).
As mentioned earlier, p53 function may be impaired by mutations or even by
alternative splicing, but there are several other factors that also need to be
considered.
By now it is clear that genetic alterations of TP53 and its dysfunction as a
consequence leads to the deregulation of cell proliferation and eventually to
tumorigenesis (Sherbet and Lakshmi 1997; Zambetti and Levine 1993; Gorgoulis
et al. 1994; Steele et al. 1998). In general, approximately 60% of all human
cancers show TP53 mutations together with a loss of heterozygosity (LOH) which
results in the total loss of wild type alleles (Sherbet and Lakshmi 1997; Levine et
al. 1991). It has also been found that the conserved regions II-V carry 86% of all
the known mutations of p53 and that 68% are missence mutations (Sherbet and
Lakshmi 1997). Such missenee mutations lead to the production of a defective
protein product that cannot bind to its target genes via their p53 responsive
elements (Sherbet and Lakshmi 1997). It has further been found that the
consequence of mutations such as allelic deletions, rearrangements or base pair
substitutions within TP53 results in a protein which often has not only lost its
tumor suppressor function, but rather has gained several new functions which
manifest themselves phenotypically within tumors (Sherbet and Lakshmi 1997).
In addition to loss of function mutations, there is evidence to suggest that some
TP53 mutations may enhance tumorgenicity (Montesano et al. 1996). Over 2000
inactivating mutations have been identified in TP53 (King 1996) and the
malfunctioning of this popular protein has been regarded as a significant event in
the pathogenesis of a number of cancers, including breast, colon, stomach,
bladder, ovary, endometrium, testicular tumors, soft tissue sarcomas,
melanomas and hematological malignancies (Sherbet and Lakshmi 1997; Klug
and Cummings 1997; Berchuck et al. 1994; Liu et al. 1994). The most frequent
mutation is found in codon 248, which codes for an arginine, which binds directly
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to DNA. This codon has been found to not only be affected in somatic cells, but
also in inherited germ line mutations, such as in the case of Li-Fraumeni
syndrome in which patients experience multiple cancers (King 1996). Mutations
in the very next codon, 249, have been found in aflatoxin-induced hepatic
carcinomas (King 1996). In breast cancer, TP53 mutations occur at an incidence
of 25-40%, with the frequency of G-T transversions being higher than expected,
and occurring predominantly within the conserved regions of exons 5-8 (Sherbet
and Lakshmi 1997). Another mutational hotspot occurs at codon 273 in ovarian
and pancreatic tumors (King 1996). In lung cancer, hotspots are found at codons
157, 248, 249 and 273 (King 1996). In esophageal and lung cancers, TP53
mutations arise earlier in disease progression (Sherbet and Lakshmi 1997;
Bennet et al. 1992; Sozzi et al. 1992) and it has been shown that a law frequency
of point mutations occur in approximately 1 in every 10 sec and in one in every
14 adenocarcinomas as well as in 4 out of every 7 Barrett's epithelium adjacent
to adenocarcinomas in the esophagus (Sherbet and Lakshmi 1997).
In summary, the codon and type of p53 mutation varies according to the cancer
type as well as the geographical distribution (King 1996) and with this study, we
intend to obtain clues as to the type of environmental factor(s) that may playa
role within our unique South African communities.
1.7 The Present Study
The aim of the present study was to analyze the molecular structure of TP53 as
well as the transcription levels thereof, using DNA and RNA obtained from
patients suffering from esophageal and laryngeal cancer, two cancers of the
upper gastro-intestinal tract known to occur at high frequencies in South Africa.
These studies were approved by the IRB of Stellenbosch University (95-069 and
97/030).
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2.1 Overview
The motivation for this study lies in the finding that laryngeal cancer in South
Africa occurs at a high incidence, relative to the rest of the world, and is
particularly common among the Coloured males. The aim of this study was
thus to analyse the molecular structure of TP53, specifically exons 5 - 8, in a
group of laryngeal cancer (LC) patients treated at Tygerberg Hospital, Cape
Town, South Africa. This included screening the DNA of patients as well as a
control group via PCR-SSCP and direct sequencing analysis. The
participants of this study were also asked to complete questionnaires in order
to determine possible etiological factors, and this, together with the data
obtained from the molecular screening, was used to establish correlations
between the occurrence of LC, the type of mutations observed, and the
various etiological factors under investigation. The more long term goals of
this study would be to determine whether TP53 mutations in primary laryngeal
cancer tumors have any implication in the recurrence rate of these tumors
even after complete surgical removal. The value of such knowledge has far
reaching effects in practice, placing physicians in an advantageous position in
determining the appropriate therapies for each individual patient.
The institutional ethics committee approved this study and informed consent
was obtained from all subjects.
The work discussed in this chapter has been submitted and accepted
for publication in Cancer Genetics and Cytogenetics (Barnard et al.
2003) and a copy of the pre-print can be found in Appendix I.
Furthermore, this work has been presented (by D.Barnard) at an
international conference entitled: Cancer of the Esophagus and Gastric
Cardia: From Gene to Cure, held in Amsterdam, the Netherlands during
the period 13 -15 December 2002.
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2.2 Materials and Methods
2.2.1 Collection of tumor samples
Fresh tumor biopsies were obtained from 44 LC patients. They consisted of
22 Coloured males, 8 Coloured females, 6 African Black males, 2 White
males and 6 were of an unidentified ethnicity. All 44 patients received
treatment and underwent surgery at Tygerberg Hospital, Cape Town, South
Africa, during the period from January to December 2000. The age of the
patients ranged between 41 and 78 years of age, with a mean of 58 years.
Upon removal, each biopsy was divided into two equal parts. One half was
used to histologically confirm poorly differentiated to well differentiated
squamous cell carcinoma. The second half of the tissue was snap-frozen in
liquid nitrogen immediately after surgical removal and stored at -70°C for
further molecular analysis in disposable polypropylene cryogenic vials
(Appendix II).
2.2.2 Collection of blood samples
Blood samples were collected in 5 ml disodium ethylenediaminetetraacetate
dehydrate (EDTA) tubes (Appendix II) from 42 of the same patients and
frozen for further molecular analysis. Data obtained from the blood samples
would serve as a control to test for a loss of heterozygosity (LOH). This would
serve as an indication as to whether any nucleotide alterations observed
within the tumor samples was somatic in origin, or whether they were
germline mutations.
In addition, blood was collected in 5ml EDTA tubes (Appendix II) from a
healthy control group consisting of 40 volunteers who were matched to the
patients according to age, gender and ethnic group. This would enable us to
distinguish true nucleotide alterations from polymorphisms known to occur
within the population.
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2.2.3 Collection of demographic data
Questionnaires were compiled in order to evaluate various aspects of the
participants' lifestyle, including physical as well as dietary exposures. Both the
patients as well as control group completed these questionnaires. An
example of this questionnaire can be seen in Appendix IV.
The data obtained from these questionnaires were used to construct a
database, which would be used for future correlation studies.
2.2.4 DNA extractions
2.2.4.1 Tumor Samples
DNA was extracted from the tumor biopsy samples using the QIAmp DNA
minikit. A glass slide (Appendix II) was weighed and, using a new, sterile
scalpel blade (Appendix II) for each individual biopsy, the frozen biopsies
were cut into smaller fragments on the glass slides (on ice) and weighed
again. The weight of the biopsy was taken as the difference between these
two weight measurements. The protocol for the DNA extraction was then
followed according to the specifications of the manufacturer, except in the
case of a biopsy sample weighing more than 25mg, where all the reagent
quantities were doubled.
2.2.4.2 Blood Samples
DNA was extracted from the blood samples according to an adaptation of the
salting-out procedure for human DNA extraction (Miller et al. 1988).
Essentially, each blood sample was transferred from the 5 ml EDTA tubes
(Appendix II) into 50 ml Falcon tubes (Appendix II) to which 5 - 6 volumes of
ice-cold cell lysis buffer (Appendix III) was added. The tubes were inverted
10x and this was followed by a 15-minute centrifugation (Appendix II) step at
4°C and 3000 rpm. A pellet was formed in the base of the Falcon tube which
Stellenbosch University http://scholar.sun.ac.za
86
was then resuspended in 9 ml nuclei lysis buffer (Appendix III), 1 ml 10%
sodium dodecyl sulphate (SOS; Appendix II), and proteinase K (Appendix II)
(to a final concentration of 100 ~lg/ml). After an overnight incubation period at
37°C, 3 ml saturated NaCI solution (> 6 M) (Appendix III) was added. This
was then followed by another 20-minute centrifugation (Appendix II) step at
4°C and 3000 rpm. The DNA was then precipitated by the addition of 100%
ethanol (Appendix II), and washed by adding 500 ul 70% ethanol (Appendix
III) and pipetting (Appendix II) up and down several times. A glass Pasteur
pipette was heated over a Bunsen burner in order to seal the tip. This sealed
tip was then used to remove the precipitated DNA strands and transfer it to a
clean 1,5 ml Eppendorf microfuge tube. The DNA was finally resuspended in
200 ul TE buffer (Appendix III).
The optical density (00) of the DNA was then determined using a Milton Roy
series 1201 spectrophotometer at 260 nm (00260). The concentrated DNA
was then diluted by adding 10 ul concentrated DNA to 490 ~ddH20 and the
DNA concentration determined by multiplying the 00260 by a factor of 2.5.
This gave an answer of DNA concentration in ~lg/~I. The purity of the DNA
was also determined by calculating the 00260/ 00280 ratio, which is optimally
at approximately 1.8 for pure DNA.
2.2.5 Polymerase Chain Reaction/PCR
2.2.5.1 Principals of PCR
Polymerase chain reaction (PCR) is a technique by which a specific target
region of known or unknown sequence is exponentially amplified. This is
achieved by designing oligonucleotide (primers) capable of complementary
binding to the regions flanking the region of interest (Figure 2.1).
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2.2.5.2 Oligonucleotide primers
PCR has the ability to exponentially amplify very specific regions of DNA.
This is achieved due to the specificity of the primers used. These primers are
usually designed in such a way that they are complementary to the
sequences flanking the region of interest, allowing for them to bind these
sites. When the DNA is denatured into its single stranded form, an enzyme
known as DNA polymerase seeks these primers, and initiates a copying
process in the 5' - 3' direction, whereby the primers serve as a starting point,
and the original DNA serves as a template.
For the purpose of this study, primers were synthesised as previously
described (Toguchida et al. 1992) (Table 2.1) using a Beckman Instruments
Oligo 1000M DNA synthesiser (Appendix II) at the Department of
Biochemistry, University of Cape Town (UCT), Cape Town, South Africa.
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Figure 2.1 Polymerase chain reaction (PCR) exponentially amplifies a specific
target DNA sequence with each passing cyde. Adapted from Microbiology 2nd
edition.
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Table 2.1 Forward (F) and reverse (R) primers for polymerase chain reaction
(PCR) amplification of exons 5 to 8 of TP53
Primer" I SequenceD Tm (0C)c
Exon 5-5'F ~ TTA TCT GTT CAC TTG TGC CC 58
Exon 5-5'R TCA TGT GCT GTG ACT GCT TG 58
Exon 5-3'F TTC CAC ACC CCC GCC CGG CA 68
Exon 5-3'R ACC CTG GGC MC CAG CCC TG 68
Exon 6F ACG ACA GGG CTG GTT GCC CA 64
Exon 6R CTC CCA GAC ACC CCA GTT GC 64
Exon 7F GGC CTC ATC TTG GGC CTG TG 64
Exon 7R CAG TGT GCA GGG TGG CM GT 64
Exon 8F CTG CCT CTT GCT TCT CTT TT 58
Exon 8R TCT CCT CCA CCG CTT CTT GT 58
"Exon 5 was amplified as two PCR products due to ItS large Size, where primers
set 5-5'F and 5-5'R amplified the 5' end and primer set 5-3'F and 5-3'R the 3' end,
bprimer sequences obtained from (Toguchida et al. 1992)
cTm is the optimal melting temperature for each primer set used in PCR amplification
during this study,
2.2.5.3 Methodology
The primers that were used to amplify each of exons 5 - 8 of TP53 using the
DNA obtained from all three sample sets (tumor biopsy, corresponding patient
blood as well as blood from the healthy control group) are listed in Table 2.1.
Each PCR mix contained the following: 10% Thermophilic DNA polymerase
10x buffer (Appendix 1111), Bovine Serum Albumin (BSA) (Appendix II) to a
final concentration of 1mg/ml, dNTP's to a final concentration of 2.5 mmol
each (Appendix II), MgCb to a final concentration of 1,5 mmol (Appendix II),
forward and reverse primers to a final concentration of 0.2 urnol each
(Appendix II), 1 - 2 units of Taq DNA polymerase (Appendix II), 250 ng DNA
template and deionised pure water (dH20) up to a final volume of 100 ul. All
the PCR's were performed in 500 ~d tubes (Appendix II) in a Biometra
Thermocycler (Appendix II) at a standard heating lid of 105°C, an initial
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denaturation period of 3 minutes at 93°C, a subsequent denaturation period of
1 minute at 93°C, an annealing period of 2 minutes at each of the respective
melting temperatures (Table 2.1), an elongation period of 2 minutes at 72°C,
and a final elongation period of 5 minutes at 72°C. For each PCR reaction, 35
cycles were performed. Extreme care was taken to prevent PCR
contamination, and all experiments included a control reaction tube in which
template DNA was replaced by dH20.
2.2.6 Gel Electrophoresis
2.2.6.1 12% Non-denaturing polyacrylamide gel electrophoresis
Successful PCR amplification as well as the absence of contamination was
verified by the electrophoresis of 10 ul of the amplified product on 12%
polyacrylamide minigels (Appendix III).
2.2.6.1.1 Casting the gel
The gels (Appendix III) were cast between two 100mm x 80mm glass plates.
The plates were first washed with Cal-liquid hand soap (Appendix II) and
rinsed with tap water. A wash with 70% ethanol (Appendix III) and drying with
paper towel followed this. One millimetre spacers where then placed on
either side of one of the back plate and the front plate placed on the spacers.
The plates were then inserted into the casting apparatus (Appendix II) and the
gel solution (Appendix III) poured between the two plates. The well-forming
comb was inserted and the gel was left to set for 30 minutes prior to loading
and electrophoresis.
2.2.6.1.2 Electrophoresis
After the gels had set, they were placed into the electrophoresis apparatus
(Appendix II) and the buffer chambers were filled with 1x Tris Boric acid EDTA
(TBE) (Appendix III) electrophoresis buffer.
Stellenbosch University http://scholar.sun.ac.za
91
Loading dye (5 ul) (Appendix III) was added to 10 ul of each sample and
loaded into the wells. A DNA marker (Appendix II) was always loaded in one
of the wells as a method of verifying the correct amplified product size.
The apparatus was then connected to an electrophoresis power supply and
electrophoresed at 150V for 1 to 11/2 hours.
2.2.6.1.3 Silver staining
After completion of electrophoresis, the electrophoresis apparatus was
disassembled. The gel was then removed and placed in a container
containing 100 ml of solution B (Appendix III) and gently shaken for 10 - 15
minutes. Solution B was then discarded and the gel rinsed in dH20. The gel
was then covered with 100 ml solution C (Appendix III) and once again gently
shaken, until the bands became visible (approximately 20 - 30 minutes). The
gel was then visually inspected on a white light illuminator and photographed
using a video printer (Appendix II).
2.2.7 Single-strand conformational polymorphism (SSCP) analysis
2.2.7.1 Principals of SSCP
Single-strand conformational polymorphism analysis is a rapid method of
detecting sequence variations. Under normal conditions, DNA has a double-
stranded helix conformation, however, when denatured, the DNA separates
into two single strands. These single strands, however, have the ability for
form secondary structures by folding and binding to itself via intrastrand
interactions. Each secondary structure is unique in that its conformation
determines its electrophoretic mobility. This leads to the conclusion that the
conformation and mobility of each single strand is directly dependant on its
nucleotide sequence, meaning that a single base change is enough to alter
this unique characteristic, resulting in a difference in electrophoretic mobility.
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Thus SSCP analysis provides a means of rapid detection of variations in
nucleotide sequence based on electrophoretic mobility.
For each of the three panels of samples analysed, a 6% mildly denaturing
polyacrylamide gel with 5% glycerol (Appendix III) was used for SSCP
analysis.
2.2.7.2 Methodology
2.2.7.2.1 6% polyacrylamide SSCP gels
2.2.7.2.1.1 Casting the gel
The gel was cast between two 445mm x 330mm glass plates. The plates
were first washed with Cal-liquid hand soap (Appendix II) and rinsed with tap
water. A wash with 70% ethanol (Appendix III) and drying with paper towel
followed this. Gelbond™ PAG polyester film (Appendix II) was attached to
the back plate by its hydrophobic side using 70% ethanol (Appendix III). The
front plate was also silinised with Gelslick (Appendix II), which would allow for
easier removal of the gel after electrophoresis. One-millimetre spacers where
then placed on either side of the back plate (with the hydrophilic side of the
Gelbond now facing up) and the front plate placed on the spacers, with the
silinised side facing towards the hydrophilic Gelbond surface. The plates
were then sealed together on all four corners using gel-sealing tape
(Appendix II) and the plates were inserted into the casting rubber boot
(Appendix II). The gel solution (Appendix III) was then poured between the
two plates onto the hydrophilic side of the Gelbond, allowing the gel to stick to
it, thus facilitating the handling of it. The well-forming comb was inserted in the
top and held in place by clamps. The gel was left on a horizontal surface to
set for approximately 30 minutes. Sufficient paper towel was wet and placed
over the well-forming combs and this was then covered by cling wrap
(Appendix II) and left in the horizontal position overnight.
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2.2.7.2.1.2 Electrophoresis
After allowing the gel to set overnight, the cling wrap (Appendix II), wet paper
towel and the casting boot (Appendix II) were removed. The gel was placed
in the electrophoresis apparatus (Appendix II) and sufficient 0.6x TBE buffer
(Appendix III) was poured in both the upper and lower buffer reservoir
chambers. The well-forming comb was removed the wells were washed with
the 0.6 x TBE (Appendix III) and a syringe in order to rid of any residual gel
solution.
Loading dye (7 ul) (Appendix III) was added to 7 ~tIof each sample and heat
denatured at 96 oe for 5 minutes. This was followed by immediately snap-
freezing the samples on ice for 5 minutes. The samples were loaded,
accompanied by a DNA marker (Appendix II) in one of the wells as a method
of verifying the correct amplified product size. The gels were electrophoresed
at a 1500V, 300mA and 50W for a period of 4 hours.
2.2.7.2.1.3 Silver staining
After completion of electrophoresis, the electrophoresis apparatus (Appendix
II) was disassembled. The gel-Gelbond structure was removed and stained
as discussed in section 2.2.6.1.3, except that 500 ml of solution B (Appendix
III) was used and 1 L of solution e (Appendix III).
2.2.7.2.2 Scoring of the 6% polyacrylamide SSCP gels
Each of the 6% SSCP gels (Appendix III) for exons 5 - 8 were scored
individually according to the various banding patterns. Scoring condition were
stringent, and to eliminate the possibility of overlooking a mobility shift caused
by a nucleotide change, bands of a very low intensity were often included in
the scoring procedure, as a precautionary measure. For each exon, peR
products obtained from tumor biopsy samples and from blood samples of the
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same patients were run adjacent to each other on addition 6% SSCP gels
(Appendix III). Representative samples from each unique banding pattern
were selected for DNA sequencing analysis.
2.2.7.2.3 Reproducibility of 6% polyacrylamide SSCP gels
To prove that these results were reproducibly, these representative samples
were again amplified and the amplicons were again analysed under identical
SSCP conditions, as described in section 2.2.7.2.1.
2.2.7.2.4 Second set of SSCP conditions: 8% polyacrylamide SSCP
gels
The same used in section 2.2.5.3 were evaluated under a second set of
SSCP conditions. This was done to improve the chances of detecting all
possibly nucleotide changes and to further prove reproducibility. The same
approach was used as described in section 2.2.7.2.1 with the exception that
an 8% polyacrylamide gel solution (Appendix III) was used instead of a 6%
polyacrylamide gel solution (Appendix III).
2.2.8 Sequencing analysis
2.2.8.1 Amplicon purification
Samples were subsequently selected for sequencing from all three of the
sample sets (tumor biopsies, blood from same patients and blood from
healthy control individuals) to represent at least one of each of the unique
banding patterns observed across exons 5 to 8. Amplicons were purified
using the Nucleospin kit (Appendix II), following the instructions
recommended by the manufacturer.
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2.2.8.2 Automated sequencing
The peR products were sequenced using the primers described in section
1.2.5.2 for the relevant exons. The Department of Genetics performed
automated sequencing at the University of Stellenbosch, Stellenbosch, South
Africa, using an ABlprism analyser (model 3100) (Appendix II).
2.2.9 Correlation studies
Dr. E.G. Hoal performed all mathematical calculations concerning the
correlation studies. The non-parametric Spearman rank correlation was
performed to determine any significant correlations between parameters
measured under demographic data and laryngeal carcinoma. SPSS version
10 software (Appendix II) was used and P:SoO.05 was considered statistically
significant.
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2.3 Results
2.3.1 12% Non-denaturing polyacrylamide gel electrophoresis
Before performing the SSCP analyses, successful amplification of all samples
were verified on 12% non-denaturing polyacrylamide gels, as can be seen in
Figure 2.2.
2.3.2 6% polyacrylamide SSCP gels
Mobility shifts were detected in exons 5, 7 and 8, but none in exon 6. The
results obtained from the various SSCP gels indicate that mobility shifts were
detected only within the patient tumor biopsy sample set and not within the
blood from the same patients sample set, neither in the blood from the healthy
control subjects. Representative examples of these SSCP gels can be seen in
Figures 2.2 - 2.12. This suggests that the nucleotide changes observed have
somatic origins and are not germline mutations neither population based
polymorphisms.
M 2 ~ 4 5 6 7 8 9 I0 I I I2.)- ........., ....., -- ....., _,.. ~ ~ ---J
Figure 2.2 A representative example of one of the 12% non-denaturing
polyacrylamide gels that were used to verify the presence of amplicons as well as
the absence of DNA contamination during peR. This gel demonstrates the
successful amplification of exon 8 for samples as well as the absence of
contamination of the negative lane (-). A DNA marker (Appendix III) was loaded in
lane M.
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Figure 2.3 (a) A representative example of the SSCP banding patterns
detected in exon 5 of TP53 in DNA obtained from the tumor biopsy samples of 7
representative patients; on a 6% polyacrylamide SSCP gel.
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Figure 2.3 (b) A representative example of the SSCP banding patterns detected in
exon 5 of TP53 in DNA obtained from the corresponding blood of 7 of the patients
(left) and from the blood of 7 members of the healthy matched control group (right);
on a 6% polyacrylamide SSCP gel.
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Figure 2.4 (a) A representative example of the SSCP banding patterns detected in
exon 6 of TP53 in DNA obtained from the tumor biopsy samples of 7 representative
patients; on a 6% polyacrylamide SSCP gel.
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Figure 2.4 (b) A representative example of the SSCP banding patterns detected in exon
6 of TP53 in DNA obtained from the corresponding blood of 7 of the patients (left) and
from the blood of 7 members of the healthy matched control group (right); on a 6%
polyacrylamide SSCP gel.
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Figure 2.5 (a) A representative example of the SSCP banding patterns detected in
exon 7 of TP53 in DNA obtained from the tumor biopsy samples of 7 representative
patients; on a 6% polyacrylamide SSCP gel.
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Figure 2.5 (b) A representative example of the SSCP banding patterns detected in exon
7 of TP53 in DNA obtained from the corresponding blood of 7 of the patients (left) and
from the blood of 7 members of the healthy matched control group (right); on a 6%
polyacrylamide SSCP gel.
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Figure 2.6 (a) A representative example of the SSCP banding patterns detected in
exon 8 of TP53 in DNA obtained from the tumor biopsy samples of 7 representative
patients; on a 6% polyacrylamide SSCP gel.
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Figure 2.6 (b) A representative example of the SSCP banding patterns detected in
exon 8 of TP53 in DNA obtained from the corresponding blood of 7 of the patients (left)
and from the blood of 7 members of the healthy matched control group (right); on a 6%
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Upon closer analysis, slight differences can be found in the banding
patterns of each gel. These differences occur between the different
sample sets within the same exon (e.g. when comparing the overall
banding pattern of exon 8 in Figure 2.6(a) to that of Figure 2.6(b)). This
can be accounted for by accepting that no two gels are identical. Often,
when running a gel, a difference of 10 minutes can alter the appearance
of the banding patterns. One also needs to take into account factors
such as slight differences in the temperatures at which the gels run.
Furthermore, fluctuations in the current can also have a significant
effect on the appearance of the gels. Further complications are brought
about by the natural tendency of human error i.e. certain fluctuations in
concentrations are prone to occur due to inaccurate measuring (i.e.
acrylamide, TBE and urea).
2.3.3 Automated sequencing
In total, 75 sequences were obtained from the selected samples, which were
then compared with the wild-type TP53 sequence (National Centre for
Biotechnology Information [NCBI] nucleotide database accession number
X54156) and it was found that the nucleotide changes observed were unique
to only the tumor biopsy samples, as was expected from the SSCP analysis
interpretation. All sequences obtained from the representative controls
correlated with the same wild-type TP53 sequence (i.e. NCBI accession
number X54156). In total, 11 nucleotide changes were found in three of the
four exons under investigation, representing 25% of the tumors investigated in
this study (Figure 2.7) (Table 2.2). Each of the 11 nucleotide changes
observed occurred in 11 different patients. In total there were G to T (n=4), C
to T (n=2), G to A (n =2), G to C (n =1) and T to A (n =1) nucleotide
substitutions, which translates to 4 transitions and 6 transversions. Only in
one case was a T-insertion found. Thus, in summary, exon 7 was mutated in
6 of the 11 cases (55%), with the G to T (n =3; codon 249), C to T (n =1;
Stellenbosch University http://scholar.sun.ac.za
106
codon 248) and T to A (n =1; codon 232) substitutions, all resulting in amino
acid alterations. The one T-insertion mentioned earlier was also found in
exon 7 (codon 255) and resulted in a frameshift. Exon 8 mutations were
detected in 3 of the 11 cases (27%), with the G to A (n =1; codon 266), G to C
(n =1; codon 273) and C to T (n =1; codon 273) substitutions also resulting in
amino acid alterations. Exon 5 contained the remaining two substitutions,
namely, G to T (n =1; codon 176) and G to A (n =1; codon 175) which also
resulting in amino acid alterations. No nucleotide changes were observed
within exon 6.
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Figure 2.8 Automated sequencing results of patients (a) 4 (b) 33 (c) 1 (d) 8 (e)
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changes observed in each of these 11 cases.
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Table 2.2 A summary of the nucleotide changes, codon positions as well as the final
amino acid alterations found in exons 5 to 8 of TP53 in various laryngeal
cancer (LC) tumor biopsies investigated in this study
Exon Patient no Ethnic group Codon Mutation Amino Acid
and sex/age Alteration
5 4 CM/48 176 TGC---t TTC Cys---tPhe
I
33 I CM/45 175 CGC---tCAC Arg---tHis
6
-
- - - -
7 1 N/A 255 ATC-~ATTC Frameshift
8 CM/66 248 CGG---t TGG Arg---tTrp
9 CM/69 249 AGG---tAGT Arq-vSer
19 N/A 249 AGG---tAGT Arq-vSer
32 CM/62 249 AGG---tAGT Arq-e-Ser
39 CM/46 232
ATC---tAAC lIe---tAsn
8 12 N/A 273 CGT ---tCCT Arg---tPro
23 CM/51 266 GGA---tAGA Gly---tArg
24 WM/65 273 CGT---tTGT Arq-s-Cys
Abbreviations: CM, Coloured male; N/A, not available at time of study; WM, white male
2.3.4 Association of observed nucleotide changes to etiologic
factors
All patients and members of the control group completed questionnaires.
Aspects covered by the questionnaires included ethnic group, gender, date of
birth, place of birth, alcohol and tobacco consumption, family history of
cancer, source of cigarettes and average number of cigarettes per day,
source of tobacco for pipe smoking, chewing tobacco, drinking and source of
beer, drinking and source of spirits, use and source of tribal medicine, induced
vomiting and method of induction, and numerous aspects of their dietary
habits.
The data compiled for both the patients and the control group were used to
test for correlations between possible etiologic factors and the occurrence of
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mutations within TP53 and to test for a correlation between Le and the type of
mutation observed. Spearman rank correlations were determined to detect
any significant associations. Significant correlations were found between the
occurrence of Le and the following: age, smoking, eating meat on a daily
basis and drinking milk on a daily basis (Table 2.3). The results were then
further stratified by dividing the groups (patients and controls) into two
categories (smokers and non-smokers), where after the Spearman rank
correlation was repeated (Table 2.4). It was found that 3 of 23 non-smokers
(13%) and 30 of 55 smokers (55.4%) were diagnosed with Le. Both milk and
meat consumed on a daily basis resulted in negative correlations with the
occurrence of Le (Table 2.3), thus indicating that they may be protective
factors against the development of Le. In contrast, smoking and age
displayed positive correlations with the occurrence of Le, thus indicating
these as risk factors for the development of Le. However, a negative
correlation between daily milk consumption and cigarette smoking was noted
(Table 2.3). From Table 2.4, where results were stratified according to
smoking, it can be seen that the association between daily milk consumption
and the occurrence of Le was not significant in either group (smoking or non-
smoking). The association in Table 2.3 is therefore spurious, and due to the
correlation with cigarette smoking, which exerts a major effect. In non-
smokers, therefore, age is the only risk factor identified. In smokers, age is a
risk factor, but with a lower correlation coefficient than in non-smokers, and
high daily meat consumption remains correlated with protection against the
development of Le (Table 2.4).
Stellenbosch University http://scholar.sun.ac.za
I I ()
Table 2.3 Interrelationships between possible etiological factors and laryngeal
cancer
Characteris- Laryngeal Pathology Age Smoking Ever Meat
tics Cancer Report Cigarettes smoked Daily
cigarettes
Pathology n=78
Report
cc=-O.970
p=O.OOO
Age n=80 n=74
cc=O.479 cc=-O.445
p=O.OOO p=O.OOO
Smoking n=78 n=73 n=77
Cigarettes
cc=O.304 cc=-O.229 cc=O.136
p=O.OO7 p=O.051 p=O.238
Smoking n=78 n=73 n=77 n=78
Cigarettes
ever cc=O.383 cc=-O.317 cc=O.229 cc=O.851
p=O.OO1 p=O.OO6 p=O.045 p=O.OOO
Meat Daily n=81 n=75 n=80 n=78 n=78
cc=-O.436 cc=O.453 cc=-O.257 cc=-O.132 cc=-O.180
p=O.OOO p=O.OOO p=O.021 p=O.250 p=O.114
Milk Daily n=81 n=75 n=80 n=78 n=78 n=81
cc=-O.264 cc=O.275 cc=-O.053 cc=-O.331 cc=-O.293 cc=-O.35
p=O.017 p=O.017 p=O.6390 p=O.OO3 p=O.OO9 p=O.757
n = total number of subjects with information on the particular parameter; out of a total of 84
subjects in study
cc = correlation coefficient
p = significance level
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Table 2.4 Interrelationships between possible etiological factors and Le
Group Laryngeal Cancer Age Milk Daily
Age
Milk Daily
Meat Daily
Non-smokers:
Age
Milk Daily
Meat Daily
n=54
cc=O.317
p=O.019
n=55 n=54
cc=-O.214 cc=O.OOO
p=O.116 p=1.000
n=55 n=54 n=55
cc=-O.413 cc=-O.078 cc=-O.080
p=O.OO2 p=O.576 p=O.560
n=23
cc=O.584
p=O.OO3
n=23 n=23
cc=-O.233 cc=O.049
p=O.284 p=O.8255
n=23 n=23 n=23
cc=-O.259 cc=-O.303 cc=-O.012
p=O.232 p=O.160 p=O 957
n - total number of subjects out of a total of 84 subjects with information on the particular parameter;
cc = correlation coefficient; p, significance level.
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2.4 Discussion
In this study, TP53 was examined in a set of laryngeal cancer patients (n=44)
all having received treatment at Tygerberg Hospital, Cape Town, South Africa.
To date, the majority of TP53 mutations have been found within exons 5-8,
the most evolutionary conserved region coding for the DNA binding domain
(Hainaut 2001), and it is for this reason that we decided to focus on this
region. However, it is possible that mutations may occur within the intronic
sequences, as well as in exons 1-4 and 9-11, which were not investigated
here. A few studies (Bradford et al. 1997; Zhang et al. 1994; Sarkar et al.
1996; Gotlschlich et al. 2000) have been conducted to investigate TP53
mutations in LC using PCR-SSCP analysis combined with direct sequencing.
The results indicate that the tumors contain mutations within exons 5-8 at
varying frequencies, ranging from 4/32 (12,5%) (Gottschlich et al. 2000), 19/61
(31,3%) (Sarkar et al. 1996),7/44 (39%) (Bradford et al. 1997) to 13/40 (32,5%)
(Zhang et al. 1994). This represents an average of 25%. Early reports (Jego
et al. 1993) indicated that 90% of the mutations in TP53 from a variety of
human cancers were single-point mutations (n=740) and the remainder
consisted of small insertion/deletions. This study identified mutations in TP53
sequence in 25% of the cases of which 91% were single-base changes,
suggesting a unifying molecular mechanism. Factors possibly responsible for
this include environmental agents as well as dietary components. It has also
been reported that small insertion/deletions within TP53 are common in
ovarian cancer (Skilling et al. 1996) and oesophageal cancer (Vos et al. 2003)
and a slippage mechanism due to mismatch DNA-repair deficiency can be
suggested as being responsible for the T-insertion observed in this study.
Data obtained from questionnaires completed by the patients, as well as the
control group, allowed correlation studies to identify smoking and age as risk
factors for the development of LC. Furthermore, daily consumption of meat
(excluding fish) has been identified as being a protective factor against the
development of LC. This protective effect of high meat consumption could be
either a direct nutritional effect, or meat may be a marker for higher socio-
economic status, and therefore an indication of other factor(s) involved in
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protection against the development of LC. The larynx is where the common
aero-digestive tract splits into the trachea and the oesophagus and smoking
has been identified as a risk factor for oesophageal cancer (Montesano et al.
1996), as well as for lung cancer (Steele et al. 1998; Soussi et al. 2001;
Soussi et al. 2001). The typical lung cancer TP53 mutations associated with
smoking (G ~ T transversions and G ~ A and C ~ T transitions) (Zhang et
al. 1994) accounted for 73% of the mutations found within this study.
Although the mutations observed in this study fall within a known TP53
hotspot for cancers in general, it is interesting to note that the particular
mutations at codons 175, 176, 248, 249, 266 and 273, accounting for 82% of
the mutations observed in this study, are known lung cancer hotspots (Soussi
et al. 2001). Similarly, the particular mutations at codons 175, 176, 248, 249,
255 and 273 are known oesophageal cancer hotspots (Soussi et al. 2001),
and also account for 82% of the mutations observed in this study. Thus, the
TP53 mutations common to laryngeal cancer (this study), oesophageal cancer
and lung cancer are codons 175 (G ~ A), 176 (G ~ T), 248 (C ~.>T), 249 (G
~ T), 273 (G ~ A) and 273 (C ~ T) (Soussi et al. 2001). Furthermore, the
overlap between LC and lung cancer (82%) and between LC and
oesophageal cancer (82%) implies that, in terms of mutations observed, there
is a 73% overlap between all three of these cancers. Comparing the results
of this study to those reported elsewhere (Zhang et al. 1994; Maestro et al.
1992; Boyle et al. 1993; Somers et al. 1992; Maestro et al. 1992; Boyle et al.
1993; Somers et al. 1992) we find that the mutations at codons 175, 176 and
248 have been previously identified as TP53 mutations in LC in other
geographical areas. However, the mutations at codons 232, 249, 255, 266
and 273 have not been previously reported, making them novel mutations. It
was also found that 100% of mutations in this study occurred between codons
175 and 273, confirming the presence of a known hotspot region within TP53.
It should also be noted here that the nucleotide changes observed within this
study are not necessary the primary cause of malignancy and could merely be
a secondary event, implying that such nucleotide changes are not necessarily
disease causing. The predominant mutation at codon 249 (G ~ T) is
associated with aflotoxin B exposure in conjunction with hepatitis B viral
Stellenbosch University http://scholar.sun.ac.za
114
infection in hepatocellular carcinoma (Dominquez-Malagon and Gayton-
Graham 2001).Although there is no data to suggest the involvement of either
of these two etiological factors in the carcinogenesis of LC, this study has
shown that the involvement of a virus or a toxin, within this unique
geographical area, is a possibility, and requires further investigation.
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3.1 Overview
The aim of this study was thus to analyse the molecular structure of TP53,
specifically exons 5 - 8, in a group of Coloured esophageal cancer (EC) patients
treated at Tygerberg Hospital, Cape Town, South Africa. This involved the
screening of DNA obtained from the patient tumor biopsies as from blood
obtained from the same patients, via PCR-SSCP and direct sequencing analysis.
The participants of this study were also asked to complete questionnaires in
order to determine possible etiological factors (a study undertaken by the MRC).
The goal of this study would be to determine whether there are differences in the
TP53 mutational pattern observed in the Coloured Western Cape community as
compared to that observed in the Black Transkei community. The value of the
knowledge obtained from this genetic study in alliance with that obtained from the
epidemiological study undertaken by the MRC has far reaching effects in
practice, placing epidemiologists in an advantageous position in their pursuit to
unravel the influence of various environmental factors on carcinogenesis. This
could allow educational programs to be initiated within communities at higher risk
for the development of esophageal cancer, promoting an understanding of the
causes and risks for cancer development within each unique population.
The institutional ethics committee approved this study and informed consent was
obtained from all subjects.
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3.2 Materials and Methods
3.2.1 Collection of tumor samples
Fresh tumor biopsies were obtained from patients over the period from 1997 to
2003. A variety of population groups are represented in this sample collection,
including the Indian, Caucasian, Black and Coloured (discussed in section1.4)
communities native to South Africa. However, for the purposes of this study, 44
Coloured patients were selected to form part of an initial screening. All patients
received treatment and underwent surgery at Tygerberg Hospital, Cape Town,
South Africa.
During the surgical procedure of obtaining a biopsy for diagnostic purposes, a
second biopsy was taken for research purposes. This second biopsy (for
research) was snap-frozen in liquid nitrogen immediately after surgical removal
and stored at -70°C for further molecular analysis in disposable polypropylene
cryogenic vials (Appendix II). Only the biopsy obtained for diagnostic purposes
were originally diagnosed histologically and the resulting diagnosis was assumed
for the second biopsy (obtained for research purposes).
3.2.2 Collection of surrounding tissue samples
During the surgical procedure of obtaining a biopsy for diagnostic purposes, a
second piece of apparently healthy surrounding tissue was taken for research
purposes. This apparently healthy surrounding tissue sample was snap-frozen in
liquid nitrogen immediately after surgical removal and stored at -70°C for further
molecular analysis in disposable polypropylene cryogenic vials (Appendix II).
Only the biopsy obtained for diagnostic purposes were originally diagnosed
histologically and the surrounding tissue was assumed to be healthy and free of
any tumorigenic cells.
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3.2.3 Collection of blood samples
Blood samples were collected in 5 ml disodium ethylenediaminetetraacetate
dehydrate (EDTA) tubes (Appendix II) from the same patients (discussed in
section 3.2.1) and frozen for further molecular analysis. Data obtained from the
blood samples would serve as a control to test for a loss of heterozygosity (LOH).
This would serve as an indication as to whether any nucleotide alterations
observed within the tumor samples were somatic in origin, or whether they were
germline mutations.
3.2.4 Collection of control samples
Due to difficulties encountered with ethical approval at the time of the study, it
was not possible to collect any external control samples for this study.
3.2.6 DNA extractions
3.2.6.1 Tumor biopsy and surrounding tissues
DNA extractions were performed on the tumor biopsy samples as well as the
apparently healthy surrounding tissue samples as discussed in section 2.2.4.1.
3.2.6.2 Blood Samples
DNA extractions were performed on the blood samples as discussed in section
2.2.4.2.
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3.2.7 Polymerase Chain Reaction/PCR
3.2.7.1 Principals of PCR
See section 2.2.5.1.
3.2.7.2 Oligonucleotide primers
See section 2.2.5.2.
3.2.7.3 Methodology
PCR was performed on all three sample sets discussed in sections 3.2.1 to 3.2.3.
For more detail see section 2.2.5.3.
3.2.8 Gel Electrophoresis
3.2.8.1 1% DNA Agarose gel electrophoresis
Successful PCR amplification as well as the absence of contamination was
verified by electrophoresing 10 ).lI of the amplified product on 1% DNA agarase
gels (Appendix III).
3.2.8.1.1 Preparation of the gel
The gels (Appendix III) were cast in 85mm x 150mm to a thickness of
approximately 5mm. The Perspex moulds were first washed with Cal-liquid hand
soap (Appendix II) and rinsed with tap water. A wash with 70% ethanol
(Appendix III) and drying with paper towel followed this. After pouring the gel
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solution (Appendix III), the well-forming combs were inserted and the gels were
left to set for 30 minutes prior to loading and electrophoresis.
3.2.8.1.2 Electrophoresis
See section 2.2.6.1.2.
3.2.9 Single-strand conformation polymorphism (SSCP) analysis
3.2.9.1 Principals of SSCP
See section 2.2.7.1.
3.2.9.2 Methodology
3.2.9.2.1 8% Polyacrylamide SSCP gels supplemented with 10% urea
3.2.9.2.1.1 Casting the gel
See section 2.2.7.2.1.1.
3.2.9.2.1.2 Electrophoresis
See section 2.2.7.2.1.2.
3.2.9.2.1.3 Silver staining
See section 2.2.7.2.1.3.
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3.2.9.2.2 Scoring of the 8% polyacrylamide SSCP gels
supplemented with 10% urea
See section 2.2.7.2.2
3.2.9.2.3 Reproducibility of the 6% polyacrylamide SSCP gels
supplemented with 10% urea
See section 2.2.7.2.3
3.2.9.2.4. Second set of SSCP conditions: 10% polyacrylamide SSCP
gels supplemented with 5% glycerol and 17% urea
See section 2.2.7.2.4. The same approach was used as described in section
2.2.7.2.1 with the exception that a 10% polyacrylamide gel solution (Appendix III)
was used instead of a 6% polyacrylamide gel solution (Appendix III).
3.2.10 Sequencing analysis
3.2.10.1 Amplicon purification
Samples were subsequently selected for sequencing from all three of the sample
sets (tumor biopsies as well as surrounding tissue and blood from the same
patients) to represent at least one of each of the unique SSCP banding patterns
observed across exons 5 to 8. Amplicons were purified using the Nucleospin kit
(Appendix II), following the instructions recommended by the manufacturer.
3.2.10.2 Automated sequencing
See section 2.2.8.2.
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3.2.11 Solving potentially discrepant results
In cases where SSCP results were non-reproducible or contradictory to
sequencing results obtained, the following 3 approaches were taken:
i. The discrepant samples were re-amplified using Taq DNA polymerase
(Appendix II) as described in section 2.2.5.3. The PCR products were
then purified using the Nucleospin kit (Appendix II) and this was followed
by a second round of automated sequencing as described in section
2.2.8.2
ii. The same discrepant samples were re-amplified using HotStarTaq™ DNA
Polymerase (AppendixII) as described as section 2.2.5.3. These PCR
products were once again purified using the Nucleospin kit (Appendix II)
and succeeded by a second round of automated sequencing as described
in section 2.2.8.2.
iii. Simultaneously, the discrepant SSCP bands of interest were excised from
the SSCP gel, using a sterile scalpel blade (Appendix II). The DNA was
eluted by mashing the gel pieces with a pipette-tip in a 1,5ml Eppendorf
tube (Appendix II) and adding 10-20 ~tIdH20. This was then left overnight
at 4°C and incubated at 3rC for 10 minutes prior to its use as a template
for a subsequent PCR reaction (again using Taq Polymerase as described
in section 2.2.5.3). Once amplified, the PCR products were purified using
the Nucleospin kit (Appendix II), followed by another round of automated
sequencing as described in section 2.2.8.2.
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3.2.12 Histological re-evaluation of tumorigenic cells
Based on uncertainties observed in the appearance of the SSCP banding
patterns, 20 tumor samples were randomly selected to be histologically re-
analyzed for the presence of tumorigenic cells as previously described (Alan
Stevens James Lowe 1997).
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3.3 Results
3.3.1 1% Agarose gel electrophoresis
Before starting the SSCP analyses, all amplicons were verified on 1% agarose
gels in order to confirm the presence of the expected product as well as the
absence of any contamination, as can be seen in Figure 3.1.
3.3.2 8% Polyacrylamide SSCP gels supplemented with 10% urea
All SSCP gels were scored individually and samples were selected for
sequencing to represent each uniquely scored banding pattern. Mobility shifts
were detected in exons 6 and 8 of the tumor biopsy sample set (Figures 3.3 (a)
and 3.5 (a)), but none in exons 5 and 7. The results obtained from the various
SSCP gels (Figures 3.2 - 3.5) indicate that no mobility shifts were detected
within the blood from the same patients sample set, neither within the apparently
healthy surrounding tissues from the same patients. This suggests that the
nucleotide changes observed have somatic origins and are not germline
mutations. All SSCP analyses were repeated once under identical conditions as
well as under a different set of conditions, as described in sections 3.2.9.2.3
and 2.3.9.2.4, however, only representative examples of the initial SSCP screen
are given in Figures 3.2 - 3.5.
M - I 2 3 4 5 6 7 8 9 lO II 12 13
Figure 3.1 A representative example of one of the 1% agarose gels that were
used to verify the presence of amplicons as well as the absence of DNA
contamination during peR. This gel demonstrates the successful amplification of
exon 8 for samples as well as the absence of contamination of the negative lane (-).
A DNA marker (Appendix III) was loaded in lane M.
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Figure 3.2 (a) A representative example of the SSCP banding patterns
detected in exon 5 of TP53 in DNA obtained from the tumor biopsy samples of 7
patients; on a 6% polyacrylamide SSCP gel supplemented with 10% urea.
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Figure 3.2 (b) A representative example of the SSCP banding patterns detected in
exon 5 of TP53 in DNA obtained from the apparently healthy surrounding tissue of 7
patients (left) as well as from the corresponding blood of 7 of the patients (right); on
a 6% polyacrylamide SSCP gel supplemented with 10% urea.
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Figure 3.3 (a) A representative example of the SSCP banding patterns detected in
exon 6 of TP53 in DNA obtained from the tumor biopsy samples of 7 patients; on a 6%
polyacrylamide SSCP gel supplemented with 10% urea.
Stellenbosch University http://scholar.sun.ac.za
4 5 6 7
Single {
Stranded
DNA
} conformations
+--- Double
stranded
DNA ---+
132
2 "I-, 4 5 6 7
Figure 3.3 (b) A representative example of the SSCP banding patterns detected in exon 6
of TP53 in DNA obtained from the apparently healthy surrounding tissue of 7 patients (left)
as well as from the corresponding blood of 7 of the patients (right); on a 6% polyacrylamide
SSCP gel supplemented with 10% urea.
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Figure 3.4 (a) A representative example of the SSCP banding patterns detected in
exon 7 of TP53 in DNA obtained from the tumor biopsy samples of 7 patients; on a 6%
polyacrylamide SSCP gel supplemented with 10% urea.
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Figure 3.4 (b) A representative example of the SSCP banding patterns detected in exon 7
of TP53 in DNA obtained from apparently healthy surrounding tissue of 7 patients (left) as
well as from the corresponding blood of 7 of the patients (right); on a 6% polyacrylamide
SSCP gel supplemented with 10% urea.
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Figure 3.5 (a) A representative example of the SSCP banding patterns detected in
exon 8 of TP53 in DNA obtained from the tumor biopsy samples of 7 patients; on a 6%
polyacrylamide SSCP gel supplemented with 10% urea.
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Figure 3.5 (b) A representative example of the SSCP banding patterns detected in exon 8
of TP53 in DNA obtained from apparently healthy surrounding tissue of 7 patients; on a
6% polyacrylamide SSCP gel supplemented with 10% urea.
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3.3.3 Automated sequencing
From 124 sequences obtained, only 4 nucleotide changes were observed in 3
different tumor samples (Figures 3.6 (a) to (c)). One single nucleotide change (C -
T) was found in codon 192 of exon 6 resulting in a stop signal. One GA deletion
was found in codon 209 of exon 6 which resulted in an early stop signal at codon
214. Furthermore, a 15bp deletion was found in codon 276 of exon 8, resulting in
a frameshift. Interestingly, another homozygous nucleotide change was found
within the same sample, further downstream, at codon 283 (C - T). In each case,
both forward and reverse sequences were obtained in order to confirm such
nucleotide changes. These can be found summarized in Table 3.1.
III 111
TCA CAe Il A il C HC TT TT eH A C Il T
dGA
Figure 3.6 (a) Automated sequencing results obtained from the DNA extracted from the
tumor biopsy sample of patient no 49. This chromatograph demonstrates a 2bp (GA)
deletion - indicated as !:iGA - in exon 6 of TP53 (as compared to the wild type sequence
deposited in the National Centre for Biotechnology Information [NCB I] nucleotide database
(accession number X54156».
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Figure 3.6 (b) Automated sequencing results obtained from the DNA extracted from the
tumor biopsy sample of patient no 59. This chromatograph demonstrates a single
nucleotide alteration (indicated by an arrow) within exon 6 of TP53 (as compared to the
wild type sequence deposited in the National Centre for Biotechnology Information [NCBI]
nucleotide database (accession number X54156».
1 1\ 1\
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Figure 3.6 (c) Automated sequencing results obtained from the DNA extracted from the
tumor biopsy sample of patient no 73. This chromatograph demonstrates a 15bp deletion
- indicated as L\CCTGTCCTGGGAGAG - in exon 8 of TP53 (as compared to the wild type
sequence deposited in the National Centre for Biotechnology Information [NCB I) nucleotide
database (accession number X54156».
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Table 3.1 A summary of the nucleotide changes confirmed with sequence analysis
Exon Patient Sexl I Codon Nucleotide j Amino Acid Alterationno. Age alteration
6 149 1F/58 209 GA deletion I Frameshift - stop at codon 214
- --6 1159 la 192 CAG - TAG Il_Stopc~(jon
8 73 M/41 J~76 15bp deletion I Frameshift
8 I 73 M/41 283 CGC-TGC Arg - Cys
Abbreviations: F, Female; M, Male; n/a, not available at time of study;
3.3.4 Solving potentially discrepant results
In an attempt to clarify the discrepant results obtained from the initial SSCP
analysis of exon 6 of TP53 (Figure 3.7(a)), several approaches were taken, as
described in section 3.2.11. Initially, the original amplicons were re-analyzed on
a second SSCP gel under identical conditions (Figure 3.7(b)), however, these
results proved to be non-reproducible. Another approach was to re-amplify the
samples in question, using Taq DNA polymerase (Appendix II) as well as
HotStarTaq™ DNA Polymerase (AppendixII) as described as section 2.2.5.3,
following by purification using the Nucleospin kit (Appendix II). These purified
samples were then used for a second round of automated sequencing, which
revealed the samples to be identical to the wild type sequence deposited in the
National Centre for Biotechnology Information [NCBI] nucleotide database
(accession number X54156). Lastly, the discrepant bands of interest were
excised from the original SSCP (Figure 3.7(a)) as described in section3.2.11, and
used as template DNA in a further PCR reaction. These amplicons were then
purified using the Nucleospin kit (Appendix II) and used in an automated
sequencing reaction. The sequence obtained was identical to the wild type
sequence deposited in the National Centre for Biotechnology Information [NCBI]
nucleotide database (accession number X54156).
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Figure 3.7 (a) A representative example of the discrepant SSCP banding patterns
detected in exon 6 of TP53 in DNA obtained from tumor biopsy tissue of 7 of the patients;
on a 6% polyacrylamide SSCP gel supplemented with 10% urea. This photo demonstrates
how the discrepant bands of interest were excised from the SSCP gel for use as DNA
template in a further PCR reaction as described in section 3.2.10.
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Figure 3.7 (b) A representative example of the SSCP banding patterns detected in the
repeat SSCP gel of the discrepant samples, under identical conditions to those of Figure
3.3(a) of exon 6 of TP53 in DNA obtained from the tumor biopsy samples; on a 6%
polyacrylamide SSCP gel supplemented with 10% urea.
3.3.5 Comparison of the TP53 mutation spectrum of the Black
community vs. the Coloured community
In doing a comparison between the nucleotide changes observed in the Black
community of the Transkei and those nucleotide changes observed in the
Coloured community of the Western Cape (Table 3.2), it was found that the only
similarities are the deletions resulting in frameshifts (codons 209 and 276) and
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that, in terms of codon position, there are no nucleotide changes common to both
these groups under investigation.
Table 3.2 A summary of the nucleotide changes observed in the Black Community of
the Transkei vs. those nucleotide changes observed in the Coloured Community of the
Western Cape
Black Community Exon Codon Mutation Amino acid change
1F=~~~~~~~9F==~~~~~~~~~~~'--'~"~~~~
of the Transkei 5 . 137 1bp deletion Frameshift
L.
(Gamieldien et al. 15 148-149 2bp insertion 1Frameshift
1998) I&;.1 &;."7 hiftI,J I,J. ,~~.,,~ c1llles I
5 158 4bp insertion II rI arneshift
5 159 1bp deletion II rI dilleshift
1~6~~1~1<Q-191~~1~2?lb~p~i~ns:e:;I~lIl'U~I~1t11~1;1c1:II~llIe:s;hJfift~~~~'-~-
[[1=077~~l~2:.,~~,~~24-~1eletion II arneshift
6bp deletion fFrameshift7 239-241
7 243-246 8bp deletion 1Frameshift
18 11296
8
209
TCT
303 GAG - GTG Glu - Val
Coloured
Community of the
Western Cape
(present study)
6 Frameshift
codon 214
GA deletion stop at
6 192 CAG - TAG Stop codon
8
8
11
276 15bp deletier I ameshift
CGC - TGC Arg - Cys
3.3.6 Histological re-evaluation of tumorigenic cells
Histological evaluation revealed that 4 of the 20 (20%) randomly selected
samples, appeared to never have been positive for squamous cell carcinoma.
These were rather attributed to adenocarcinoma (ID 75), chronic inflammation
(ID 84), neuro-endocrine carcinoma (ID 183) and a complete lack of any
neoplasm (ID 88). Of the remaining 16, histological re-evaluation indicated 5
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(31%) to be absent of squamous cell carcinoma. Otherwise stated, 9 of the 20
(45%) samples re-evaluated were negative for the presence of squamous cell
carcinoma. The results from the histological re-evaluation of tumorigenic cells
can be found in Table 3.2. Furthermore, of the samples listed in Table 3.2,
numbers 49, 75, 76, 80, 84, 88 and 89 were included in the molecular analysis of
TP53 performed in this study. Based on their histological stats, numbers 49, 76
and 80 were expected to be genetically altered, however, genetic analysis
revealed that only sample number 49 was altered within the TP53 region under
investigation.
Table 3.3 Tumor biopsy samples' originally histologically diagnosed as compared to the
re-evaluated diagnosis performed during this study
Study Original Histologically Study Original Histologically
sample Histological re-evaluated sample Histological re-evaluated
number diagnosis diagnosis number diagnosis diagnosis
18 1+ - 85 + +
49 1+ + 86 +
69 + 88 -
70 + - 89 +
75 ' - - 183 - -
76 + + 187 + +
80 + + 188 + 1+
81 ]+ 1+ 202 t_ -
82 ]+ 1+ 204 + + ~~
84 - - 205 + +
..
+ Indicates a positive diaquosis for the presence of squamous cell carcinoma within the tumor biopsy
sample
- Indicates a negative diagnosis i.e. the absence of any squamous cell carcinoma within the tumor biopsy
sample
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3.4 Discussion
The aim of this study was to identify similarities between the nucleotide changes
observed in the high incidence Black community of the Transkei (Gamieldien et
al. 1998) and the Coloured community of the Western Cape, in order to possibly
identify mutagens or carcinogens common to both these areas. This was done
using PCR-SSCP and direct sequencing analysis whereby the DNA binding
domain of TP53 (exons 5 - 8) was screened in DNA obtained from the tumor
biopsy samples of 44 Coloured EC patients originating from the Western Cape.
As controls, the corresponding blood as well as apparently healthy surrounding
tissue from the same patients were also included in this screening process.
Based on the information obtained from the SSCP gels performed on DNA
obtained from tumor biopsy tissue, corresponding blood as well as apparently
healthy surrounding tissue from the group of Coloured EC patients, it appeared
that very few nucleotide changes were present within exons 5 - 8 of TP53. It also
appeared that the nucleotide changes observed were present only within the
DNA obtained from the tumor biopsy tissues, with no indication of any such
changes within the corresponding blood or the apparently healthy surrounding
tissues, as seen in the Transkei study as well (Gamieldien et al. 1998).
Upon further investigation, it was confirmed that from 124 sequences obtained,
only 3 samples contained nucleotide changes (Table 3.1). The nucleotide
alteration at codon 209 is a 2bp deletion (,~GA) which results in an early stop
signal at codon 214 and has been found in numerous cancer types, including
esophageal squamous cell carcinoma (SCC), head and neck cancers, ovarian
carcinoma, breast carcinoma, colorectal carcinoma, melanomas, ampullary
tumors, thyroid carcinoma, B-chronic lymphocytic leukaemia, pancreatic cancer,
astrocytoma, myelodysplastic syndrome, gliomas, rectal cancer,
oligodendrioglioma and glioblastomas (Soussi et al. 2001).
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Similarly, the nucleotide alteration at codon 192 results in an early stop codon
and has been found in esophageal squamous cell carcinoma, head and neck
squamous cell carcinoma, ovarian carcinoma, breast carcinoma, colorectal
carcinoma and melanoma. However, in addition to these, also mentioned in the
previous paragraph for codon 214, the alteration at codon 192 has also been
found in esophageal adenocarcinoma, vulvar sse, cervical cancer, basal cell
carcinoma, plasma cell leukaemia, gallbladder cancer, bladder carcinoma,
acitinic keratoses, hepatocellular carcinoma, skin sse, non-small cell lung
cancer, skin dysplasia, non Hodgkin's lymphoma, gastric carcinoma and
cutaneous lymphoma (Soussi et al. 2001).
The nucleotide alteration at codon 283 results in an amino acid alteration as has
also been found in colorectal carcinoma, breast carcinoma, 8-chronic
lymphocytic leukaemia, chronic myelocytic leukaemia, bladder carcinoma,
ovarian carcinoma, vulvar see and non-small cell lung cancer. However, it has
never been reported in any form of esophageal carcinoma, thus making it novel
to esophageal see.
Likewise, the 15 bp deletion at codon 276, has never been reported and is thus a
novel mutation. Two of these 4 nucleotide alterations were e - T transitions and
it has been suggested that oxidized, deaminated cytosines are the main cause of
such events. Furthermore, the deletions noted in this study could be accounted
for by the a slippage mechanism as a result of a mismatch DNA-repair
deficiency, as discussed in section 2.4
There were, however, some discrepant results that needed clarification. A
certain mobility shift pattern that occurred repetitively throughout exon 6, could
not be reproduced under identical conditions, neither under the second set of
ssep conditions. Sequencing analysis of these samples revealed the
sequence to be identical to the wild type TP53 sequence as deposited in the
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National Centre for Biotechnology Information [NCBI] nucleotide database
(accession number X54156).
In order to eliminate any potential enzymatic errors, the very same samples were
re-amplified using both Taq DNA polymerase (Appendix II) as well as
HotStarTaq™ DNA Polymerase (Appendix II). These amplicons were also
purified using the Nucleospin Kit (Appendix II) and used for automated
sequencing. These results were also identical to the wild type TP53 sequence
as deposited in the National Centre for Biotechnology Information [NCBI]
nucleotide database (accession number X54156).
In a further attempt to solve this obscurity, the bands of interest were excised
from the SSCP gel (as described in section 3.2.10) and used as template in a
further PCR reaction. Automated sequencing of these amplicons once again
resulted in a wild type TP53 sequence as compare to the sequence deposited in
the National Centre for Biotechnology Information [NCBI] nucleotide database
(accession number X54156).
It is generally accepted that a result has to be reproducible at least under
identical conditions and preferably under a second set of conditions in order for it
to be considered a true result. If these criteria are not met, as is commonly seen
with the technique of SSCP analysis, the result is simply considered to be an
artefact. In all the above attempts, the discrepant results discussed in section
3.3.4 were not reproducible. This goes to prove that they were merely artefacts,
either of the SSCP gel or of the PCR.
In achieving the aim of this study, a comparison was made between the TP53
mutational spectrums within the previously studied Black community of the
Transkei (Gamieldien et al. 1998) vs. the Coloured community of the Western
Cape. It was subsequently found that there are no similarities in the observed
mutational spectrum of the DNA binding domain of TP53 within these two
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population groups (Table 3.2). Nucleotide changes were observed in 9% (4/44)
of the Coloured EC tumor biopsies investigated, opposed to 14,5% (11/76) in the
Black Transkei population (Gamieldien et al. 1998), which, for the most part,
identified insertions and deletions of varying size.
None of the nucleotide changes identified are common to both studies, indicating
the possibility different carcinogens being involved. It has been previously
identified that EC in South Africa is largely dietary related, where maize and
wheat are the central food sources. Fungal contamination of these foods by
Fusarium moniliforme are believed to play a major role in the tumorigenesis of
EC once ingested. In addition, it is hypothesized that a nutritional deficiency is a
further complicating factor (Marasas et al. 1988). However, the culture of
harvesting one's own maize and wheat crops is traditionally accepted and
practiced by the Black population of the Transkei and is very rare within the
Coloured Western Cape community. If contamination by Fusarium moniliforme is
the leading cause of EC development within the Black community of the
Transkei, it can, almost with certainty, be ruled out as the leading carcinogen in
the Coloured Western Cape community.
Furthermore, the involvement of various human papillomavirus types have also
been suggested and cannot be ruled out, although the tumorigenic mechanism
remain unclear (Montesano et al. 1996).
Of the 20 samples that were histologically re-evaluated, 6 were included in the
molecular analysis of TP53. According to the results obtained from the
histological re-analysis of these selected samples, 3 were identified as squamous
cell carcinoma. However, the molecular analysis of the DNA binding domain of
TP53 revealed that, of these three sampes, only 1 was genetically altered. This
could possibly be explained by the fact that only the DNA binding domain of
TP53 was investigated. No other upstream or downstream exons or any other
regions (known to include regulatory elements such as promoters, enhancers,
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silencers, etc) were investigated. Furthermore, no intronic sequences were
investigated for the purposes of this study, although it has been found that similar
regulatory elements are also know to occur within these regions. This could also
be the reason for the overall low frequency of nucleotide alterations within TP53
observed within this study (9%).
Furthermore, the results found in Table 3.2 indicate that out of 20 randomly
selected samples, only 55% were histologically confirmed to contain squamous
cell carcinoma. This could also be a major contributing factor to the overall low
frequency (9%) of nucleotide changes observed in this study. For similar future
studies, it would be recommended to perform such a histological evaluation prior
to the initiation of the molecular aspect of the study. Any samples which prove to
be absent of the desired species (such as squamous cell carcinoma in this
study), should be immediately excluded from the study. This would minimize the
number of complicating factors and allow for a more accurate interpretation of
results.
This study has indicated that only 4 nucleotide alterations were found within the
DNA binding domain of TP53 in a group of 44 (9%) Coloured Western Cape EC
patients, a very low frequency. Furthermore, based on the type of nucleotide
alterations observed, we have demonstrated that different carcinogenic
mechanisms are involved as compared to the high EC incidence Black Transkei
community.
Further investigation is required in order to identify the factors responsible for the
development of EC within the Western Cape Coloured community. Suggestions
would include analyzing the structure of the intronic as well as promoter regions
of TP53 and subsequently finding correlations between the nucleotide alterations
observed and possible etiological factors responsible. Furthermore, analyzing the
activity of the TP53 promoters could help to further unravel the ambiguity of the
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high prevalence of EC within the Western Cape Coloured community vs. the low
mutation frequency observed within the DNA binding domain of TP53.
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4.1 Overview
The aim of this study was to quantitate and compare the levels of TP53
transcription in esophageal cancer tumor tissue to the TP53 levels in healthy
esophageal tissue obtained from patients from a unique geographical and ethnic
background. The cohort of patients in this study consisted of Coloured patients,
all having been treated at Tygerberg Hospital, Cape Town, South Africa. There
is no evidence for any such analyses having been performed within the available
literature to date, not within this unique population, neither using the technology
used within this study.
Following the principal of the central dogma whereby DNA is transcribed into
mRNA which is in turn translated to protein, the measuring of TP53 transcription
levels within tumor biopsy samples as compared to the TP53 transcription levels
within the corresponding surrounding tissue of the same patients, could shed
some light on the status of TP53/p53. This could possibly lead to the
identification of errors occurring between these two final stages of transcription
(to mRNA) and translation (to the final protein product), complementing the
existing bank of knowledge on p53 protein levels.
To date, countless studies have been performed in order to determine the levels
of p53 expression within tumor cells. Immunohistochemistry has thus far proven
to be the most popular technique employed for these purposes, providing greatly
contrasting data; with p53 detected in normal esophageal mucosa at frequencies
ranging from 0% (Manges et al. 1996) to 11,7% (Fagundes et al. 2001) and p53
over expression detected in 45% (Chyczewski et al. 1999), 48,6% (Mizobuchi et
al. 2000), 51,3% (Manges et al. 1996), 53% (Rosa et al. 2003), 53,9% (Saeki et
al. 2002), 67,4% (Shi et al. 1999) and 100% (Fagundes et al. 2001), within
esophageal squamous cell tumor samples. By determining the mRNA levels of
TP53 within this study, it could help to generate a more complete picture and aid
in the unraveling of these contrasting results.
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Bearing in mind that immunohistochemistry is a technique used for the detection
of final protein levels, several techniques are currently available for the
quantification of mRNA levels and include methodologies such as Northern
analysis, microarrays, the RNase protection assay system (Promega) as well as
Taqman technology (Appendix II). However, it was decided that in order to
accurately quantify TP53 mRNA levels, the LightCycier system (Appendix II)
would be implemented. This decision was based on several advantages
presented by the LightCycier system, including aspects such as the renowned
speed at which the analysis is performed (each run taking approximately 40
minutes); the extremely accurate as well as rapid temperature control based on
air heating (maximum of 20°C/s); the optimal size of the product being analyzed
varying greatly, from 100 up to 500 bp can be accurately analyzed and generally
the software provided is more user friendly and flexible. Furthermore, the
University of Stellenbosch had recently acquired such a LightCycier System,
implying that the application thereof has already been established at this facility
thus enabling easy access.
All the information within this chapter referring to the LightCycier system was
obtained from the following website: http://www.lightcycler-online.com.
4.2 Materials and Methods
4.2.1 Collection of samples
Tumor samples were collected and preserved as described as section 2.2.1.
4.2.2 Sample selection
This study was performed on biopsy samples obtained from 2 patients (patient
numbers 204 and 205) and corresponding surrounding tissue biopsies obtained
from the same sample selection described in chapter 3. Samples were selected
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based on the following criteria: firstly, tumor biopsy samples were histologically
confirmed to be malignant, and secondly, the tumor biopsy samples, as well as
the corresponding surrounding tissue from the same patient had to weigh 25 mg
or more, in order to extract sufficient amounts of RNA. Due to ethical difficulties
encountered, it was not possible to include tissues from healthy individuals as
controls.
4.2.3 RNA extractions
4.2.3.1 Preparation for RNA extractions
Based on the sensitivity of the molecular analysis of all RNA species, certain
criteria had to be met prior to the start of RNA extractions. These criteria include
factors such as ensuring an RNase free workspace. Due to the fact that DNA,
just as RNA, is a nucleic acid and therefor possesses many of the same chemical
properties, it is crucial to prevent DNA contamination. Thus, wiping all surfaces
and instrumentation with RNase Away (Appendix II) expelled of both RNases and
DNA contamination. In a further attempt to eliminate RNases and DNA,
disposable apparatus were used as far as possible. Any Perspex apparatus
used was washed using DEPC (Appendix II) water. Furthermore, RNase and
DNA free water (Appendix II) replaced regular distilled water.
4.2.3.2 Methodology
RNA was extracted from tumor biopsy samples and the corresponding
surrounding tissue of the same patient as well as from cells obtained from a
cultured NG 63 human osteoblastic cell line (used as a control for the success of
the study), using the High Pure RNA Isolation Kit (Appendix II).
For the tissue samples, a mortar and pestle were initially cooled with liquid
nitrogen (Appendix II), while, simultaneously, the tumor and corresponding
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surrounding tissues were frozen in liquid nitrogen. Once the mortar and pestle
were cold enough, the recommended volumes of lysis buffer from the High Pure
RNA Isolation Kit were added to each of the tissue samples individually. This
mixture was then homogenized to a fine powder. After allowing the powder to
return to a liquid phase at room temperature, the protocol for 'Isolation of total
RNA from cultured cells' was further followed as advised by the manufacturer,
with the following exceptions. The DNase incubation period was extended to 1
hour. The elution buffer (eluted in a final volume of 60 ul) incubation period was
also extended to 2 hours and followed by centrifugation as per prescribed
protocol. This step was repeated by again pipetting the same eluent onto the
glass filter fleece and allowing a second incubation period of 2 hours. This was
once again followed by a centrifugation step as per prescribed protocol.
The cells from the cultured NG63 osteoblastic cell line were extracted as
recommended by the manufacturer for 'Isolation of total RNA from cultured cells'.
4.2.3.3 Gel electrophoresis
4.2.3.3.1 1% RNA agarose gels
The successful extraction of RNA from the tumor tissue as well as corresponding
surrounding tissues as well as the control NG 63 human osteoblastic cell line was
confirmed on 1% RNA agarose gels.
4.2.3.3.1.1 Casting the gels
The Perspex gel casting apparatus (15cm x 1Ocm) was first rinsed with DEPC
water (Appendix II), followed by 70% ethanol (Appendix III) and 10% bleach
(Appendix III). Finally, the apparatus was wiped with paper towel spotted with
RNase Away (Appendix II). The gel solution (Appendix III) was then poured and
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the 50 ~dPerspex well combs inserted. The gel solution was then allowed to set
for approximately 30 minutes.
4.2.3.3.1.2 Electrophoresis
For each of the tumor and surrounding samples, as well as the positive control, 2
volumes of RNA sample buffer (Appendix III) was added to 1 volume of extracted
RNA. This was then incubated at 65°C for a period of 5 minutes. This was
followed by placing the samples on ice for 2 minutes during which 2 ul RNA
loading dye (Appendix III) and 2 ~dethidium bromide (Appendix III) was added.
The samples were then loaded and electrophoresed at 100V and 10W until the
dye front had migrated across 70 - 75% of the length of the gel.
4.2.3.3.1.3 Visual inspection
The presence of successfully extracted RNA was then visualized under a ultra
violet light using a UV™Transilluminator apparatus (Apparatus II).
4.2.3.4 Determining the RNA concentrations and purity
The optical density (00) of the RNA was determined using a Milton Roy series
1201spectrophotometer at 260 nm (00260). The concentrated RNA was diluted
by adding 3 ul concentrated RNA to 297 !-lI dH20 and the RNA concentration
determined by multiplying the 00260 by a factor of 4. This gave an answer of
RNA concentration in ~lghd. The purity of the RNA was also determined by
calculating the 00260100280 ratio, which is optimal between 1.6 and 1.9 for pure
RNA.
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4.2.4 Reverse Transcription Polymerase Chain Reaction (RT-PCR)
4.2.4.1 Principals of RT-PCR
Reverse transcription polymerase chain reaction (RT-peR) works on the same
principal as conventional peR, whereby a template is amplified with the aid of
oligonudeotide primers and a polymerase enzyme. The main differences
between RT-peR and conventional peR lie in the fact that peR amplifies DNA
from a DNA template. RT-peR, however, amplifies DNA from an RNA template,
resulting in complementary DNA (cDNA). Furthermore, RT-peR is not an
exponential amplification of the original RNA template, but rather creates a
scenario whereby the amount of onginal RNA template is directly proportional to
the amount of final cDNA product, i.e. each template RNA molecule is copied into
one cDNA molecule. This is achieved with the aid of an enzyme known as
reverse transcriptase (Figure 4.1). RT-peR therefor allows one to apply
conventional peR to a form of template that is a direct reflection of the onqmal
RNA present.
1
Reverse
Transcriptase RNase
I
I
I
I
I
DNA
Polymerase
primer ~
(needs new
primers)
Primed
RNA
RNA:DNA
hybrid
DNA copy of
RNA template
(eDNA)
dsDNA
Figure 4.1 Reverse transcription polymerase chain reaction (RT-PeR) copies each
original RNA template into a complementary DNA (eDNA) template, which can then be
used in a conventional peR reaction.
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Thus, an example of such an application would be to use mRNA as a template
for cDNA synthesis. This would enable one to investigate a number of facets
concerning mRNA, which could answer several questions concerning the events
between initiation of gene expression and the final protein product of such an
initiation.
4.2.4.2 Preparation for RT-PCR
Preparations were done as discussed in section 4.2.3.1.
4.2.4.3 Methodology
RT-PCR was performed with the First Strand cDNA Synthesis Kit (Appendix II)
as prescribed by the manufacturer using the random primers provided. In each
case, approximately 1 ~lg RNA was used template (as determined in section
4.2.4).
4.2.4.4 Gel electrophoresis
4.2.4.4.1 1% DNA agarose gels
The successful reverse transcription of mRNA into cDNA was confirmed on 1%
DNA agarose gels.
4.2.4.4.2 Casting the gels
After washing the Perspex gel casting apparatus (20cm x 10cm) with Cal-liquid
hand soap (Appendix II) and rinsing with tap water, the apparatus was dried with
paper towel and the gel solution (Appendix III) poured. The 20 Perspex well
Stellenbosch University http://scholar.sun.ac.za
160
combs were placed in the appropriate positions and the solution allowed to set
for approximately 30 minutes.
4.2.4.4.3 Electrophoresis
For each sample, 2.5 ~dloading dye (Appendix III) was added to 5 ul cDNA and
loaded. The gels were then electrophoresed at 150V and 150W until the dye
front had migrated 70 - 75% across the length of the gel.
4.2.4.4.4 Visual inspection
The cDNA was visually inspected under ultra violet light usmq a UV™
Transilluminator apparatus (Appendix II).
4.2.5 Quantitative analysis of TP53 mRNA levels using the
LightCycler system
4.2.5.1 Principals of the LightCycler system
One of the many applications of the LightCycier system (Appendix II) is the
accurate and reproducible quantification of gene expression. In addition to the
many applications, the LightCycler system has another major advantage over
conventional PCR, namely ultra-rapid cycling. This is achieved by the use of air,
which allows for a virtually massless process. The air is warmed by a heating
coil, which is controlled by thermocouples in a thermal chamber, which allows for
a programmed temperature accuracy of ±0.3 °C. Furthermore, a fan distributes
the temperature evenly to ensure identical PCR conditions for each capillary.
Rapid temperature transition rates of up 20°C Isecond can be achieved in this
way.
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peR occurs in specially designed borosilicate glass capillaries which can hold a
maximum of 20 JlI (Figure 4.2). These capillaries have a high surface-to-volume
ration, which ensures that equilibrium is rapidly reached between the outer air
and the inner peR components. This system is accompanied by software that
allows one to follow amplification in real-time.
Figure 4.2 Borosilicate glass capillaries used in the LightCycler carousel.
The combined advantage of the high surface-to-volume ratio of the capillaries
and the air used in thermocycling allows for a complete peR run of 30 - 40
cycles to be completed within 20 - 30 minutes.
Furthermore, the borosilicate glass capillaries are ideally suited at cuvettes for
fluorescence measurement, due to its optical properties. This allows for the
direct application of fluorescence chemistry, whereby the intensity of the signal
produced by a fluorophore is relative to the amount of peR product. This
fluorescence is detected from the tip of the capillaries at preprogrammed interval
during peR cycling (on average once every cycle) and can be monitored visually
with the aid of the provided software.
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A light emitting diode (LED) serves as the source of light with the optical unit
having three detection channels which can measure at 530 nm, 640 nm and 710
nm respectively. The LED focuses light (at the appropriate wavelength) on the
capillary tips and excites the fluorophore. The resulting fluorescence light is
conducted back into the optical unit, where a set of filters and mirrors separates
the light into different wavelengths that can be detected by one of the three
channels. It is result of this fluorescence that is plotted on a graph to give real-
time visualization.
The Lighteycler carousel is capable of holding 32 capillaries (Figure 4.3), which
are continuously rotated in the thermal chamber during peR. The mechanics are
designed in such a way that the optimal position for the carousel as well as the
optical unit is determined for each capillary, prior to initiation of the peR run.
Figure 4.3 A lightcycler carousel
accommodating 32
borosilicate capillaries.
By monitoring the peR on cycle-to-cycle basis, it is possible to identify exactly
when the peR is in the log-linear phase, i.e. where the peR product doubles with
each cycle (Figure 4.4). As can be seen in Figure 4.4, the start of the increase in
fluorescence is determined by the initial concentration of each sample, with
higher concentrations increasing first.
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Figure 4.4 Amplification results in an increase in flouresence. A typical graph
demonstrating the increase in fluorescence during amplification of a 300 ng (blue
line) and 3 na (red line) of human aenomic DNA.
This monitoring of the PCR is achieved with the aid of a dye known as SYBR
Green I, which binds to the minor groove of double-stranded DNA (dsDNA)
(Figure 4.5). SYBR Green I is thus more specific and sensitive than ethidium
bromide, due to the fact that fluorescence is greatly enhanced when bound to
dsDNA. This would mean that as the PCR progresses, different intensities of
fluorescence signals can be detected, increasing as the amount of dsDNA
increases. It is for this reason that the fluorescence is measured at the end of
every elongation step, at a wavelength of 530 nm, which is optimal for SYBR
Green I. It is this fluorescence from cycle to cycle, that is monitored visually with
the accompanying software (Figure 4.4).
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Figure 4.5 PCR and SYBR Green I (A) During denaturation, all template DNA becomes
single-stranded which does not allow for the binding of SYBR Green I, resulting in a very
low level of fluorescence. (B) When primers anneal, a certain degree of dsDNA is
present, to which SYBR Green I will bind, increasing the level of fluorescence slightly.
(C) During the elongation period, the primers are extended, allowing more SYBR Green
I to bind, further increasing the level of fluorescence. (D) At the end of the elongation,
all the DNA is in the double-stranded form and therefor the maximum amount of SYBR
Green I is bound as fluorescing.
Another application of the Lighteycler system is the determination of each
amplicons melting curve via a process known as melting curve analysis (Figure
4.6). Each dsDNA has its own specific melting temperature (Tm; which is
defined as the temperate at which half the DNA is in the double-stranded form
and the other half in the single-stranded form) which in mostly determined by the
Ge content and the length of that fragment. Determining the Tm of peR
products is achieved with SYBR Green I and allows the confirmation of peR
product identity as well as differentiating between different fragments, such as
non-specific peR products and primer-dimers.
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Figure 4.6 Melting curve analysis of a J3-actinexample; (a) demonstrating a typical
graph obtained when plotting the fluorescence vs. temperature and (b) demonstrating a
typical graph obtained when plotting the log of the fluorescence obtained vs.
temperature. This fagurethen also demonstrates how different sets of peaks can be
obtained such as the first one seen at approximately 770C which could merely be the
result of non-specific amplification of primer-dimer formation. However, the peak of
interest i.e. the melting point, can be seen at approximately 85°C and can be identified
by the high levels of fluorescence of each sample, at exactly the same temperature.
As can be seen from Figure 4.6 (A), the fluorescence decreases as the
temperature increases. Melting peaks are derived from this data (Figure 2.6 (8»,
which indicate that at lower temperatures, non-specific products show a peak, but
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no peaks are seen at higher temperatures. The inverse can be seen for the ~)-
actin fragments, showing how one can distinguish target products from non-
specific ones.
One also needs to consider that not samples contain the same amount of nucleic
acids and therefor not all PCR reactions will contain the same amount of nucleic
acid as a starting template. This is compensated for by inclusion of an
endogenous reference as control. This endogenous control must be chosen in
such a way that the conditions of the study (e.g. induction) do not influence the
expression of this endogenous control.
Finally, the data obtained from the LightCycler system can be interpreted in one
of two ways: absolute quantification or relative quantification.
When performing absolute quantification, it is necessary that the absolute
quantities of the standard be known and accurate pipetting is absolutely
essential. This type of quantification enables one to determine the exact copy
number of any given molecule (e.g. mRNA transcript).
When performing relative quantification, however, the approach is slightly
different. It is not necessary to have a standard of known concentrations. Rather,
target quantity is expressed relative to an endogenous reference. This is
achieved by firstly generating a standard curve for both the target as well as for
the endogenous reference. The amounts of the target and endogenous
reference are then determined from the respective standard curves. Finally, the
target amount is divided by the endogenous reference amount, resulting in a
normalized target value.
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4.2.5.2 Oligonucleotide primers
4.2.5.2.1 Endogenous Reference
Human glyceraldehyde-3-phosphate dehydrogenase (hGAPDH) is a glycolytic
enzyme that catalyzes the conversion of glyceraldehydes-3-phosphate to 1,3-
diphosphoglycerate. GAPDH mRNA as well as protein are known to be
abundant in most cells types and was chosen as an endogenous control, based
on previous quantitative studies done on various cancer types, including
esophageal cancer (Ikeguchi et al. 2003; Li et al. 2003; Ikeguchi et al. 2002; Liu
et al. 2002; Li et al. 2002; Park et al. 2002; Hu et al. 2001; Shen et al. 2001; Oka
et al. 2001; Yajima et al. 1998). The primers (Table 4.1) were designed and
optimized by Dr. Heidi De Wet and synthesized by Whitehead Scientific.
4.2.5.2.2 TP53
TP53 primers were designed and optimized for TP53 analysis (by D.Barnard),
according to the following criteria: the PCR product should range between 100
and 250 bp. The primers were also designed to lie within neighboring exons.
This would allow for easy verification of DNA contamination of RNA; a PCR
product arising from mRNA template (cDNA) would be contain the intron between
the two primers as thus be larger than the PCR product arising from the mRNA
(cDNA) product which contains no intron. Contamination could therefor be
verified on conventional agarose gels as well as on the LightCycier system,
where two melting curves could be observed in the case of two PCR products
being present.
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Table 4.1 hGAPDH and TP53 primers used in this study
Primer" Sequence Tm DNA cDNA I
(0C)2 product 3 product" I
hGAPDH_r o fV\G GTC GGA GTC AAC GGA TI 3' 53 1954 bp II 226 bp I
1954 bp
i
I Huh, LJ _ 5' CTC CTG GAA GAT GGT GAT GG 3' 153 226 bp I
TP53_F AAT CTC CGC AAG AM GGG GA 3' I~ 218 bp 126 bp I
i TP53_R 5' GGT GAA ATA TIC TCC ATC CA 3' 58 218 bp 126 bp I
I
1F refers to forward pnmer and R refers to reverse primer
2The melting temperature used for each primer pair during PCR amplification
3Size of PCR product obtained from a DNA template
"Size of PCR product obtained from a cDNA product
4.2.5.3 Methodology
4.2.5.3.1 hGAPDH and TP53 melting curve analysis
Melting curve analyses of both hGAPDH and TP53 were performed with each
PCR amplification in order to confirm the absence of unwanted products such as
those arising from DNA contamination or primer dimers.
4.2.5.3.2 hGAPDH and TP53 standard curves
Based on the relative quantification method described earlier (section 4.2.5.1),
tumor biopsy number 204 was selected at random for the generation of the
hGAPDH and TP53 standard curves. This was done by creating a series of
cDNA dilutions as follows: undiluted, 1:10 dilution, 1:2 dilution and 1:100 dilution.
Lightcycler-PCR was then performed for each of the two primer pairs, using each
of the above mentioned dilutions as template. LightCylcer-PCRs were performed
in the appropriate capillaries (section 4.2.5.1) using the LightCycler - FastStart
DNA master SYBR Green I kit (Appendix II) under the following conditions: each
mix contained MgCb to a final concentration of 3 mmol, 1.0 ul of the LightCycler
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- FastStart DNA Master SYBR Green I mix, forward and reverse primers to a
final concentration of 0.5 mmol, approximately 1 ~lg cDNA template and the
provided sterile water up to a final volume of 10 u]. Using the provided software,
the LightCycler run was programmed as follows. An activation step at 95°C for 9
minutes initiated the run. This was followed by the PCR step which consisted of
a denaturation step at 95°C for 5 minutes, an annealing step at the appropriate
melting temperatures for each primer pair for a period of 5 minutes, followed by
an elongation step at 72°C for 8 minutes. A total of 50 such cycles were
performed and where the acquisition mode was set to measure fluorescence only
once after every elongation step. The PCR step was followed by a melting curve
step whereby the reaction was kept at the appropriate melting temperatures for a
period of 5 minutes, followed by an increase in temperature to 95°C at a constant
transition rate of 0.20°C/s. The acquisition mode was set to measure
fluorescence continuously during this increase to 95°C. The final cooling step
was performed at 38°C for a period of 10 minutes. A constant transition rate of
20.0°C/s was maintained throughout the run, except in cases where specified
otherwise. Extreme care was taken to prevent PCR contamination, and all
experiments included a control reaction tube in which template DNA was
replaced by dH20.
4.2.5.3.3 hGAPDH and TP53 measurements
The levels of both hGAPDH and TP53 were then measured in the undiluted
samples of each of the 4 samples discussed in section 4.2.2 by performing
LightCycler-PCR as discussed in section 4.2.5.3. The relative quantities were
then determined from the corresponding standard curves.
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4.3 Results
4.3.1 Sample selection
Samples were histologically confirmed to be positive for malignant cells and can
be seen in Figure 4.7. The results deomonstrated in Figure 4.8 are those
obtained after performing an RNA extraction on fresh cultured cells from a NG63
human osteoblastic cell (lane 2) versus those results obtained after performing
an RNA extraction from the poorly preserved tumor and surrounding tissues
selected for this study (lanes 1 and 3). The RNA in lane 2 demonstrates the
typical profile seen in genomic RNA, with the upper band representing the 28S
rRNA and the middle band representing the 18S rRNA. In some cases, an even
lower band can be seen, representing the tRNA species. The faint smear seen
across the length of the gel, represents the mRNA species, varying in molecular
weight. As can been seen here, the intensity of the 28S rRNA is twice that of the
18S rRNA species, which is typically seen in an ideal RNA extraction. This would
indicate that the technique employed for the RNA extraction was without fault.
Although there appears to be a general smearing of the gel, this can be
accounted for by the fact that the agarose used was fairly old, and does not imply
any negativity in terms of the techniques employed.
In contrast to the expected bands at their expected intensities seen in lane 2,
lanes 1 and 3 rather appear as gross smears, with no defined bands. This
already served as the first clear indication of severe RNA degradation resulting
from the insufficient sample preservation discussed earlier.
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(b)
Figure 4.7 Cross section of a typical tumor biopsy sample (not one of the two used
in this study) used to histologically confirm the presence of malignant cells where (a)
illustrates the presence of malignant tissue and (b) illustrates normal healthy
esophageal tissue.
4.3.2 Confirmation of successful RNA extraction on 1% RNA agarose
gels
123
Figure 4.8 A representative example of a 1% RNA agarose gel demonstrating
the RNA extracted from the two tumor biopsy samples (lane 1 - patient 204 and
lane 3 - patient 205) as well as from cells from a cultured NG63 human osteoblastic
cell line as a positive control (lane 2).
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4.3.3 Concentration and purity of extracted RNA
The RNA concentrations for the 5 samples (2 tumor biopsy tissues, 2
corresponding surrounding tissues and HG63 human osteoblastic cell line
as control) varied from approximately 0.6 ~lghd to 1.2~lghd with the 00260/
00280 ratio averaging at 1.7
4.3.4 Reverse Transcription Polymerase Chain Reaction (RT-PCR)
1234--+
Figure 4.9 A 1% DNA agarose gel illustrating the eDNA obtained after
performing RT-peR on RNA obtained from both of the two tumor biopsy samples
(lane 1 - patient 205 and lane 3 - patient 204) as well as from the corresponding
surrounding tissues from the same patients (lane 2 - patient 205 and lane 4 -
patient 204). Two negative controls (-; containing water as template) and one
positive control (+; provided in the kit) were also included.
In Figure 4.9, the results of the RT-peR performed on the RNA extracted from
the tumor biopsy as well as the corresponding surrounding tissue from the same
patients can be seen. Here again, the effects of the severe RNA degradation
resulting from the poor preservation techniques can be seen in the form of
smears rather than defined bands at particular intensities
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Even though the RNA obtained (from the two tumor biopsy as well as the
corresponding surrounding tissue samples selected for this study) proved to be of
an insuffident quality to obtain any recognizable results, the study was taken one
step beyond to further prove this. By attempting to apply the generated RNA to
procedures performed on the LightCycler system. This was approached by
initially performing a melting curve analysis on cDNA obtained from the RNA
extracted from the freshly cultured cells of a NG63 human osteoblastic cell line.
The results can be found in Figure 4.10 and represent an excellent example of an
hGAPDH optimized primer pair, showing only one peak at the expected
temperature, with no non-specific products or any primer-dimers.
4.3.5 hGAPDH melting curve analysis
Figure 4.10 demonstrates a typical melting curve under optimal conditions, were
are the samples denature at the same temperature, resulting in all the peaks
lying on top of one another, at one particular temperature.
9 bON' _P91 10
10Repll_ fJltl'tOAP _P81:1Q
11 hOM' _P24.h1 10
12 RepII_ ofhGAP _P24h1:1D
11ftON'_Pdh110
'4 RepII. afhGAP _P48tt,: to
1\5 hGN3 P72tl1 18
18 RepII_-ofhGAP _P72h1:1Q
17 h(MP _NegCon
Temperature ('C)
Figure 4.10 A representative example ofa hGAPDH melting curve under
optimized conditions, using cDNA generated from RNA obtained from cultured
cells of a NG63 human osteoblastic cell line as template.
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In Figure 4.11 (a - c), the very same primers (hGAPDH) and LightCyder program
were used to perform a melting curve analysis on the eDNA generated from the
RNA obtained from one of the two tumor biopsy samples. Initially, the sample
dilution series was prepared in single, however, later duplicate series were
prepared. The reason for this melting curve analysis being performed three
times at three separate occasions and by two different individuals was to
eliminate the possibility of inaccurate pipetting being the cause of the discrepant
results. The only condusion that can be drawn from these final results are that
the RNA extracted from the tumor biopsy and surrounding tissues were of such a
poor condition that no results were obtainable, irrespective of the technique or
technology applied.
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Figure 4.11 (a - c) hGAPDH melting curve analysis performed on eDNA generated
from RNA extracted from sample 204 tumor biopsy. This analysis was performed
three times, two of which were done in duplicate.
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4.3.6 hGAPDH standard curve
Finally, a standard curve was generated using hGAPDH primers and cDNA
generated from RNA obtained from freshly cultured cells from a NG63 human
osteoblastic cell line (Figure 2.12). This was simply to once again demonstrate
that the hGAPDH primers were efficiently optimized and to prove that the RNA
extraction method employed in this study was sufficient and not the reason for
the poor quality of the RNA extracted from the tumor biopsy and surrounding
tissue samples used in this study.
It was then for the above mentioned reasons that the study was halted here, and
no further experiments were performed on these sample.
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Figure 4.12 A representative example of a hGAPDH standard curve under optimized
conditions, using cDNA generated from RNA obtained from cultured cells of a NG63
human osteoblastic cell line, as template.
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4.4 Discussion
The conclusion of this study is that RNA obtained for the purposes of this study
were of a poor condition and not suitable for the applications attempted in this
study. This section will therefore explain why this was the case, and furthermore
discuss recommendations for future attempts at such a study.
The first point to note is that the samples used in this study were selected based
on their immediate availability and were collected and stored at -80°C in
disposable polypropylene cryogenic vials. The original intended uses of these
samples were for the application of molecular analyses on a DNA level. This
method of preservation may be insufficient for any molecular analyses involving
RNA. This could be due to the renowned short half-life of RNA as well as its
tendency to degrade rather easily.
In future, a recommended solution for this problem would be to start with an
improved planning strategy. If samples are collected for molecular analysis, and
one of tile intended uses could include RNA related studies, the samples should
be preserved more appropriately. This would mean that immediately after
obtaining the sample, be it blood or tissue, it should be immersed in an RNA
stabilizing agent. Examples of such products include the RNA/DNA Stabilization
Reagent for Blood/Bone Marrow (Roche) and RNAlater Stabilization Reagent
(QIAGEN).
Furthermore, although no recognizable results were obtained from this study,
three important contributions were made to possibly similar such studies in
future. Firstly, if one intends to perform molecular analyses on any RNA species,
the correct method of preservation from the very beginning is essential. By
employing RNA stabilizing agents in this preservation process, one dramatically
increases the half-life of the RNA species, enable its safeguarding for extended
periods.
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Secondly, a very well optimized RNA extraction method from tough tissues (such
as the human esophageal tissue used in this study) has been developed. By
making the minor adjustments discussed in section 4.2.3 to the High Pure RNA
Isolation Kit (Appendix II), and also keeping in mind the precautionary measures
discussed in the same section, it is now possibly to extract large quantities of
RNA from small amounts of tough tissue types.
And finally, for future TP53 studies involving RNA analysis, primers have now
been designed and optimized, enabling one to both identify the presence of TP53
RNA species as well as the absence of DNA contamination in a single peR
amplification step.
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The spectrum of mutations in TP53 in laryngeal cancer patients from a
high-incidence population shows similarities to many of the known
mutational hotspots
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Abstract LarVll~l',lIt"l1lc'er (lF) is the <ixrh 1110,;( (0111111\)11cancer In the \Iorld and the s,:c',md 111()'! 1'()1l11l1\1Il
rl'sl'ilAorv canCI'r. with al'llr<l\ilnal"ly :"(i().I)()O ncxv cases \\orld\\ilk. .mnuall-, ThC'lll\'I'lwnislll\
oj 1\IIIl\lll)2CllC',i, III Le n-m.iin unknown. alll1<\\1)211 '1\\01-,11\," .md akolwll'ClIhlll11PII()t\ .JrC C(llhldercd
I" hc maim risk laelms, Muiuuon« within T!'53 il,,,c' been ,;(101\)2ly Ililpliciled a, lrcqucur \'\t,nl:,
III :;c'\ er.il CllJ)l't'f'. VVl' >,;cI"L'L'llcd l~\~)jh) ;:.;ullI'53 rol' mut.uion- In Di\/\ ItU!l1 tumor hi()p~!l':-; (I; 4-+ l
"ml blood saillple, (II ,[21 lrom thc sal11t' Le paucnrs. and blo"r1 s:\lnpks fWI11:1 hcnlihv. m.uchc.l
,'(llltr,,1 ,,'roup (/I c)()). usil\~' 1'01>I\lcTaSe chain rca.tion sill~k-"r'U1d conforJ1L1tiol\ 1)(,hI1l0rphiSiIl
i}'('!,-SS('!'i <l1\:llv.'" and direct scqllcIKln.~, Slgllllieallt jllhlll\c' corr. l.uion-, were I\,UIHI hcl\\CCII
Uh:' (.)(_'(_'lIITl'llCl' \)!' Le dnl! dgC .md :'llh1h.illg. Wlll'!\.'<b dail_: meat cnll:--lllnpt!\)l'I \\",t" il j'1(),\sihk
]'wleelll,' jado!'. In nuuor-dcrivcd -.unplc-; \1\\11:11ion-. \\ crc I\lUIld III tilt,',' ol th,: ,'\Olh lIlldt'l
ill\t',qi,~atioll. rq)I't'\t'1l1illt! 2:;(,'; nl' the' ,,,anlpk·,\. The lllUl;.lttPllS were unique \0 the' tumor hiup."lt>.,
illdlCdlJl1g ~I "';Olll:llll· (\!ïf!il1 ll,lr mut.uronx 'fhe lbL! courinn thal lhl' rCf!iull h",'l\\,,'('ll l'\_){hm:--. ! ~::'
.md _27_~uI' TP53 is d mut.uioua! hot-pot regioll rol' callccr:-; in gL'tll;?!it!: six novel mutation-, were
Iound \\ ulun lh" "\l1lc' rC~ion 200:1 U'e\ ier Inc .\11 rI!2hl' ró('!'\ cd.
I. Introduction
Laryngeal cancer (Le). often referred to simply as throat
c.uiccr. is the sixth most common cancer in the world [II
and. next t(\ lung cancel', it is rhe second most common
rc'spir:\tory cancer [2] Being prevalent in males over the
age of 55, it occurs at il global incidence of approximately
h.ilf a ruillion nc« elses each year [31 and pre,,:nh with a
(lO'>; overall 5-year survival rate 141, Despite advances in
current therapies, olle of the leading cause'S (If treatment
r.uhu«. spculically :lIter slllgIt'iti removal of the tumor, re-
m.uns rccurrence-, due to the presenu: of tumorigenic cells
within the surgical margins ur cervical lympl: nodes 13]. A,;-
(\)rding to the upper ilcH)digt:stive trae! (UADT) cancer lig-
lIIC~ fur 11)90 ..l) I, South African men and women Iall ill the
11Iphcst incidence ,'akgory lor Le 151. with Colored males
!!lh~--I-()();-\/1H!S ..,e,,' Irn!)l llla!!I.:'! 21Hl_; !.J\l'V1Cl ln,: '--\11 right-..: l'e\~'rvcd
d; lj: I (,I, 1() I (1iS{)! ())---i()(l('\\ OJ j{ j( l{ J()4-)
displaving tile highest number of Ill'VV CISe'S pn .nuuun
(IO,V)!I()().()()()/vcarl 151, 1"111 il dclinltioll nl ('"llIlt'lL SCl'
section 2,
The e xact causes ot Le remain Ullkl}OWIL rel'(\Jtt't! lïsk
factors include smoking and heavy ak'ol)<)1 consumprion [hi,
Muiauou-, within T['53 have been obxer, cd as frequent
events ill many cancers [71, This pt'llC is loc.ucd Oil the
short arm (lf chromosome 17 and ellcodt's a Yl.' al1111l0 acid.
53 kDa protein, which is cxprc-e-cd in the nucleus ol Ik
cell IRI, This phosphoprotein IR.91 i, :1 tumor supplC\sm
protein and is responsible 1\\1' negative cell cycle rt'gulati()n
[101, II has ul-o been found to play .m import.uu mk
in genomic slability as well as in DNA rep.ur 1111, More than
95'.; (\1' the observed nucleotide altcr.uiou- withill 11'_'3 art'
point mut.uious. leading to the synthesis uI' ,I mutant protein
[12] that loses it.s tr.mvactiv.uionul activity 1131
EX()!lS 5 through R have heen found tu encode the DNA
binding domain ur p53 [141, and most mutauou-, rcponed
occur in this region, The aim of this study was tl) search lUI
nucleotide changes within cxon-, 5 to ~ 01 TI)'., and t(l tcst
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I) li,iiUtU/i .: / ( (j('f!t'!l(\
tor correl.uion-, with possible cau-auve eli()Ic,~ic fac((.rs in
il ~r(llip ol lC p.rucnt-, tlCdtl'd dt T\ ~l'rhlTg Hospital. Cape
lown. SUlith Arril·d.
2, Matcrials and methods
.:: J. .\'{l/lfJ/e.\
Frc-h tumor s.uupl« hiopsic, 1()~5-1- Ill!:') were obtained
lr.nn -.f-.fle p.u icntx: 22 Colored males, ~ Colored lcmalc».
1\ AI',C\l1 Blad; male». 2 \Vhlte males. and (1 nt unuk-nnticd
crhnicitv. The Colored group is otmixed <Incestry. c()nsistin~
m.unlv ol' Khoi ()I'i!:,ins, hut ;Ibn includinj; Cauc.r-.i.m. Ahi-
c.m. vlaluv, .md San origins 115 I. ;\11 patient-. underwent
Illvestigatioll at TyglTbcrg Hospital. Cape Town. South
,Africa, during the period from January to December 200n,
The age range of the patients was -1-1~ 7R yean; (with a mean
,)1' 5R year,). Each hi'lp') was divided Illtu two secnous.
.uul hhl<lloglc evaluation ot ihe (llll' ,,~CIlllil confirmed p,.\nr!)
dillerl'llti;ltl:d to 11t'l1 dt!1crentidll'd xqu.uuou-, cell c.uci-
noma. The xccond xccuon of ti"uc \VdS snap- frozen ill
liqUid nitn'gl'll Illlll1l'diatcl) alkr surgic;d removal and II;\S
stured at inc tor further molccul.u unulyxi-, Blood sam-
ple, II ere a\ ailable from -+2otthe same patienl'i as ctllltmis.
;\ CUlllp;lIïSllli (lj the daLi obtai lied trom these sample
seh I\as dUlll' to determine the occurrence of loss or hetero-
l\ !éu,il \ (LOl I). which woukl indicate whether the: observed
mutuuon-, .uc genl'ti"ally inherited or somatic III origin. In
.uldition. blood WdS obtained from a healthy control group
Iii -.fOI, marched according to age. gender. and ethnic
):'I'llu]'. t(\ distinguish mutations from pns .<ihlc polymer-
phislllS. The' study II as approved hy the institutional ethics
conuninee and informed consent v, as obtained from all
slIbll:l'tS.
Ouestionnaires were completed hy dil patients and hy
memhers nl' tilt' control group. eo\e>ring aspects ;;uell ,I~ age,
gende\. ethnic group, place of birth. tobacco and alcohol
consumption, and \ .uious diet.uv habits. Data obtained Irom
these' questionnaires were used to construct il database for
lurthc: ,'(lITe' l.u ion st udie-.
")3. Tissu: s.murics .uu] /)NA extraction:
DNA was extracted Irom the tumor biopsy samples using
the QL\mp I);\A minikit (Qiagl'n. Valencia. CA, USA.\.
Using il new. sterik scalpel blade for each sample. the frozen
hiopsles wert' cut Into smaller fragments (Uil icc) and
weighed. The protocol was followed according tll the spel:i-
Iic.uiou-. "I the munutucturcr. except that all the solution
volumes were doubled fur biopsies weighing 25~50 mg.
DN A was obtained from the blood samples according to an
adaptation ol the salting-out procedure for human DNA
extraction 1161. Essentially, icc cold cell lysis butter 020
mIlIllilL sucrose, I Triton X- !(JO, 5 nun..l/l . \:lgCI., II!
mrnol/L pH 7.h Tri-: \Ias .uldcd tl' c.rch hl\)ot! S;I!llple-
(5 (J volumc- » 1"llow,'Li hv d I )-mlnllk l'l'ntrlfU~dtl()11 q,,1'
at -.f C and .'\JOO rpm The pl'ikt \\ ,IS ihcn III
lJ ml. nuclei l\slS butler (-I(I(i ll1111nl!L i'\;tCI. [0 lIl1110l/L
pil :-\.2Tris, 2 mmol/L pH x.2 ITH;\). I ml, lUI;; \OdIUIIl
dpdcn I ,ulLlte (SDS I, .uid pr()il'ill,l\l' K (Io;t tillal ((\II('CII1 r;l
tion of [O() !lgirnLJ. After ;1Il overnicht incubation pcrio.l
at .\/ C. ., ml of saturated NaCI I ·6 mol/l I xoluuon II as
added, followed by another 2()-lllinlltl' l.'Cntrilug;ltioll step;ll
-I C and ,(l()() rpm. The DNA wa-: then I'll:C'I)ILttcd In
addition of 100"1 ethanol. washed in 7()(; cth.mo]. ,IiHI re-
xuxpeudcd in 2()() ft [ 'IF huiler ( I () nunol.'! pH i", Tris. :'
mmol/l . pH 7.5 EDlA I.
2.-f. Pol, tncrus« chain rcuctu»: (fil R) uII1/JI,!lc(//{O!i
Primers used to separately amplify cx on-; 5 to S (li TP.'3
were as previouxlv de'LTihed 1171 (Table I ) and synthe.'M,'t!
using a Beckman Instruments (Fullerton. CA. USA) OlIg()
I ()(){)M DNA s)ntlh:,;i/'T ;\11 peR ampllli,.'diiolls were I'u
limned at il standard heating lid temperature ol 105 C. an
initial dcn.uur.uion \)1' ; rrunutcs at Lr; C, ,I slIhSCqUl'l1l dl'lIa-
turntion period (lf I minute at 93 C. an ;lIlnedilng p,'rlod ot
2 minutes at the revpeerivo Illclting temperatures (Table I).
all elongation period of 2 minutes at 72 C. a III I a fin~t! t:lnnga
tion period of 5 minurc-. al 72 'c. III tot.il. .'5 cvclc- l\l'Il'
performed for each PCl; rc.uuon, wirh c.uh lUO-pL nu-,
containing the following: lOx buffer (Prullll'ga, Madi"'11.
WI. USA: 500 mmol/L KC!. [00 mn« <Ill TIIS, anel '1'11[1)11 A-
100 lo il linal eoncentranon of () I ), l'vlgCI, (Pn>nlc):':t: lP
a lillal l"\IICClllration uI' 1.5 nunol'] ). prillK'ls fU(\lard ;\lld
reverse (tu a un.tl C,)\lt:Clllrat I' \11 (\1 () 20 urnol/L c.u.h). T.«]
polvmcr.r-c (Prullll'ga: 1~2 Uillts per rl:al:tii\n). and dciunill:t1
'('"hic I
lorw.ud !I:) <lIlt.! 1\'vcrSt' (R) plïm(T\ 1(1\"pnly!11l:r:h ..: .hain rt';I\.!\(lilIP(t~l
;ullpliticlli\)11 {lf ~'\nn, :) fCl S lP5_1
IC,
[\(lll .) 5'1'-
E,,,,, )- .'ïR
IT\ TCl GIT C.\C rlfi HiC CC
TC\ HiT GCT (;TG \( '1 CCI TG
E \\)11 S-.~·F
[X(,)11 5---.~·R
TTC L\e .\('( (CC (;n.CC(; C-\
Ace eTG GG(' AAl' ('i\(i ('( c: TC
·\CG AC\ GCin CTG Ci IT GCC C-\
eTC CC\ Cii\C .\CC CC.\ (iTI (il'
(;.1
(d
[\U11 (1 F
l.xon () R
L\()f} 7 I
F\\\]1 7 R
GGC ere Arc TTG (i(il' CHi TCi
Mi TCiTGC\ (;C,G n;c, C\.\ C;T
('-I
rd
!-'(>11 X l-
E\.\\11 8 R
CT( i ('Cl err CCT lt I CT I rt
rcr eer CC.\ ccc C I I ( I I (il
l.x..n :=; \VJ\ ;!1l1pli1iC'd two pel<. j11{idlli.._\'''; dlH' UI ir ...."ill'
pril11(ï' .,cl )---.)'F and ~·_·-.5ï\ :ull):liih'li " l'lhl dlHJ ['!'IIIh..'l \l'l :) .:,'1- dlh_!
.1·R the :\' end.
h Primer :'.Cqth..-ncc-, pbtaincd frnlll Tngu\_'lli(Lt ct ;II_ !!7
T~l!j, 111,-'!lldlin~ !t'lllj1\',:ra\Ui\' l'<.\ch prlllil'r "l'! u~;__,d in !'CR
\,';Il!P!l durin~ ihi-, -rudv
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}SSCP
banding
patterns
/)
purt' w.ucr (dl-l-O: lip Il) ,I Illlal volunie 1)( lOl) ul.} D\A
lc'llipiail' IV;" added [l> d 1111;11C"lll·entratl\'l1 01250 Ill,' per
,;t1nl'k ~c\treillc c;lre II a, t.ikcn lo prcv en: PCR contaminn-
1IIlIl. .u«l all cxpcrnncut« included a control reaction tube In
II luch Ill) template D\i;\ w.r-, added. The pre-enee (lf [)\A
prtldUCh and the absence (lf cout.urunauon were vcruicd by
cthidiurn bromide ';Lllning alter clcctrophore-;», (lf lO ~IL (lf
.uuplilic.I D:'\,\ "Il 1.:'/; p"hacl)I;II11ide I1linigcl.; (Bi" Rad
Labor.uoric«. Hercules. CA. USA) Il~l.
':.5. SllIg!c-\!rw/(!, O/l!O/I/lu/!liilcJl/)ohll/{I)phi)ll/ (SSC!")
anal vs::
Aurplicon-. obtained from n,un, 5 8 W,Tl: analyzed with
SSCP ~!l'I, clln.;isting Id (J'( polyacryl;lmide !Bio-Rad: 30',
.icrvl.unidc-bis solution. 29: I). 5',( glycerul, 6'; lOx TBE
butier (lOR 12Tri" . .'i.'i g boric acid. 7...+ 12 EDTA in a total
1olumc of IIIO() mi. dH:O: pH R..~(I). () (l(1(/( annnonrum
Pl:IHtlLlk. ;1I1d 1(10 ul. Tcmcd. in <I total volume of 20() inl.
cIfLO. (ic'1T311nd lilu: \\d.' IIsed til LlcilJtdil' thl: hdndlin~ III
the: g,:I\, which WlTC then ckctrnplwrcsl'd at [SOO V .WO
mA, ;tllli 'i0 'vV and rOO!l1 rcmpcr.uur.: for .~ hour, .,() minutes,
W,II1~ ;t 1).(Jx TBE ruuning butter. This was dOlle both for
.uupl icon-, obtained from tumor hlopsy samples (II .= 44) and
tor those obtained Irom lhl: two blood sample sets (control
hloo.l trom I',tt lents It u LOH. II 44. and control blood
Inl poh tnorpluvm-; II -r- 4()\ In dcurminc whether LOf I or
polvmorphism-, OCCUIll'CI.
Each sseI' ,!lel (c.!! .. Fi!!. l A) was scored individual I)
;t1'l'ordlll,~ ru the various h;l1ldlng p.utcrn-, 1.<1 to r). Scoring
l:ollClitiolls were stnngcnt. and to eliminate the possibility
(If ()\'t,tliloking a mutation. bands (,f a \"('1) low intensitv or
with the <lightest mobility shilts were often included ill the'
A
f:-~f:-~f:-~I-r::ol-~I-r::o
-.D\OO\o\oooot---t---'<t''<t'oo
'<t''<t'MMNNNNNNNN
;1 b l b d b d b c ct d ct
({ut!
Sl:Ollng procedure, ;" d prcc.iuuonar, mc.r-ure F"l êill'iJ
cxon. PCR product-, uhLlIllcd trom tumor hlup\) s<imple,
and from blood 'amples ol the sallle: patiellh II ere: run adp
cent to each other 011 SSCP gels. Rcprcscru.uivc x.unplc:
from each unique pattem were then s,:IcCll:d for DNA \l'-
queueing analyxi«. T<, PI(\\(, th.u thc-«, result, were rcproduc-
iblc. these rcprc-.cntauvc s"mpks were then rc.unpliti,«! .m.l
the .unplicon-, were a,~;lill dll,tlYL.,'d und,'!' idcIIllc,t] sseI'
Gel coneli Iion" ii' de,eri bed "bOl e The xarnc all1pllcolh \Vc'I'c'
also evalucred under a \,:c,)1Id ,,~I,If sseI' conduion-,
polvacrvl.unidc. 5'// 121\ccrol (Bio-Rad: ,lW'; acr) l.unidc-bi-,
solution. ~9: I l. (J'; lOx TBL Buller IIOx g Tlls. 5.'i 12b"lIl
acid. 7.4 g FDT ..\ In ,I tut,d volurne uI IOO() ml. dIU); I'll
~LI()). O.O()', ammonium persullut«. and 100 pt 'Iemed 111
a lotal volume or 200 ml dH20. Thi .; w.i-, done lo IH{j1 l' thai
the results were icproducihlc and also ro iIl1IH()\C thl: chances
(lf detecling all possibll: ruutauons.
2.6, niVA \('qU(,IIClll~
Samplc-. were subscq ucutl , selc:ciL'd lor sel] ucnc lIlg (Fig.
IB \ trom each of the three DNA. silmple .;ets lo lcpn':S('1I1
at least olie (lj c'ildl of the I ariou- h,llldlllg patterns lor lh,'
four C:XOIIS LInder illH'stigatioll. Amplicon-, were purified
using the Nuclco.Spin kit I\Ltche:r,:v-Nagcl. Duren. Ci,T
many). following the instructions recommended by the man-
utacturer. The PCR products were then sequenced USlllg
all ABlPlISIll allall zcr unudc l '100: Applied Bi'''ySICllh.
Ft.hter Cilv. CA, USA)
2.7. CO//e/UIWII <nulic»
The nonparametrie Spcarmnn rank corrc l.u ion w.», ]lC/-
formed lo determine .uiv siguiucarn corrclauon- hctwc,:n
B
Double
stranded
DNA
h,:_:_ I I,I\IIH.'I A~ ,.\n I..~\;lmpk(lf cl (\'( pul)'tl\.:r_\Ï<lll1ldc \P·\fli':1 f'':1. Si, glyct'["nJ S.')ll) g('! nm Jnr.~ hour-, -.;()nunut,-, ,il l."i){) \' .m.! loom [l~rr;pCr;l{l!l\'
lhi, gel ~~nllt<liil\ n'pr{':';l:l1L.Hl\';.~ \.'\dlllple." of PCR prl1duct:-i nl' (,'\(\11 7. obtained trom ttlllllll' hi(lp;.,y D:",L\ (Tl i.llld 1)\),;\ lkri,'cd 1HlIli th.. P;d\cIIL. bliH,d
ILl'" the 1.:11l1lf(l! fur LOll ";dmpk -·,i.._'lBl. T!«. "L'{_I["l[l~ 'iy'ik'!!l !\. dl.'Ili(l!htcncd here. t'rp[!l ti t(1 C i!idJ:..~~lllng Ih(' v.uiou-, mnhiill} ,hifh dCk'<":!l'd, \';lrlJl!(ll1'-..
ill balldint:' paftnih bl..~t\l,.'cn d T lane <Jnd ;l Blane \\'Iluld iudi. .."ik ih.u ally nucleotide l:lnnp\..':-; I1h:'.l:rvcd \\ iihiu thl' tun)!)[ If',:\ i:.., pr(lh:!hh ..,nllu!ll li':
l\ligin Thi-, Vv';\,\ \lTi!it.'d wnh Sl..'qul.'!Kill!~: q\H1L-I H) rl~prC'St'nt;JIHHI ol lhc \u ..!l!Cl!Ct' (lh!aillt'd Ir(111l I!ll' rumor U[\L\ 1"\\1' t".\:)l) 7 pi P:_~\ll'lll iIH!ii._-~di;l~) J
IlWIé\\10[1;\1 pos!t!\l!l ~(), \\hert' hoth:l Tand .'\ Gill hl: seen The St'qtlt~llCe dtï)!lsikU III N(1)l LIL'CC,-\iill1 nu, X::;;·t!~hl "111\\'.-,,,;\1 -\ !\lllLtli')i1I\\;ild.!\
1\ ;\ T,i
Stellenbosch University http://scholar.sun.ac.za
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l'''Llll\éltTS me.r-ured under dClllo>!raphic dald and Ltryll:,:,~,d
l,lllïJlUlHCl. SPSS \c:r~i()n I() .'olt w.uc wa-. used (SPSS.
Chic'I~(l. II . l·S.\ I. and i' (l.()<; was conxidcrcd ,talisticllh
\!~~I1I!I~.:anl.
3, Results
, ito/JIlin shiits '/,'1('(/('(/ h· sseI' anulvvi:
Rc-ult-, obtained (Will sseI' ."cls indicate' that mobi lit I'
,hlft-; were detected only within the patient salllpk sct and
not within the control blood lor LOH xct. suggesting a S(l-
m.u«:
1.:':. !),\'.-\ sel/lfcl/('lllg
In total. 7::' seqUt'nCé, were ohtained trom the selected
,;II11Pit's. which were then compared with the wild type 1'P53
>c'quélh'e t National Center rnr Rio!êchIHllo:,:y Intonnution
I '.;CB I I nucleotide dalllbdsl' al:cessi')11 numher X541 56) lind
it W;!s Iound that the mut.uion-, observed were unique j(l
Jlllly Ihe IUIlI"r hl"psió .Ór \11 s<'qul'IlCl'S obtuincd from the
representative control« correl;lted with the same wild-type
/1'53 sequence (i.c' .. NCB I acce"inll number X541 5()). In
I(lUI. Il 1I11c1eOIidt, changes were found in three of four
l'\()Il, under investigation, reprc-cnunj; 2ye: 01 lilt: tumors
1111 l'SII)Cdlcd ill this study (Table 2) Tilt' Il mutations ob-
snvnl occurred in Il dillerent patients. III total, there were
ei ;Til/-ell.elT(1I 21.G '.'\111 2).G1C(1I II.
and T /A (Ii II mutnuon-, which rcprcscru., four uauvi-
tions. six transversion" and Il 'l-in-cn ion which was found
III onlv one ClSe. Exon 7 \Va, mutated in il (lf II pancut :
i))c, 1. with (i·;r (1/ 3: n)t!o1l249). elT (1/ I: codon
~.1S), and T tA (II I, codon 2:1:2) cllatl;':,'~. all rcsulrinu
ill .unino acid alterations. a, wcII as one 'r~inserti()n (codon
2)5 I IC'iultillg ill a frame shift. Exon II mutations were de-
tcekd ill .' of II patients (27';{). with (J·····)A In I: codon
T:lhk ')
\lH11!1Lll\ nj' lhl' ll1ul<ltillll:-- ()hl;iill\.~din 1..:\\)11' S---:.; (ll TP53 ill Le tumor
hh\p·~,!t::..,
l-rhni,: g!I!UP
I.von P,-lllcnt no. and sc\/age Codon Muiauon
.vuuno acid
.rlier.uion
"U'.!
I'I.U;
'1G('····,11 C (" S.. , I'lh'
CC;C .. ,CAC A,,,·'II,,
C\l!-I~
C\I145
17i>
175
()
KL( I n/a 2SS .\TC ·ATTe Ir.un...'"llift
Kl.O C\I/(>6 2lS ( CiCj ·;l(j(' '\r~ ,Irr
KLC'i C\I!(,iJ 2,·~~) \CG ,Vir ;\r_Z---fScr
KI.('I') N.\ .2·f') \(i(; ,,\C i I ,\r,~,·....)S(_'1
KIlT (\1/62 21\) ~\(iG~AGI -\rt~~-)S\..-'I
KI('.11) C\I/'\(1 ,~ .2 ·\TC_,\ \C 11,'--' ""Jl
KL(T'. N.\ 27 1 CGT ,eCT Arg- "Pro
KLC; C\k; I 2(J() CiG,\-+ \(_j,\ Gil -·,,\rg
KLC21 Wl\!!(l'i 273 CGT ,TGT Ar::; ·Cys
,\hhr,'lill/i,'ns: (';\1. (o\nred male: ,_:\. 11I\t av .ulahle ; vv~t v hue
lll:!k: -~-'. ahSl'IlCt' (lf t,'.\(1I1 Cl murauon-.
2()(»). (i..·,C II/ I. codon 2--; I. <Inc! (',T 1/1 I. (_()doll
277, ) ,:han:,: tlS: e X( III :1 cont.u nl't1 1Il,' r,~m.umn g t \I (l mut d Ii(In s.
Withe; ;1'111 l:cot!oIl17(J);lI1dC ).\(Ii I.t·"doll
17S I l:ha11:,:e\. all re.sultill)C III .uuuu: lIud .rltcr.iu.ur-; '.;Il
rmuation. were Iound In l'.\<l11 fl.
3.3. ASS(lciil/i(J1l lil' ,,/r\eITer! mulcotid« chaucc:, I,'
cl i. -Ioi:«. /iI' 'Ion
OU"sll()!ln;lirl'~ \V"re' Cllllll'ktt'd .rll P:Jtit'lll, IIlld mem
bcr-. of Ihl' conuol group. !\spC,:h t'()\ crc.l hy the: 'jut"li\!lI'
ndlres ll1c1u(\ed ethnic !,'n>lIJl. !,cll,kr. dak ol birth.
nl birth. alcohol and lohll,'Ul cUlhumplli In. t.uiulv 111:-.I(}ry(r!
cancer. sourl'e ol cigllrc'ltes ~111dal't'r;lg': numher Ill' ,'1:':,\I\'lll'S
per day. "HIITe or tobl\L'C() tor pipe SI11<,klll;':. Che\\IIIQ ltl
hacco. drinking and source ui heer. drinkill).: ;1I1d silllr~e (lI
spirits, lise lind source of tribal medicine. induced \ulllitlllg
and method ill induction. und 11111l1erUUSaspcct-. ur diet.u \
habits. .
The data compiled tor both the paucut« and the Ul!llnd
grllllp were used ill \t'st for <:OITt:llltioll' het l\l'Cn [l(\"lhk
eliologie lactOis and the occurrence ol muiauou-, wrtliin
1/'53 and Ii) lól lor a corrcIauon IXI\\l"'1l LC and IIll'
type i If mutations observed. Spearman rank cOITc'iallilns Wl'rl'
determined to deleet any sl:,:nillcanl as.'.lluatl( 111S. Sii:llillCdnl
correlations were found between the occurrence (If LC and
the lollilwillg: Ilge. smoking. eatlllg me.rt on ;] d.ul. h;hi,.
and drinking milk on a dmly hasis (Table 3). The rcxultx were
then further ~lralililld hy dl\idlll):.' the ~1"111" (Jlatll:nis .u«I
controls) into IWi) categoric;; ('illl\lkt'h and nonxn« l~l~r, j.
whereafter the Spearman run], corrcl.u ion \\ as
Crable 4 l. Illvas found tklt :I ol 2.' IlOlblll(lkê1' (I
and .~() of )) smokers ("" -Vi I lILlie di"c'IHlS,'d V\uh lt
Both milk and meat consumed (Ill ;1 dad) -bdsis resulted III
Ilt:gativc corrcl.uion-. with tilt' OCClllTeIK<.l (If I.e (Table: 3!.
thus indicating thatthey may bl: protective lau!)rs a;':,lilbt lhe
development (lf LC. In contrast. sm()kill~ and age ~lisllla\ <,Li
positive correlations with the occurrence u( Le. ihu-, Illllicll
ing these as risk factors fnr the dc'\l'loPII1<'l1t (l1'1 (': hill\<:\Cl.
a negative correlation between ddily milk (Ollsu111ptl'1Il .uul
cigarette smoking w;" noted (Table 31. From Table ..L whcr,:
reqtlh ale str.uified .iccordiug lo ,m'Jklll} ..•. II c.rn hl' Sl'l'11
that the a-sociauon hetween daily milk ciln'Ulllptioll and the
Ol'CUITl'Ill'l' (lf LC WilS not slgnlticant III ('nh,'! !'J()IIP (,mok·
ing or nonsmoking). The association III Table :~ IS theretore
spurious. and due to the correlation wilh ci).'arclle s1l1ok1l1g.
which exerts II major elfeet III nou-anokcr-. Ihnt'i"re. ;Ige
is 111,:only risk (actor identified; lil 'lllokns. IIi!C h II II'\"
factor. bul with a lower correlation tJilcllicllJlll than ill nou-
smokers. and high daily me.u (OIl,UInl'tIOII rcnuun-. ((liTt'·
luted with protection against the dcvclopmcnr (Jl I'c
(Table 4).
4, Discussion
In this study. TP53 was examined in a st't ot laryngeal
cancer patients (Il 44) all having rccc» cd treatment \..ll
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(J. 4"i L" .. ' o..4--L':;
P ()!I!JII P tl.(l()il
Slllliklil:::-' ,,-ï~:;II'l'\1C\ Ii jl !i
O.,';{)·4 Cl (1,22tJ C"'_- IJ I :;h
jl I' (I (j) I /' {} ::: _~ 1-;
j',," ,mi\L:d 7~ /I 7,\
( ), ~S ~ II 1 I c, ().:::2q ..:"
/' o.oo I I' l).i)(llj P 1I.II·h I' O.llIlil
\k", ([;1\1\ X I /I /) Jl ,0 u 7'1'
LOL () -1.'(, LT Ii 4" Cl' -il.Li7 IJ I 32
I' lU)(I() /' ()I)()I) T' 0021 P (l..).')\)
\lilk ~Llil: Ii xl /I 75 XU
,'L' IUil-1 L'l' (I 27' ,,',--' lI.ilS1 \,:c lin I
I' !lll'lJO I' I) (H !_~
if .. 7;';
u... i) 1,\11
P (II I·j
\...\.' (},2t).1,
r I} I li I')
Tygl'lberg Ilospitul. Cape TUWIL South Alric.t. To date, the
llIajurity of TI'53 mutations have been round within cxou-,
) S. the most evolutionarily conserved rcgilln cOlling lor
the Di\A hindln_g domain 1191. and it is lor this reason that
In' decided t(, Iocus Oil this region. It is possible. IH1\V"'"L'L
thai mut.uion-. Illay occur within the intronic sequcnccv. as
II,'II :(l. III l'\O(h 1-4 .md C)-·II. which we did not investigate,
,\ kw -tudic-. 17,20-221 have investigated 11'53 mutations
in Le USlllg PCR-SSep <In;.dySis combined with direct se-
qUI:Il,:ing The results indicate that the tumor, contain mura-
[IiIIIS within cxons S b at varying trcqucnciev. ranging trom
Tahk J
Tl1!~'l;\,_.Ltiiilll',htp" hel\\ een pn~"ihk l'ijolo(__:il' t.u-u.r-, ,IIHI Le
Sm,)kl'r"
~\::... ' Ii = )~
u. Iii 17
/' O!)ILl
1/ ~)
,:. '1121·1
/' ill 1(,
il )~
jl_,:!! ?
/' !I (III_'
/I
'"> -~
Le 11.584
/' II.OW
II - 23
c, 02""
/' 11.",4
1/ 2,
02:1')
I' U.232
Ii 2.1
Cl. -11012
T' 0.9S7
1/ '-l
LOC 1i,1I1 II I
I' IOIiO
/! -::;.+
cc ~ o.ms
/' 0.57h
cc = i).OS(1
j' ()'ii,O
('C lI.nV)
I' n~~).c:;
1/ _:3
'.·e lUO;
p 1!.16()
-----------_.
\hhr('\ i.ni.n»: I v.rrioblcs]: n. [pta] numher il! suhil'l..:t' with intouu.ruon
nH !hc p;lrtlL'L!lar p.u.uucu-r: utll of ;t (ntel! or Si) suh.iee!. -, in ,.;tudy: Cc
CUr!\-L.I[l\ll\ l·Oi._·(lll'llïll: IJ ..... !f:.'.t1illl:;lliLl· k\i..'\
4 (lI' 32 (12.5'; ) 171, 19 ill' 61 (IIY; ) 1201. 7 ill -1-4(;(Jc; i
[211, tli I.' 01'40 L'2,.)'i() 1221, This represents all a\l'r~\gc
ot 2)'.; , Early reports 1231 Indicated ih.n lJ()', "t thl' muta
tion-. III Tl'53 ITOIll il variety (If human canLt'IS were slllgk
point mutuuou-, (Ii 7·H), and the remainder (unsisted uj
small iuvcruon/dclcri.iu«. This >;Iudy idcl\lillcd unu.u ron-, III
TI'53 seque'nCt' in 2)', (\f the ,',N's, ui winch 91 \VeTl'
single-hase change" suggL'sting a unilving molecular mcch-
anism. Factors possibly responsible tor thi-: include cnviron
menral agents and dietary components. It has also been
reported that small insertion/delcrions within TP53 ar,'
common in ovarian cancer 1241 and es()ph;lgeal c.uiccr [251.
and a slippage mechanism due to mismatch D1\;\-rcp:III
dcticicnc , can he s\lggcslCd ;IS hein;, rcsplilhihk rllr the T
insertion observed in thi-; -rudv
Data from qnesrionnairc« completed I" the p.uicnt-. <tIJd
hy the control group allowed corrcl.uion siudics ro id,'nlil>
slI\oking and age a, risk factors for the development of Le
Furthermore. daily consumptiou ur !lIcat r.e\L'ludlllg :ish I
has been identified ~!Sa protective LIl'tur :1,C;lllht the' ein l:lol'-
ment ol Le. This protective dfcct ol high II\l~<lt lï\llSlIllipriDIl
could he: either a direct nutritional elfeet. or II1cal 11Id\ be a
marker lor higher sociocconouiic "alliS, and thcrcIor, dil
indication of -ome other tactor ill' tactors 111\ oh ed ill protec-
tion against the development ur Le Th,' larynx IS \\ her,'
the common aerodigcsuvc tract splil'-. into the trachea and
the esophagus, and ';Illoking has heen identi lied as a risk
factor for esophageal cancer [261 and for lung cancer [27.2RI,
The typical lung cancer Tf'53 muration-, associalt'd with
smuking, G----"T transversiou- élnd G----,,;\ anti c--/r trun-,i-
tions 1221. accounted rol' 7Y;:; ill' the mut.uiou-. lound III the
present study. Although the ruetauons ob-.crvcd III thl' pres-
ent study fall within a known TI'53 hoixpot lor cuuccr- In
generaL the particular mutunou-, at (Odl\llS 17~, 176, 2-+S.
249,266, and 27:\, accounting for i'\2'/; (lf the mutution« WI'
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Appendix II
Product Supplier/Manufacturer
Absolute ethanol
Agarose Seakem LE
AgN03
Ammonium per sulfate
Bleach
Boric Acid
Bromophenol Blue
BSA
Cal-liquid hand soap
Cling wrap
Deionized formamide
Disposable O.5ml, 1.5ml and 2ml tubes
DNA marker IX
EDTA
EtBr
Formaldehyde
Gelbond
Gel sealing tape
Gelslick
Glycerol
Heraeus Biofuge Pico
HotStart Taq DNA Polymerase
MgCI2
Merck (Pty.) Ltd.
BMA
Merck (Pty.) Ltd.
Merck (Pty.) Ltd.
Snobrite
Merck (Pty.) Ltd.
Merck (Pty.) Ltd.
Promega
Cal-Chem
Pick In Pay
Sigma
Eppendorf
Roche
Promega
Merck (Pty.) Ltd
Merck (Pty.) Ltd
BMA
3M
FMC Bioproducts
FMC
MSE Multex
Qiagen
Promega
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Mini-gel casting and electrophoresis apparatus
Mini-gel power supply - EPS 3500
MOPS
NaCI
NaOH
Nuclease-free dH20
Nucleospin Kit
Oligo 1000M DNA synthesizer
Pipettes
Primers
Proteinase K
Rubber bootie
SOS
Sequence analyzer 3100
Sodium Acetate
Sucrose
Taq DNA polymerase
TEMED
Tris
Triton X-1 00
UNOli Thermocycler
Urea
Video Graphic Printer UP- 860 CE
5ml EDTA tubes
50ml Falcon tubes
190
Bio-Rad Laboratories
Pharmacia
Promega
BDH Chemicals
Sigma
Sigma
SABAX
Macherey-Nagel
Beckman Instruments
Eppendorf, Pipetman,
Nichipet, Labsystems
UCT, Whitehead Scientific
Roche Diagnostics
Life Technologies
BDH
ABlprism
Merck (Pty.) Ltd.
Merck (Pty.) Ltd
Promega
Sigma
Merck (Pty.) Ltd.
Sigma
Biometra
BDH Chemicals
Sony
BO Vacutainer Systems
Greiner bio-one
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10x =ca buffer
30% Polyacrylamide
40% Polyacrylamide (37:5: 1)
Promega
BioRad
BioRad
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Appendix III
Buffers and Solutions
Cell lysis buffer
Sucrose
Triton X-100
MgGI2
Tris, pH 7.6
Nuclei lysis buffer
NaGI
Tris, pH8.2
EDTA, pH 8.2
Saturated NaCI Solution (>6M)
NaGI
dH20
TE Buffer
Tris
EDTA (pH 8.0)
dH20
1OxTBE buffer
Tris
Boric Acid
EDTA
dH20
1xTBE buffer
1OxTBE buffer
dH20
O.6xTBE buffer
1OxTBE buffer
dH20
12% Polyacrylamide minigels (2 gels)
dH20
1OxTBE buffer
30% Polyacrylamide (29: 1)
3% Ammonium per sulfate
TEMED
192
320mM
1%
5mM
10mM
400mM
10mM
2mM
23.4g
1L
0.1M
0.01M
150ml
108g
55g
7.4g
1L
100ml
900ml
60ml
940ml
4.8ml
1ml
4ml
210111
20111
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Loading dye
Bromophenol blue
Glycerol
Tris, pH 8.0
0.2%(w/v)
50%
10mM
Solution B
A9N03
dH20
19
1L
Solution C
NaOH
NaBH4
Formaldehyde
dH20
159
0.19
4ml
1L
6% Polyacrylamide SSCP gels
dH20
1OxTBE buffer
Glycerol
30% Polyacrylamide
3% Ammonium per sulfate
TEMED
134ml
12ml
10ml
40ml
4.2ml
100111
8% Polyacrylamide SSCP gels supplemented with 10% urea
dH20 120ml
1OxTBE buffer 20ml
40% Polyacrylamide (37:5:1) 40ml
Urea 209
3% Ammonium per sulfate 4.2ml
TEMED 100111
10% Polyacrylamide SSCP gels supplemented with 17% urea
dH20 80.5ml
1OxTBE buffer 9ml
Glycerol 7.5ml
30% Polyacrylamide (29: 1) 50ml
Urea 25.59
3% Ammonium per sulfate 3.15ml
TEMED 75111
70% Ethanol
Absolute ethanol
dH20
70ml
30m I
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10% Bleach
Bleach 10ml
dH20 gOml
5x MOPS Buffer
MOPS, pH 7.0 0.2M
Sodium Acetate 0.05M
EDTA, pH 8.0 0.005M
1% RNA agarose gels
5x MOPS Buffer 20ml
DEPC-treated or Nuclease-free dH20 72ml
Agarose Seakem LE 19
37% Formaldehyde 17.6ml
EtBr (1Omg/ml) 5~1
RNA sample buffer
Deionized formamide 10ml
37% Formaldehyde 3.5ml
5xMOPS, pH 7.0 2.0ml
RNA loading buffer
Glycerol 50%
EDTA 1mM
Bromophenol blue 0.4%
1% DNA agarose gels
Agarose Seakem LE 19
dH20 100ml
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QUESTIONNAIRE: OESOPHAGEAL CARCINOMA
PROMEC
PO Box 19070
Tygerberg
7505
. 1. Patient general information
Name and address:
Telephone no: ________ (h)
_________________ (w)
2. HospitallInstitution information
2.1 Name HospitaVfnstitution
I
I
Day Month Year
2.5 Final classification of tumor
Description I
"'_____'--"'.-r---..-.c-u-es~lo-n-n-a-lr-ecom pleted by:
Name I
~========~I~el~.~{w=)~=== ~1
Date completed
3. Patient Demographic Information
D 3.1 Sex Male = I; Female == 2
o DayAge Month Year3.2 Date of Birth
3.3 Occupation
Official ~se Only
Official Use Only
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2Previous year I
T , I IDr"".";" 1<:~ vPJlr<: I
T .nI'Jltinn I I
3.4
B
3.5
I
3.6
Anthropometry
Weight in kg
Length in m
Place of birth
I
Region:
District:
Location:
Where did you spend most of your time for
the period:
.-- --.1. Age up to 18 years:
I
Region:
t=======~ District:
f------------;. Location:
L_ ~
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4b. SufTers loss in Body Weightp Yes~ 1; No~2
_ Period I
4. Habits
4.2
§
§
§
o
4.1 Smoking cigarettes
Never = 1; Yes = 2; Yes, but stopped = 3
Average number per day
Shop-bought = 1; Home-grown = 2; Both = 3
Smoking pipe (tobacco)
Never = I; Daily = 2; Weekly = 3; Seldom = 4
Shop-bought = I; Home-grown = 2; Both = 3
4.3 Chewing tobacco
Never = I; Daily 2, Weekly = 3, Seldom 4
Shop-bought = I, Home-grown = 2, Both = 3
4.4 Drinking beer
Never = I; Daily 2; Weekly = 3, Seldom = 4
Shop-bought I, Horne-made 2, Both 3
4.5 Drinking spirits
Never = I; Daily = 2; Weekly = 3, Seldom = 4
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D
§
4
Shop-bought = 1; Home-made = 2; Both = 3
4.6 Tribal medicines
Never = 1; Daily = 2; Weeldy = 3; Seldom = 4
Shop-bought = 1~ Home-made = 2; Both = 3
4.7 Inducing vomiting
Self-inflicted
5. Dietary Information
5.1
D
5.2
~
5.3
D
5.4
§
5.5
D
5.6
Main cereal in diet
Maize = 1; Sorghum = 2; Wheat = 3; Other = 4
Maize meal intake
Seldom = 1; Daily = 2; Weekly = 3; Monthly = 4
Home-grown = 1; Bought = 2; Both = 3
Amount in tea-cups per day: one = 1; two = 2; etc.
Maize meal used for home-made beer
Yes=1;No=2
Home-made beer intake
Seldom = 1; Daily = 2; Weekly = 3; Monthly = 4
Amount in tea-cups per day: one = 1; two = 2; etc.
Maize meal for home-made beer
Shop-bought = I; Home-grown = 2; Both = 3
Other food components added to daily diet
Mark clearly the type of food only:
Never/Seldom = I; Almost Daily (~5x/week) = 2;
1-2xJWeek = 3
Green, leafy vegetables
Green pod vegetables
Imifino (wild/veld greens)
Beans in llmngqusho
Fruit
Milk
Margarine or butter
fficial Use Only
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o 5.6
6.0
6.1
6.2
6.3
6.4
6.5
6.6
6.7
5
Meat (beef/mutton/porklchicken/mince/sausage)
Fish
SufTers from heartburn
General:
Bronchoscope
Barium meal
Description of lesion (position etc.)
Fistula
CXR
Hb
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6VOLUNTEER CONSENT FORM
1. I, the undersigned, voluntarily agree to take part in the fOllowingstudy:
THE VALUE OF p53 MUTATION IN PATIENTS WITH SQUAMOUS CELL
CARCINOMA OF THE HEAD AND NECK
2. I have been fully informed of the purpose and nature of the study as well as the
advantages and possible adverse effects resulting from the undermentioned
procedures and/or treatment, as explained (see attached sheet - "summary of
information given to patients") and I understand what it says.
3. Nature of the procedure and/or treatment to be taken is:
i) Biopsies from tumor to be taken during surgery. ii) blood samples (10 ml for
molecular analyses) are to be collected in separate tubes.
4. The procedure will be carried out by/or under the supervision of a qualified nurse
(blood collection) and a surgeon (tissue collection).
5. I understand that I can recall my consent at any time.
Name of volunteer: ----------------------------------------------------------------------------------------
PostaI address: ----------------------- ----------------------------------------------------
Telephone Numbec------------(h) ----------(w)
Signed at -----------------------------------------this ------------day of --------
Volunteer Person who informed volunteer
ASfNitness
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7SUMMARY OF INFORMATION GIVEN TO PATIENT
a) Tissue sampling: Tissue samples (tumour) to be taken only when surgery is
performed. Therefore, there is no additional risk beyond that encountered
during the normal surgical procedures.
b) Blood samples: 10 ml blood for molecular analyses.
c) Questionnaire: To be completed to provide additional information about
possible contributing factors that could have been involved in the development of
the disease. From these data, information will be obtained whether
environmental factors and/or the traditional lifestyle are associated with the
occurrence of the disease.
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